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CHAPTER 1
Literature Review
1.1 Importance of Breast Cancer.
Breast cancer has long been recognised as an important disease seriously affecting
the health ofwomen and men. The Chambers Encyclopaedia of 1751 described it as
"a most dread disease, particularly of the celibate and barren". In this century,
studies of risk factors, causative agents and molecular biology of the disease has
increased our knowledge of the initiation, development and progression of'breast
cancer. One overall aim is to treat cancer effectively and ultimately to prevent the
occurrence of cancer. A means of getting closer to this aim is to identify the genetic
events which occur in breast cancer and understand their biological consequences.
Recent surveys show that 1 in 9 women in the United States of America (American
Cancer Society 1991), and 1 in 14 women in Scotland will develop breast cancer
(Scottish Breast Cancer Screening Program Report 1993), and it will be responsible
for the death of 25% of these women (Sondik 1994). The incidence of breast cancer
has probably increased during this century, and is most noticeable in women up to 50
years old (Kelsey and Berkowitz 1988, Ranstam et al 1990). The majority of cancers
occur in women aged over 50 years; incidence in this group may have increased due
to an increased life expectancy (Sondik 1994). This suggests that an accumulation of
genetic events over time may be necessary for the development of non- familial
breast cancer (Armitage and Doll 1954, Peto et al 1975). At a macroscopic level the
cumulative effect of these genetic disregulatory events is reflected phenotypically by
the overall histopathology of breast cancer.
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1.2 Histology and Pathology of the Breast.
Breast cancer presents clinically as a heterogeneous disease and is classified by
histopathological type, and other features such as cancer grade and biological
markers (discussed below). Breast cancers can present either symptomatically or
from routine mammographic screening.
1.2.1 The Structure of the Normal Breast.
The normal breast consists of a branching network of ducts, formed by epithelial
cells, which originate at the lobules and terminate at the nipple. Lobular units
produce milk during lactation and are surrounded by fatty cells. Milk is secreted
into the ducts and channelled to the nipple. Epithelial cells in the non-lactating
breast are largely under the influence of progesterone and oestrogen, and undergo
monthly changes of proliferation and apoptosis (Page and Anderson 1987).
1.2.2 Breast Cancer.
Detection of a breast lump commonly leads to a biopsy for pathological investigation
and determination of oestrogen receptor status. In addition many cancers are
detected by routine mammographic screening, such as in the Edinburgh Randomised
Breast Screening Project. Mammographic abnormalities indicating breast cancer may
be detected in 2.2% ofwomen at the primary screen (prevalence screen) (Anderson
et al 1991). The prevalence screen may include some cancers which are clinically
symptomatic and some non-palpable lesions. Subsequent screens (incidence screen)
may detect early lesions and cancers which arise between screens are true "interval"
cancers, which may include groups of cancers representing early and or rapidly
growing cancers. Cancers detected at screening are important in the investigation of
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molecular lesions, particularly when attempting to establish a sequence of events in
cancer progression. Benign lesions of the breast include atypical ductal hyperplasia,
radial scars and fibroadenoma. Each can cause disturbance to the tissue architecture
due to cellular proliferation. Transformation steps between benign and malignant
lesions have not been clearly identified (Bodian 1993). Breast cancer is sub classified
into several histopathological types (reviewed in Page and Anderson 1987). In situ
cancers are classified according to the presence and type of neoplastic cells within the
ducts, without infiltration into the surrounding stroma. In situ cancers can be either
ductal, lobular type, or Pagets disease of the nipple. True invasive breast cancer is
frequently ductal carcinoma of no special type. Special types of invasive cancer
include lobular, tubular, medullary or mucinous cancers, and are characterised by
particular patterns ofgrowth. Invasive cancers often also have an in situ component.
Classification is not always unequivocal and cancers of mixed type occur. The
cancers can be further classified by grading, using the criteria of gland formation,
nuclear pleomorphism, and frequency of mitosis (Elston 1987). Higher cancer
grades signify increasing aggressiveness (Tubiana and Koscielny 1991).
1.3 Initiating Events of Breast Cancer.
1.3.1 Environmental Factors.
The contribution of environmental factors in the aetiology of breast cancer is unclear.
Environmental mutagens, cigarette smoking, and diet have all been implicated in
increased risk (Hunter and Willet 1993, Kelsey and Horn-Ross 1993, Palmer and
Rosenberg 1993). In addition reproductive history and hormonal influences in
individual patients can also contribute towards increased risk. These factors can
apply in tandem and present a complex pattern from which to assess individual risk.
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The salient points from several review articles are discussed below (Kelsey and
Horn-Ross 1993, Hunter and Willet 1993, Palmer and Rosenberg 1993).
1.3.2 Diet and Cancer Risk.
High fat diets have been suggested as a risk factor in breast cancer. High fat diets
may increase the incidence ofmammary tumours in rodents (Tannenbaum 1942), and
differences in the frequency of breast cancer between countries and continents have
suggested that dietary factors which apply in a general fashion throughout a
population may play a role in the development of the disease in man (Kelsey and
Horn-Ross 1993). The increased frequency of breast cancer in Japan from 1900 to
the present has been linked to the Japanese diet becoming westernised (Hunter and
Willet 1993). In addition, Americans of Japanese origin, residing in the United States
of America, have a similar frequency of breast cancer to Americans of European
origin (Haensel and Kuntasa 1968). However this association may be weak as
reproductive or hormone status may also have changed in these populations
(Bernstein and Ross 1993). Conducting properly controlled trials for the effects of
diet on human cancer initiation has proved difficult.
1.3.3 Environmental Mutagens and Cancer Risk.
The impact of environmental mutagens on the development of breast cancer is not
known. Epidemiological studies of the effects of compounds such as tobacco smoke,
alcohol, ionising radiation, and pesticides on the incidence of breast cancer have
failed to find any strong associations (Adami et al 1990, John and Kelsey 1993). For
example, tobacco smoking is thought to only marginally increase breast cancer risk
(O'Connell et al 1987); indeed one study indicated a weak protective effect (Baron
1994).
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Animal models have been used to test chemical mutagens in vivo. Mutagens, such as
N-nitro-N methyl urea have induced the development of tumours when injected
directly into rodent mammary fat pads (Sukumar et al 1986, Zarbl et al 1987). These
studies indicate a potential role for chemical mutagens, but extrapolation to human
breast cancer is complicated by interspecies variability and incomplete knowledge of
mutagen biochemistry.
1.3.4 Steroid Hormones and Cancer Risk.
Oestrogens and progestogens play an important role in the normal development and
functions of the breast (Anderson and Battersby 1989, King 1993). The biology and
deregulation of oestrogen and oestrogen receptors is discussed below (section 1.11).
Increased risk of breast cancer has been associated with early age of menarche, late
menopause, nulliparity and full term pregnancy at an older age (Kelsey et al 1993).
An early age for a first child and performance of breast feeding are thought to have
some protective effect (MacMahon et al 1970). These effects are thought to be due
to the influence of steroid hormones on the breast cells (Byers et al 1985),
particularly oestrogen and progesterone. The incidence of breast cancer in men is
only 0.0IX that of women, although cancers in men are morphologically identical
(Thomas 1993); they may be associated with rare abnormalities of the androgen
receptor (Trapman and Brinkman 1993, Wooster et al 1992).
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1.4 Genetic Factors in Breast Cancer.
For environmental or hormonal factors to influence cellular growth characteristics
they must in some way disturb normal genetically controlled cellular mechanisms.
These genetic control mechanisms may also be affected by mutation or disregulation
which may not have an environmental basis. Genetic factors can be categorised into
two main types; those which are inherited and occur constitutionally; and mutations
or deregulations which occur in somatic cells. This section will outline different
kinds of genetic disregulation and focus on a subset of these.
1.4.1 Inherited Genetic Lesions.
A familial element has been identified in many early onset breast cancers, but it has
been estimated that familial cancers only represent 4-9% of breast cancers (Houlston
et al 1992). Familial cancers are characterised by an autosomal dominant pattern of
inheritance. They can be bilateral, show multifocality and can be associated with
other cancers such as ovarian cancer (Adami et al 1990). Intensive studies are
currently underway to identify the genes involved. One system ofgermline mutations
involves the p53 tumour suppressor gene, originally identified in families with
multiple cancer types (Li and Fraumeni 1969) and is discussed in section 1.7.3. Two
genes, BRCA1 and BRCA2 have been identified as candidate genes by linkage
analysis in breast cancer families (Futreal et al 1992, Hall et al 1990b, Wooster et al
1994). BRCA1 has recently been identified as a potential transcription factor, and
located to 17q 12-21 (Miki et al 1994). Several mutations, which result in protein
truncations, missense mutations and altered splice sites, have been detected in
BRCA1 in families with breast and ovarian cancer (Freidman et al 1994, Simard et al
1994, Castilla et al 1994). BRCA2 is genetically linked to markers on chromosome
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3ql2-13, however its precise location and the function of the gene remain unknown
(Wooster et al 1994). These two genes may account for two thirds of familial breast
cancers, or about 5% of all breast cancers (Ponder 1994), therefore other key genes
remain to be found. The extent of involvement of these genes in sporadic cancers is
not yet known. Linkage analysis of genes and markers on the long arm of
chromosome 17 have indicated that there may be another breast cancer associated
gene located in this region (Easton et al 1993, Narod et al 1991).
1.4.2 Non-familial Breast Cancer.
The majority of breast cancers are sporadic and occur in women aged over 50, and
are not associated with a family history of cancer (Kelsey et al 1993). This suggests
that these breast cancers may arise from an accumulation of disruptive somatic
molecular events over time, which may include those genes involved in hereditary
cancer.
The number of genetic events required for the transformed phenotype may be
variable, and range from a theoretical one, to two (Armitage and Doll 1957,
Knudson 1989), to many (Fearon and Vogelstein 1990, Thompson et al 1992). In
contrast to breast cancer, a clear sequence of genetic events has been identified in
colon cancer, and associated with particular pathological stages of cancer
progression (Fearon and Vogelstein 1990). The breast presents a more complex
pathological picture as precursor lesions have not been identified (Bodian 1993).
The variety of pathological types may suggest that different genetic disregulatory
pathways or different sequences of events may be involved, which may share
common events. Proto-oncogenes and tumour suppressor genes have been
implicated as targets for molecular disregulation (Bishop 1991) and may play an
important role in breast carcinogenesis and progression; they are discussed below.
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1.5 Mechanisms of Gene Deregulation.
1.5.1 Chromosomes.
Gross chromosomal disruption is evident in some breast cancer cell lines (Ali et al
1988a, Sasi et al 1991, Sato et al 1991), and is also evident in cell material from
surgical specimens of breast cancer (Gebhart et al 1986). Chromosomal
deregulation can be represented by translocations (either balanced or unbalanced),
dicentric chromosomes, acentric chromosomes, double minutes, deletions,
duplications and complete or partial aneusomy. These abnormalities are usually
detected by staining metaphase chromosome spreads prepared from actively dividing
cells. In vivo metaphase spreads are difficult to obtain. Extrapolation of in vitro
chromosomal deregulation in cell lines to in vivo cancers may not be a valid
comparison, as cancer cells which grow in culture may represent a biased sample of
the whole population. In addition cells in culture show clonal expansion during
culture (Meltzer et al 1991), indicating that the karyotype of established cell lines
may not accurately reflect the chromosomal status of the original breast cancer. The
transformed phenotype of cancer cells as a result or resulting in gross chromosome
disruption is likely to be due to the action(s) of specific gene(s), which are
deregulated by either a physical disturbance (direct gene disfunction) or a regulatory
disturbance (indirect gene disfunction).
1.6 Direct Gene Disfunction.
Direct gene disfunction can arise from a physical alteration of the basic nucleic acid
sequence of the gene or its promoter regions. This could take the form of: point
mutations, variable sized deletions or insertions, translocations or amplifications.
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Each of these has the potential to abrogate or increase transcription, or alter the
amino acid sequence of the gene product.
1.6.1 Normal Gene Function.
The basic structure of a typical gene is shown in Figure 1, and consists of a non-
transcribed promoter region, and a transcribed region consisting of introns and
exons. Gene transcription results in the formation of a messenger RNA (mRNA),
which is enzymatically spliced in the nucleus to form a functional mature mRNA,
consisting only of exons. Gene translation takes place in the cytoplasm, on
ribosomes attached to the endoplasmic reticulum. Amino acids bound to transfer
RNA (tRNA) bind specifically, according to the triplet code, to the mRNA located
on the ribosome. The protein is formed when peptide bonds are synthesised
enzymatically between adjacent amino acids. Post-translational processes complete
the three dimensional structure of the protein. The promoter region of a gene plays a
key role in the initiation of transcription and can be regulated by promoter, enhancer
or gene suppressor proteins. Sequences within the promoter which are recognised
by these proteins are called cA-acting sequences, and the binding regions of the
proteins are termed trans-acting elements. Several sites of initiation can be present
within each promoter region, and includes common sequences such as CAAT and
TATA. Genes may also have enhancer elements, a sequence which is orientation
independent and can increase transcription even when located up to several kilobases
away. Enhancer elements can also be located within introns. Suppressor proteins
are described below.
1.6.2 Chromosome Translocation.
Translocations are frequent events in cancer tissue cells (reviewed by Cleary 1991)
and can be influential in the development of some cancers, such as in chronic myeloid
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Figure 1.
Ideogram of gene transcription and gene translation. Gene translation takes place
within the nucleus of the cell. Single stranded mRNA is transcribed from double
stranded DNA consisting of introns and exons, followed by gene splicing to form a
mRNA consisting only of exons. mRNA enters the cytoplasm and attaches to a
ribosome located on the endoplasmic reticulum. Amino acids bound to tRNA bind in


















leukaemia (deKlein et al 1982) which is associated with the Philadelphia chromosome
(t9:22, [q34,qll]). Chromosome analysis of breast cancer cell cultures has identified
many structural and numerical chromosome alterations, including DNA deletions and
translocations (Dutrillaux et al 1990, Ferti-Passantonopoulou et al 1987). Some
chromosomal abnormalities may be primary or secondary events in the oncogenic
process, however others may merely reflect non-specific chromosomal disregulation
as a result of other primary events. The difficulties involved in assessing the
karyotype in solid tumours, as discussed above, suggests that molecular techniques
may be a more universal method of determining chromosomal damage.
1.6.3 Loss ofHeterozygosity.
DNA deletion is another common form of chromosomal damage. Examining loss of
heterozygosity has proved an effective method of identifying candidate DNA
sequences of relevance to cancer development. Most genes are present as one of
two or more alternative forms, and are termed alleles. Polymorphisms between
alleles can be detected by various molecular methods, and when present are classified
as homozygous (both alleles being the same) or heterozygous (alleles are different).
Where individuals are heterozygous at a particular locus, comparison of normal and
cancer DNA can detect loss of one allele. Loss of heterozygosity is widely observed
in cancer DNA and is frequently detected via anonymous DNA sequences. The real
significance of loss is usually unclear until further exploration of the DNA region
reveals candidate genes.
Loss of heterozygosity has been observed at a large number of loci in breast cancers
and has identified regions of chromosomes 1, 3, 6, 11 16, and 17 which may contain
genes important to the development and progression of breast cancer (Borg et al
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1992, Devilee et al 1989, Futreal et al 1992, Lundberg et al 1987). Regions
frequently lost may indicate the presence of a tumour suppressor gene. Allele loss at
17q leading to the presence of hemizygosity has previously been reported in 60% of
breast cancers (Cropp et al 1990) however loss at any single locus is a less frequent
event (Devilee et al 1991, Sato et al 1991).
1.6.4 Gene Amplification.
In other animals than man, gene amplification (an increase in the number of gene
copies) is a developmentally programmed event which allows high levels of
expression of a particular gene at a specific time (Stark et al 1989). In man, gene
expression is controlled by promoters or silencers which effect transcription
(Marshall 1991), and gene amplification does not normally take part in this process.
In cancer cells however, genes can be amplified in an oncogenic process, either by
changes in cell DNA ploidy or by specific gene amplification.
The mechanisms by which genes amplify in man are not clearly understood, however
some regions of chromosomes are prone to amplification (Lammie and Peters 1991).
Amplified regions ofDNA can extend from a few hundred to thousands of kilo base
pairs (Stark et al 1989). Large amplifications can sometimes be seen by light
microscopy as either extended chromosomal regions, termed homogeneously stained
regions, or extra chromosomal elements, usually called double minutes (Stark et al
1989). Genes can be amplified as the result of physico-chemical alterations to cells,
such as hydroxyurea, hypoxia, ultraviolet and ionising radiation (Schimke 1988,
Stark et al 1989). Gene amplifications are not always stable and gene loss, including
regions of amplification, can occur in the absence of selection pressure (Saito et al
1989).
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Several models of gene amplification have been proposed, and categorised into
replication driven and segregation driven models. Replication driven models include
: i/ Onion skin model - head to head or head to tail tandem arrays of amplified units
created by independent recombination events, Figure 2 (Stark et al 1989); ii/
Extrachromosomal double rolling circle model- a single round of local DNA
replication forming a circle containing an inverted duplication which is excised from
the chromosome by double recombination and then amplified as a double rolling
circle, Figure 3 (Passananti et al 1987); iii/ Chromosomal spiral model- an inverted
duplication is formed when replication switches strands, Figure 4 (Nabaltonglu and
Meuth 1986). Segregation driven models include : M Deletion plus episome model- a
circular sequence created by either a recombination across a replication loop which
contains a functional replication origin or by re-replication. The episomes formed are
acentromeric and will therefore segregate randomly at mitotic cell divisions (Schimke
et al 1986) ; ii/ Sister chromatid exchange model- sister chromatids recombine
unequally before mitosis to form head to tail joining of amplified domains, forming an
extra long chromosome arm with amplified gene copies separated by long stretches
of co-amplified material, Figure 5 (Guilotto et al 1986).
1.7 Tumour Suppressor Genes.
Apparent changes in the activity of specific genes may not involve physical changes
to the coding or promoter sequence of a gene. Alterations in the rate of protein
production may be due to abnormal levels of promoters, enhancers or suppressors
(Marshall 1991, Spandidos 1985), proteins which effectively switch on or off gene
transcription. These genes are subject to deregulation in some cancers and are
usually detected by loss of heterozygosity analysis (see section 1.6.3). Tumour
suppressor genes can regulate cell growth in a negative fashion by blocking
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Figure 2.
A model for amplification of mammalian DNA involving unscheduled DNA synthesis
plus recombination. The drawing is from Stark and Wahl (1984). Bi-directional
replication at an origin generates a bubble that can undergo further rounds of
unscheduled DNA replication, resulting in a nested set of partially replicated
duplexes. There are only two contiguous chromosomal strands. It is possible for
linear duplex DNA to become detached from the structure if two replication forks
can approach one another very closely (pathway 3). Recombination within the same
duplex could generate extra chromosomal circles (pathway 2), while multiple
recombinations among different duplexes could resolve the structure into an












A model for amplification of mammalian DNA involving inverted duplications. The
drawing is from Stark and Wahl (1989). A circular model containing an inverted
duplication (rectangles) harbouring the gene to be amplified (dots) is excised from
the chromosome, yielding also a chromosomal deletion (not shown). After the
inverted sequence is replicated once, homologous recombination takes place between
a copy of the newly replicated sequence and the copy yet to be replicated. This
results in a flip of the replicating forks (small arrows) so that they are now chasing
each other. Further replication leads to amplified arrays of inverted duplications
derived from a single initiation ofDNA replication during a single S phase.
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Figure3
EXCISIONOFCIRCLECONTAMNQ ANNVERTEODUPUCA 10NFROM CmOMOQOMALCm
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Figure 4.
A model for inverted duplication formation and intrachromosomal amplification. The
drawing is from Stark and Wahl (1989). (a-d) Formation of a head to head (C'/BC)
joint by copy-choice recombination, (d1) Structure obtained if a head-to head (C'/BC)
joint and a tail-to-tail (G/H'G') joint are formed by similar events at both ends of the
replication bubble, (e) Amplification of the resulting inverted duplication by






















































A model for gene amplification in which sister chromatids recombine unequally
before mitosis. A lineage is shown in which copy number increases maximally at each
cell division. Note that only one pair of sister chromatids is shown and that each
daughter cell still has an unaltered chromosome. After the third step there are four
copies of J1 and two copies of J2 but only one copy of J3. J2 might be a single copy
number if the increase were not maximal at step 3. The model predicts formation of
both single copy and amplified novel joints in head-to-tail arrangements.
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transcription of genes or by involvement in cell cycle control (Marshall 1991). Few
tumour suppressors have been extensively studied in breast cancer, the notable
exceptions being p53 and the retinoblastoma gene (Rb). It is yet to be resolved
whether familial breast cancer genes BRCA1 and BRCA2 can act as tumour
suppressor genes. The loss of tumour suppressor action, can occur in a "two hit"
process, in which the first "hit" may take the form of an inherited disregulation in one
allele and the second "hit" occurs somatically to knock out the remaining allele,
resulting in complete inactivation of both copies (Knudson 1989). This is known to
occur in both the Rb gene in familial retinoblastoma (Cavanee et al 1983), and in p53
in colon cancer (Van Den Berg et al 1989) and is likely to result in cell proliferation
(Hollstein et al 1991, Nigro et al 1989) contributing to a transformed phenotype.
The involvement of these and other, as yet unidentified, tumour suppressor genes in
breast cancer oncogenesis is indicated by the frequent loss of hetero2ygosity at
specific chromosome locations, such as lp and lq (Borg et al 1992), 6q (Devilee et
al 1991), lip and 13q (Devilee et al 1989), 13p (Lundberg et al 1987), 16q, (Sato et
al 1990), and 17q (Futreal et al 1992). Candidate genes have not yet been identified
at all of these loci.
1.7.1 Retinoblastoma Gene.
The retinoblastoma gene (Rb) plays a critical role in the development of
retinoblastoma (Knudson 1971). It has been shown that Rb protein acts to halt
progression through G1 phase of the cell cycle (Goodrich et al 1991) and the
biological consequence of loss of Rb function may be unscheduled cell proliferation.
Mutations which abrogate Rb function have been found in a wide variety of cancers,
including breast cancer (Friend et al 1986, Lee et al 1988, T'Ang et al 1988). Loss of
heterozygosity at chromosome 13ql4, the chromosomal location of the Rb gene, has
been observed in 21-29% of breast cancers (Devilee et al 1989). Structural
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abnormalities in the Rb gene have been found in 19% of breast cancers (Varley et al
1989), suggesting that mutations in Rb may contribute to the malignant phenotype in
some breast cancers. Loss of Rb function has been found to correlate with more
advanced and less differentiated breast cancers (Varley et al 1989). However, other
important breast cancer genes may be located close to the Rb locus, such as BRCA2
(Wooster et al 1994), perhaps indicating that the role of the Rb gene is not fully
determined.
1.7.2 p53 tumour Suppressor Gene.
Mutations in p53 contribute to the development of up to 50% of all human cancers
(Marx 1993), and are present in approximately 50% of breast cancers (Cattoretti et
al 1988, Osborne et al 1991). Recent studies have shown that the p53 protein
transactivates other genes (CIP1/WAF1) whose products inhibit the cyclic kinases
required to drive cells through the cell cycle (Harper et al 1993, El-Deiry et al 1993).
Allele loss in breast cancer has frequently been observed on the short arm of
chromosome 17, and 17pl3, a location where the p53 gene resides (Coles 1990,
Devilee et al 1990). Mutations in p53 can occur in 25-40% of sporadic breast
cancers (Lemoine et al 1994) and is associated with an aggressive cancer phenotype
and poor prognosis. Its role in breast cancer progression remains unclear.
1.8 Oncogenes.
1.8.1 Introduction.
Oncogenes and protooncogenes are a large family of genes which, unlike tumour
suppressor genes which can switch off gene transcription, can switch on or increase
transcription of target genes (Rochlitz and Benz 1989). Oncogenes were originally
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identified as the transforming sequences of acutely transforming retroviruses (usually
prefixed v-), which were subsequently shown to be mutated forms of host genes
(usually prefixed c-) which had been transduced from the normal host genome by
retroviruses (Bishop 1991).
1.8.2 Oncogene Function.
Most oncogenes have a normal counterpart within the mammalian genome, the
exceptions being some oncogenes ofDNA viruses such as ElA, and E6 (Shenk and
Flint 1991, Laimins 1993). Oncogenes can be classified into four main categories of
protein: growth factors; growth factor receptors; transducers of growth factor
responses; and transcription factors (reviewed in Hunter 1991). Most oncogenes are
involved in the cascade of events by which growth factors stimulate cell division
(Cantley et al 1991), and it is only when they are inappropriately activated that they
can take part in the oncogenic process (Hunter 1991).
1.8.3 Oncogene Activation.
The activation of protooncogenes can occur in different ways. Activated oncogenes
implicated in human breast cancer include: amplification of c-myc, L-myc, N-myc, c-
int-2 and c-erb B2; rearrangements of L-myc, N-myc, c-myb, c-mos and Ha-ras;
allelic loss of Ha-ras; and amplification or mutation of Ki-ras, Ha-ras and N-ras
(Cline et al 1986, Lidereau et al 1988, Rochlitz and Benz 1989). Many of these
abnormalities are present at low frequencies in breast cancer populations, with
amplifications of c- myc and c-erb B2 and allelic deletions ofHa-ras and c-myb being
most prevalent (Rochlitz and Benz 1989, Callahan 1989). The oncogenic potential
of nuclear receptors has also been recognised (Hunter 1991), and disregulation of
members of this family may be candidates for involvement in breast cancer, both
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oestrogen receptor and thyroid hormone receptor (THRA1) are discussed in
sections 1.11 and 1.12.
Oncogenes and tumour suppressor genes are scattered throughout the genome, see
Figure 6. Several genes of potential importance in the development of breast cancer
are located on chromosome 17, see Figure 7, and include the p53 tumour suppressor
gene on the p arm, and BRCA1, c-erb B2 and THRA1 on the q arm. This thesis
focuses on detailed examination of chromosome 17q, and on c-erb B2 and THRA1,
partly because c-erb B2 was initially associated with poor prognosis in breast cancer
(Slamon et al 1987) and THRA1 which can be co-amplified with c-erb B2 (Tavassoli
et al 1989, Tsuda et al 1989).
1.9 C-erb B2.
1.9.1 Introduction.
C-erb B2 is a member of a growing family of tyrosine kinase receptor genes, which
includes c-erb B1 (the epidermal growth factor receptor gene), c-erb B3 and c-erb
B4 (which have as yet unknown functions).
1.9.2 Oncogenic Potential of c-erb B2
C-erb B2 was first identified as a potential oncogene in rodents with
neuroglioblastoma (hence called neu) where a single point mutation in the
transmembrane region of the protein was identified as having transforming abilities
(Bargmann et al 1982). The single point mutation may result in a constant activation
signal transmitted to the cytoplasm (Shih et al 1981). In later studies of transgenic
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Figure 6.
Ideogram of human metaphase chromosomes illustrating the approximate locations of some
oncogenes and suppressor genes. A more detailed map of chromosome 17 (within box) is
illustrated in Figure 7. Genes illustrated are;
c-abll Abelson murine leukaemia viral oncogene homolog .
c-abl2 Abelson murine leukaemia viral oncogene homolog 2.
c-akt murine thyoma virus oncogene homolog.
BCL1 B cell CLL/lymphoma 1.
BCL2 B cell CLL/lymphoma 2.
c-blyml avian lymphoma virus derived transforming sequence.
DCC deleted in colorectal cancer,
c-elkl member ofETS oncogene family.
c-elk2 member ofETS oncogene family.
c-erb B1 (EGFR) epidermal growth factor receptor, avian erythroblastic leukaemia viral oncogene
homolog.
c-erb B2 avian erythroblastic viral oncogene homolog 2.
c-erg avian erythroblastosis virus E26 oncogene.
c-ervl endogenous retroviral sequence 1.
c-etsl avian erythroblastosis virus E26 oncogene homolog 1.
FAP familial adenomatous polyposis coli.
c-fes feline sarcoma (Snyder-Theilen) viral oncogene homolog.
c-fins colony stimulating factor 1 receptor, McDonough feline sarcoma virus oncogene homolog.
c-fos FJB murine osteosarcoma viral oncogene homolog.
c-Ha-ras Harvey rat sarcoma viral oncogene homolog.
c-hst F1 heraran secretory transforming protein.
ICAM1 intercellular adhesion molecule 1.
c-intl (WNT1) wingless typeMMTV integration site 1, human homolog.
c-int2 murine mammary tumour virus integration site oncogene homolog.
c-jun avian sarcoma virus 17 oncogene homolog.
c-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog.
c-Ki-rasl Kirsten rat sarcoma 1 viral oncogene homolog.
c-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog.
MCC mutated in colorectal cancer,
c-met met proto-oncogene.
c-mos Molony murine sarcoma viral oncogene homolog.
c-myb avian myeloblastosis viral oncogene homolog.
c-myc avian myelocytomatosis viral oncogene homolog.
c-N-ras neuroblastoma RAS viral oncogene homolog.
p53 TP53 tumour protein p53.
c-rafl murine leukaemia viral oncogene homolog 1.
c-rafB2 murine sarcoma viral oncogene homolog 2.
RARA retinoic acid receptor alpha.
RARB retinoic acid receptor beta.
Rb retinoblastoma 1.
c-rel avian reticuloendotheliosis viral oncogene homolog.
c-rosl avian UR2 sarcoma viral oncogene homolog.
c-sis platelet derived growth factor beta polypeptide.
c-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog.
c-ski avian sarcoma viral oncogene.
THRA1 thyroid hormone receptor alpha.
THRB thyroid hormone receptor Beta, avian erythroblastosis leukaemia viral
oncogene homolog. 28
Figure6







































Oncogenes and cancer related genes located on chromosome 17. Genes illustrated
are as follows;
p53 TP53 tumour protein p53.
NF1 neurofibromatosis 1.
c-erb B2 avian erythroblastic viral oncogene homolog 2.
THRA1 thyroid hormone receptor alpha
RARA retinoic acid receptor alpha
TOPOH topoisomerase II.
BRCA 1 breast cancer 1, early onset.
HOX 2 homeobox 2A, 2B, and 2C.
WNT3 wingless typeMMTV integration site 3, human homolog
PBH prohibitin
nm23 non-metastatic cells 1
GH 1 and 2 growth hormone 1 and 2
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mice the presence of the mutated gene was shown to cause mammary carcinoma in a
single step process, as demonstrated by the development of polyclonal tumours at an
early age (Muller et al 1988). Other strains of mice transgenic for neu develop
monoclonal tumours which metastasise, suggesting that the genome of the host
animal may be influential in the development of tumours, and that additional
transforming events may be required in some instances (Bouchard et al 1989).
Meanwhile, DNA cloning studies in man had identified protooncogenes called c-erb
B2 and HER2. Sequencing of neu, c-erb B2 and HER2 established that they shared
an identical sequence (Coussens et al 1985), and the gene was mapped to
chromosome 17q21 (Fukushige et al 1986). Initial studies in human breast cancer
indicated that c-erb B2 was frequently deregulated (Slamon et al 1987), however the
active point mutation identified in rodents has not been found in the equivalent
transmembrane coding region in human breast cancers (Lemione et al 1990). It
remains possible that mutations may occur in other parts of the gene. DiFiore et al
(1987) showed that c-erb B2 protein expression lacked transforming activity in NIH
3T3 cells under the control of SV40 promoter despite detectable levels of c-erb B2
protein. However a further ten fold increase in c-erb B2 protein expression in these
cells under the influence of the long terminal repeat of the Molony murine leukaemia
virus was associated with transformation of the cells. This was an important study as
it indicated the potential for native c-erb B2 involvement in cancer development.
Further studies supported the view that c-erb B2 was involved in growth promotion,
with increased rates of proliferation associated with c-erb B2 overexpression in cell
lines. The proliferation could be inhibited by c-erb B2 protein specific monoclonal
antibodies (Chazin et al 1992).
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1.9.3 Biology of c-erb B2.
C-erb B2 is a protooncogene which encodes for a transmembrane receptor protein
with a high degree of homology to epidermal growth factor receptor (Coussens et al
1985). The receptor is a member of the tyrosine kinase family, and which consists of
an extracellular binding domain, a single transmembrane domain, a single protein
tyrosine kinase domain, and at least one regulatory domain (Bargman et al 1986).
Signal transduction following the binding of a growth factor to its ligand is complex,
and includes internalisation of the receptor/ligand complex (Schlessinger et al 1988),
followed by changes in cytoplasmic biochemistry, illustrated in Figure 8. It is not yet
known if ligands bind to homodimers or heterodimers of c-erb B2 receptor.
Biochemical changes include increases in intracellular cyclic AMP and degradation of
phosphoinositides, which result in a release of calcium ions and the activation of
protein kinase C (reviewed in Rozengurt 1986). Protein kinase C is a protein
modifying enzyme which may influence the transcriptional activity of some genes,
such as c-fos and c-myc (Curran and Franza 1988, Heikkla et al 1987). The c-erb B2
receptor protein is 185 kD in size and is called pl85. Several ligands have been
identified but the importance of the action of pi85 is not understood. GP30, a 30kD
growth factor secreted by MDA-231 cells (Lippman et al 1991) can stimulate
phosphorylation of cells overexpressing c-erb B2 protein and can also inhibit the
binding of specific antibody to c-erb B2 protein (Lupu et al 1990). GP30 can also
bind and activate EGF receptor and inhibit growth of cells which overexpress EGF
receptor (Hudziak et al 1989, Lupu et al 1990). Another potential ligand, heregulin,
is a 45kD protein which specifically induces phosphorylation ofpi 85. It was purified
from breast tumour cell lines (Holmes et al 1992) and is similar to other proteins in
the EGF family. The exact relationship between pi85 , GP30 and heregulin is not
clear, but it is possible that there is a family of receptors for related growth factors.
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Figure 8
Ideogram showing receptor proteins of four members of the c-erb family, epidermal
growth factor receptors (EGFR), c-erb B2, c-erb B3, and c-erb B4 located within the
cell membrane. Receptor ligands represented include epidermal growth factor (EGF)
which is specific for EGFR, and ligands gp30 and heregulin which may bind to c-erb
B2. Ligands may bind to homodimers or heterodimers of c-erb receptors. C-erb B2
ligand binding to c-erb b2 receptor activate a tyrosine kinase pathway which results
in an internalisation of the ligand:receptor complex, followed by changes in
cytoplasmic biochemistry. These changes include increases in cyclic AMP and
















Specific ligands for c-erb B3 and c-erb B4 have not been identified but may include
ligands for c-erb B2.
1.9.4 Existing Studies of c-erb B2 in Clinical Breast Cancer.
1.9.4.1 Introduction. Following the evidence that c-erb B2 was disregulated in
rodent tumours and in a clinical series linking gene amplification with poor prognosis
in breast cancer (Muller et al 1988, Slamon et al 1987), a large number of
retrospective clinical studies were carried out (reviewed in Singleton and Strickler
1992). Studies of clinical samples have either measured c-erb B2 protein by specific
immunohistochemistry or western blotting, assessed c-erb B2 gene amplification by
Southern or dot blotting of DNA, or determined c-erb B2 mRNA concentrations in
RNA extracted from samples by northern blotting. All these studies have examined
the potential link between c-erb B2 disregulation and cancer prognosis.
Contradictory findings have been reported for many clinical associations, and no
clear picture of the involvement of c-erb in cancer prognosis has developed. Tables
1, 2 and 3 list a number of studies and their conclusions. Differences between studies
may include techniques used, population of origin, type and handling of samples and
variable methods of interpretations. It remains clear today that c-erb B2 is frequently
considered to be disregulated in breast cancer, either by gene overexpression or gene
amplification.
1.9.4.2 C-erb B2 Overexpression. C-erb B2 protein (pi85) overexpression in
tissues is usually assessed by immunohistochemistry using specific monoclonal or
polyclonal antibodies. Recent reviews have attempted to correlate the results of the
numerous studies since 1987 which assessed c-erb B2 protein expression
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retrospectively in breast cancer populations (Singleton and Stickler 1992). The
frequency of overexpression varied between 11 and 40%, and was more common in
in situ cancer, with 42 to 61% of these cancers demonstrating positive staining
(Barnes et al 1992, Gusterson et al 1988). The highest frequencies of overexpression
have been found in the comedo subset of in situ cancers (77%), and in Pagets disease
of the nipple (91%) (Alfred et al 1992, Lammie et al 1989). Normal breast tissues do
not appear to overexpress pi85, even in the presence of overexpressing cancer tissue
(DePotter et al 1989, Gusterson et al 1988). Other lesions of the breast, such as
fibroadenoma, fibrocystic breast disease, hyperplasia with or without atypia, and
metaplastic tissue have not shown pi85 overexpression (Alfred et al 1992, Gusterson
et al 1988, Lodato et al 1990), suggesting c-erb B2 expression may act as a marker
of the transition between benign and malignant disease in some breast cancers.
However it remains unclear whether the contribution of c-erb B2 in this process is
causal or a by-product of some other event associated with malignant transformation.
1.9.4.3 Inter-study Variability. The nature of the association between c-erb B2
overexpression and poor prognosis has been complicated by the incomparability of
different studies. Poorer prognosis associated with overexpression has been found in
axillary node positive cancers (Borg et al 1990, Slamon et al 1989) and alternatively
in node negative cancers (Paik et al 1990, Ro et al 1989, Wright et al 1989), and is
absent in other studies (Ali et al 1988b, Barnes et al 1988). Possible reasons for the
discrepancies between studies and the consequent conclusions include differences in
populations studied and in experimental techniques. Some of the details of the
clinical sample study sets used are given in Table 1. Many studies failed to define the
pathological types within their study set (Bacus et al 1990, Schroeter et al 1992,
Walker et al 1989a, Wright et al 1989). Others consisted of selected groups of
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cancers such as node negative (Press et al 1993), in situ cancers (Barnes et al 1988),
or Pagets disease (Lammie et al 1989).
Differences between studies may also arise because immunohistochemistry is
sensitive to differences in experimental technique, particularly to tissue fixation
methods (Doyle and O'Leary 1992). Differences in antigenicity have been found in
frozen and fixed breast tissue (Slamon et al 1989). The antigenicity of pi85 is more
effectively preserved by methacarn fixation than by formol saline (Gusterson et al
1988), however the latter is the fixative used routinely in pathology laboratories.
Studies can also involve tissues from more than one laboratory, and so may include
specimens which have been fixed and processed differently. Direct comparison of
immunohistochemistry results may also be confounded by the subjective nature of
assessing staining intensity. Criteria for scoring results range from presence or
absence of stain (Penault-Llorca et al 1994), percentages of cells with positive
staining (Thor et al 1989), to intensity of staining (Tsutsumi et al 1990). More recent
studies have used computer aided image analysis in an attempt to quantify pi85
protein (Press et al 1993).
The polyclonal antibody, 2IN, is frequently used for immunohistochemical studies of
c-erb B2 (Gullick et al 1987), however specific monoclonal antibodies have been
developed (Mab-145ww, 3B5, 9G6, TA1, pABl ) (Beckman et al 1992, De Potter et
al 1990, Konmoss et al 1990, Tsutsumi et al 1990). These antibodies, directed
against different epitopes of pi85, may have different binding affinities and
contribute to differences in detected frequencies of overexpression between studies.
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Table 1. Some studies which have assessed c-erb B2 overexpression using
immunohistochemical techniques. The number of cases studied (N), antibodies used
and histopathological cancer type varies between studies. Differences were detected
in the frequency of c-erb B2 overexpression between Pagets disease of the nipple,
insitu ductal carcinomas (DCIS), and invasive ductal carcinomas (DCI). Not all
studies assessed prognostic value, but in those which did, most found an association
between poor prognosis and c-erb B2 overexpression. Others found no association,

























































































1.9.4.4 C-erb B2 Expression and Cellular Proliferation. In vitro studies of
breast cancer cell lines have shown an association between c-erb B2 overexpression
and cell proliferation (DiFiore et al 1987), however the relationship between these
factors in clinical cancers may not be a simple one. Comedo type in situ cancers have
both high levels of c-erb B2 overexpression and a high rate of proliferation (Barnes
et al 1988). However, attempts to correlate c-erb B2 overexpression with cellular
proliferation in invasive cancers have failed to demonstrate a direct relationship (Ro
et al 1989). Therefore the association of c-erb B2 activity with increased
proliferation found in cultured cell lines, may not apply to all clinical cancers. C-erb
B2 overexpression does not appear to be associated with changes in DNA ploidy as
only weak associations with aneuploidy have been reported (O'Reilly et al 1991, Ro
et al 1989)
1.9.5 C-erb B2 Gene Amplification.
1.9.5.1 Clinical Studies. Approximately 25% of invasive breast cancers contain c-
erb B2 gene amplifications, although detection frequencies varied between studies
from 9.1 to 33% (Clark et al 1991, Meyers et al 1990), see Table 2. Differences
between study populations are similar to those discussed for c-erb B2 overexpression
(section 1.9.4.3). Technical restrictions also apply to studies of gene amplification,
usually measured by Southern or dot blotting. These techniques require relatively
large quantities of DNA and are therefore biased towards larger cancers and low
copy number amplifications may not be detectable if there is a significant contribution
of normal DNA from a cancer (Ali et al 1988a). Gene amplification is generally
assessed using radio labelled probes, specific for c-erb B2, which are hybridised to
total sample DNA contained on a dot or Southern blot. The quantification of gene
copy number is made by comparing the radiation signal intensity of the c-erb B2 test
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Table 2.
Some studies which have assessed c-erb B2 gene amplification by either Southern
blotting (S) or dot blotting (D) techniques. Differences between studies include
number of cases studied (N), and cancer population studied. The percentages of
cancers with c-erb B2 gene amplifications varied between studies, as did the















































gene with that of a control single copy gene, such as collagen genes (Venter et al
1987), tubulin (Corbett et al 1990), p53, or myeloperoxidase (Slamon et al 1989).
The majority of c-erb B2 gene amplifications in invasive breast cancers are small, in
the order of 2 to 4 extra copies of the gene (Borg et al 1990), however,
amplifications greater than 40 copies have been recorded in some invasive cancers
(Ali et al 1988, Berns et al 1992, Tavassoli et al 1989). It is not known whether the
degree ofgene amplification or the basic amplification mechanism is significant in the
biology of breast cancer, therefore an understanding of factors involved, whether
active (promoting amplification) or passive (allowing amplification to occur) is
important. C-erb B2 can also be amplified in situ cancers (Liu et al 1992) but
amplification has not been detected in benign lesions (Smith et al 1994).
1.9.5.2 Gene Amplification Mechanisms. For most clinical cases the region of
DNA included in an amplification unit, which includes c-erb B2, on chromosome 17
is not known. Amplifications of DNA segments including several loci on
chromosome 17 have been observed in three of six invasive cancers with c-erb B2
amplification (Keith et al 1993). The amplified region included genes for
topoisomerase II and retinoic acid alpha receptor and the thyroid hormone receptor
gene (THRA1), all these genes have the potential to contribute to the malignant
phenotype (Keith et al 1993). Retinoic acid and THRA1 are nuclear receptors whose
functions include promotion of gene transcription (Bollag and Holdener 1992, Damm
1992). Topoisomerase II is an enzyme which can catalyse breakage and rejoining of
DNA, and may be involved in basic cellular processes such as DNA repair, and
chromosome replication (Liu 1989). This suggests that this region of DNA contains
other important genes which may have a potential role in oncogenesis. That
amplification of retinoic acid receptor, THRA1, and topoisomerase II have not been
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observed in the absence of c- erb B2 amplification (Keith et al 1993, Tavassoli et al
1989, Tsuda et al 1989) may suggest that c-erb B2 is an essential gene within this
region. This important point has not been adequately tested, and it remains possible
that another critical gene is co-amplified with c-erb B2. However, the transforming
activity of c- erb B2 in vitro (DiFiore et al 1987) and in transgenic animals (Muller et
al 1988) would suggest that c-erb B2 is a relevant target. For most clinical cancers
the physical nature of gene amplification is not known, although models of gene
amplification, discussed above (section 1.6.4), would predict that amplifications are
present as either extended chromosomal regions or extra-chromosomal elements
(Stark et al 1989). In situ hybridisation on metaphase spreads of some breast cell
cultures, incorporating c-erb B2 probes, have shown that the amplified copies of the
gene are integrated at many sites in several rearranged chromosomes (Smith et al
1994), indicating that the new c-erb B2 copies may occur in abnormal locations.
Whole chromosome duplication does not appear to be a major factor in c-erb B2
amplification (Paterson et al 1990, Tsuda et al 1989).
1.9.5.3 C-erb B2 Messenger RNA. The presence of elevated levels of pi85 on
cancer cell membranes could be the result of different disregulatory mechanisms,
such as posttranslational protein folding, the presence or absence of ligand, or
increased gene transcription. The concentration of c-erb B2 mRNA within clinical
samples of breast cancer is estimated by reaction of extracted RNA in Northern blots
using radio labelled c-erb B2 cDNA probes. Also, excess c-erb B2 mRNA can be
detected within tissue sections by reactions of these probes by in situ hybridisation.
Excess c-erb B2 mRNA has been detected in 30 to 43% of invasive breast cancers
(May et al 1990, Parkes et al 1990), and in 61% of invasive breast cancers with
lymphocytic infiltration (inflammatory cancers) (Guerin et al 1989).
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Studies which concurrently assessed c-erb B2 gene amplification and mRNA found
that gene amplification could only be clearly detected in approximately half those
cancers where excess mRNA was apparent (Guerin et al 1989, King et al 1989,
Parkes et al 1990). This suggests that transcriptional control mechanisms and not
gene amplification may be responsible for excess mRNA in a proportion of breast
cancers. In addition, mRNA production is not always in proportion to the c-erb B2
copy number (King et al 1989) indicating that abnormal transcriptional control
mechanisms may also be active in the presence of gene amplification.
1.9.5.4 Combined Studies of c-erb B2 Gene Amplification and
Overexpression. Table 3 lists those studies which matched the results of c-erb B2
gene amplification and pi85 overexpression in individual invasive breast cancers. In
three large studies, approximately eighteen percent of breast cancers showed both
amplification and overexpression (Borg et al 1990, Ciocca et al 1992, Slamon et al
1989). However, recent studies detected greater frequencies of overexpression (up
to 50%) and amplification (up to 38%) (Iglehart et al 1990, Kerns et al 1990). These
high frequencies may reflect technical improvements, such as the use of more
sensitive antibodies.
These results suggest that the majority of c-erb B2 gene amplifications may lead to
functional expression of the protein. However, the data also suggest that a
proportion of cancers which overexpress pi 85 may not show gene amplification
(Borg et al 1990, Iglehart et al 1990, Kerns et al 1990), and conversely, amplification
can occur without overexpression (Ciocca et al 1992, Uehara et al 1990). This
suggests that for some cancers, mechanisms which turn on or off genes are likely to
play an important role in the effect of c-erb B2 in breast cancer. The direct
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Table 3. Some studies which have compared c-erb B2 gene overexpression and c-
erb B2 gene amplification. N= cases studied
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relationship between c-erb B2 expression and c-erb B2 gene amplification remains
unclear, due to the inconsistent findings between studies. This thesis aims to clarify
this relationship with the development of better methods of detecting gene
amplification, see below.
1.9.6 Differential PCR.
A sensitive determination of gene amplification in an unbiased breast cancer
population is necessary for an informed analysis of the role of c-erb B2 in breast
cancer. Improved sensitivity may be possible by adapting the polymerase chain
reaction (PCR) for the detection of gene amplification in fixed breast cancer tissues.
A major advantage of this technique is that all cancers, including those too small for
analysis by Southern blotting, can be tested for gene amplification.
The polymerase chain reaction (Saiki et al 1988) has facilitated detailed study of
specific genes, and has been further developed to detect gene amplifications (Frye et
al 1989). The standard polymerase chain reaction cannot be regarded as quantitative
due to the exponential nature of the reaction and high sensitivity to minor changes in
reaction conditions (Saiki et al 1988). Differential PCR was developed to
semiquantify gene copy numbers in breast cancer (Frye et al 1989), using cell lines
with a known amplification of several genes, including c-erb B2 and the epidermal
growth factor receptor. The technique involves co-amplification of a single copy
reference gene with the target gene within one reaction tube. An estimation of gene
copy is indicated by the ratio between the quantities of the two PCR products. The
differential PCR developed by Neubauer et al (1992) used a complex algorithm of
four different differential PCR reactions for detection of c-erb B2 amplification in
fixed breast tissue. Using this method, Liu et al (1992) detected amplification of c-
erb B2 in 25 of 122 node positive invasive cancers (21%), and 13 of 27 in situ
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cancers (48%). Using a one step differential PCR, c-erb B2 amplification was
detected in 40% of ovarian cancers (Hruza et al 1993), compared to the 3 to 21%
previously found by Southern blotting analyses (Imayanitov et al 1992, Zhang et al
1989). This indicates that dPCR can be a very sensitive method of detecting gene
amplification in cancers, in a wide range of clinical samples.
1.9.7 C-erb B2 and Cancer Progression.
The role of c-erb B2 in breast cancer initiation and progression remains unknown.
Inconsistencies between studies and lack of information on its biological functions,
make its contribution to cancer biology difficult to assess and there remains
confusion over its prognostic significance. A model of cancer progression involving
c-erb B2 has been proposed by Allred et al (1992). They hypothesised that c-erb B2
plays an important role in initiation of breast cancer, and that overexpression
decreases within individual tumours as they evolve from in situ to invasive lesions;
alternatively he suggests that many invasive carcinomas arise de novo, without an in
situ stage, and not involving deregulation of c-erb B2.
The identification of "early" and "late" events in cancer progression has been difficult
due to the considerable heterogeneity of breast cancer. However, histopathological
features such as type, grade, lymph node status and size, along with biochemical
features such as oestrogen receptor status (see section 1.11) may form a
chronological framework. The relationship between these features and c-erb B2
deregulation will be addressed in this thesis, with a view to assessing the role of




The contribution of c-erb B2 to stages of breast cancer progression may be due to
molecular mechanisms which switch on and off gene expression. Nuclear receptors,
in particular oestrogen receptors, may be directly or indirectly involved in the
regulation of c-erb B2 expression. Another nuclear receptor, the thyroid hormone
receptor can be co-amplified with c-erb B2.
Genes and their products which influence the activation or suppression of other
genes are known to be important in the development of the malignant cell phenotype.
One major family of such genes, known as trans acting genes, are the nuclear
receptor genes, including the genes for steroid receptors, thyroid hormone receptor
(THRA1, also known as c-erb A) and vitamin D receptors (King 1992).
1.10.2 Nuclear Receptor Biology.
The products of nuclear receptor genes generally operate within the nucleus of the
cell (reviewed in King 1992). When complexed with their ligand, they can directly
influence the transcription of target genes. Nuclear receptor genes all encode proteins
of a similar basic structure, with a carboxyl terminal region which binds ligand, a
transactivation region and a DNA binding region which binds the target gene DNA.
The active portion of the latter region consists of an amino acid sequence capable of
binding zinc ions in two loops, known as zinc fingers. Nuclear receptors become
active upon binding their specific ligand. The receptors then shed their associated
heat shock proteins (hsp) allowing the receptor to perform DNA binding. The
receptors can bind to target DNA via recognition sites within the zinc finger, but the
method of alteration of transcriptional control is presently unknown. It is possible
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that the transactivation region becomes capable of stabilising general transcription
factors, such as TFIID, following DNA binding (O'Malley et al 1990). DNA binding
is also associated with receptor dimerization and tetrameric structures are also
known to occur (Tsai-Pflugfelder et al 1988).
1.10.3 Nuclear receptor zinc fingers.
Zinc fingers consist of a region of up to 30 amino acids formed into two loops which
co-ordinate a zinc ion within the centre of each loop. These amino acid regions are
highly conserved between receptors and are critical for DNA binding specificity
(Mader et al 1989), positive control of transcription (Schena et al 1989) and DNA
dependant dimerisation (Umesono et al 1989). Small groups of amino acids within
these loops have specific functions such as binding to the phosphate backbone of
DNA and binding to specific DNA bases. It is suggested that alterations in zinc
finger sequences may play a part in altered receptor function in dysfunctional cells
(Freedman and Luisi 1993). For example, mutations in the DNA binding region of
the vitamin D receptor are associated with reduction of receptor activity and
consequent hereditary rickets (Hughes et al 1991). Similarly, mutations in the DNA
binding region of the androgen receptor are present in patients with testosterone
insensitivity syndrome (Trapman and Brinkman 1993). It is therefore possible that
other mutations in the DNA binding region of other nuclear receptors, such as
THRA1 or oestrogen receptor, may decrease or increase the consequent action of
the target gene, or may alter the specificity of the DNA binding region for its target
gene site.
1.10.4 Response Elements.
Nuclear receptors bind to specific cis-acting DNA sequences, called response
elements, usually located within the promoter region of target genes (Damm 1992).
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Table 4.














The response elements that react with different nuclear receptors all have a similar
DNA structure, consisting of two hexameric half-sites separated by three DNA
bases. Although the sequences of the half-sites vary considerably in nature, consensus
sequences for some receptors have been determined (King 1992) and are shown in
Table 4. The consensus thyroid receptor response element is clearly identical to the
oestrogen receptor element, minus three intervening bases (Glass et al 1988).
Although these consensus sequences are not fixed (some consensus sequences
include only one n base between the thyroid receptor element half-sites) there is
clearly a great deal of similarity between the response elements to which nuclear
receptors bind (O'Malley et al 1990). The palindromic nature of the response
elements indicate that receptors are bound as dimers. Alteration in the number of
intervening bases between the half-sites of the response element can inhibit
dimerisation of the respective receptor (Freedman and Luisi 1991), probably due to
altered spatial interactions between the two molecules.
Regardless of the similarity of their response elements, receptors remain able to
discriminate between different target genes, even when response elements differ by
only two base pairs, as do glucocorticoid and oestrogen receptor response elements.
The ability of each receptor to specifically discriminate is determined by the identity
of three amino acids in the DNA binding region of the first zinc finger (Danielson et
al 1991, Mader et al 1989, Umesono et al 1989). It is also possible that response
elements are not the only mechanism for interaction between receptors and DNA
sequences. The production ofmRNA of the oncogene c-myc can be up-regulated by
the presence of oestrogen and consequent oestrogen receptor activity in cancer cells
(Dubik et al 1992). However, analysis of the c-myc promoter region in these cells,
did not locate a response element corresponding to known receptor response
elements, see above. It is possible therefore, that in addition to the mechanisms
outlined above nuclear receptors can act on oncogene DNA sequences with no
homology to recognised response elements.
1.11 Oestrogen receptors.
Oestrogen has a major hormonal role in the normal and cancerous breast (Anderson
1989, Hulka et al 1994). The association of oestrogen hormones with cancer risk
indicate that hormonal status can be important in the aetiology of breast cancer
(Hulka et al 1994) as discussed previously (section 1.3.4). Oestrogen receptors are
typical nuclear receptors and are present in 6 to 10 % of normal breast epithelial
cells, but in reduced concentrations after menopause (Petersen et al 1987). Many
invasive cancers have detectable levels of oestrogen receptor, and such cancers are
generally thought to have a better prognosis (Habel and Stanford 1993). However,
approximately 40 percent of invasive breast cancers have no detectable oestrogen
receptors (Habel and Stanford 1993). Anti-oestrogen therapy, such as tamoxifen, is
currently used to treat oestrogen receptor positive breast cancers, and a good
response to treatment is anticipated (Early Breast Trialists Collaborative Group
1992). Tamoxifen competitively binds to oestrogen receptors, reducing the cell
growth response associated with the action of oestrogen on breast cancer cells.
Tamoxifen binding does not inhibit receptor binding to its response element, but does
inhibit its transactivating functions (Fuqua 1994).
The heterogeneity of oestrogen receptor concentration and differing responses to
hormonal treatment suggests that there may be many ways in which oestrogen and
1994). Indeed oestrogen and oestrogen receptor are involved in a complex pathway,
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which includes the conversion of oestrone to oestradiol, the binding of oestrogen to
oestrogen receptor in the cell nucleus, and the binding of this complex to oestrogen
response elements in target genes, resulting in a block or enhancement of gene
oestrogen receptor can be disregulated in breast cancer (Fuqua 1994, Hulka et al
transcription (Hulka et al 1994).
It is possible that oestrogen receptors are lost during carcinogenesis (Malet et al
1989), however the loss of oestrogen receptors is not thought to be due to deletion
of the relevant gene (Piva et al 1988). The loss may be due to reduced transcription
of the gene following its methylation or mutation, or to defective transcriptional
mechanisms. Oestrogen receptor variants have been reported in a small number of
breast cancers (Murphy and Dotzlaw 1989) and may be due to post-translational
mechanisms such as alternative splicing (Miksicek et al 1993). Mutations have been
found within the receptor coding region of the gene in clinical breast cancers (Fuqua
et al 1991), indicating that some cancers may have non-functional oestrogen
receptors.
Target genes for oestrogen receptor action may also be important, however few
specific target genes have been identified for oestrogen receptor. Studies in cultured
cells have identified transforming growth factor alpha, transforming growth factor
beta, insulin like growth factor 1, and somatomedin C as potential target genes
(Barrett-Lee 1991), however there are likely to be many more. The up-regulation of
gene transcription by an oestrogen-oestrogen receptor complex may increase cellular
proliferation (Barrett-Lee 1991) therefore genes which have proliferative functions
may be potential targets. A positive association between c-erb B2 overexpression
and absence of oestrogen receptor has been observed in some breast cancer studies
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(Borg et al 1990, Tandon et al 1989), although other studies have found a less clear
cut correlation (May et al 1990, Gullick et al 1991, Slamon et al 1987, Zeillinger et al
1989). The relationship between oestrogen receptor status and both c-erb B2 gene
amplification and overexpression is addressed in this thesis.
1.12 THRA1.
Another nuclear receptor, the thyroid hormone receptor gene alpha (THRA1), has
been associated with deregulation of c-erb B2, however this association is a physical
association involving co-amplification of both genes in some breast cancers
(Tavassoli et al 1989). The THRA1 gene (C-erb Al) codes for the thyroid hormone
receptor, and is located closely distal to c-erb B2 on chromosome 17 (Laudet et al
1991), both being assigned to the same band, 17q21. The thyroid receptor has a
typical nuclear receptor structure and mode of action.
The oncogenic potential of THRA1 was first established in its viral counterpart v-erb
A, a mutant form of the THRA1 gene which alters the neoplastic phenotype of
erythroid cells transfected with the avian erythroblastosis virus (Glass et al 1988,
Graf and Beug 1983). v-erb A enhances the activity of v-erb B in transformation of
avian erythroid cells, but can not transform cells without the presence of v-erb B
(Damm, 1987).
Breast cancers can have amplification units containing both c-erb B2 and THRA1,
however a functional relationship between these genes has not been demonstrated in
human breast cancer. Attempts to measure THRA1 mRNA in c-erb B2-THRA1
amplified cancers have failed to show any increase (Tavassoli et al 1989), suggesting
that gene transcription does not occur even in the presence of increased gene copy
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number. In addition, THRA1 is always amplified with c-erb B2 and is never present
as a single gene amplification unit (Tavassoli et al 1989, Tsuda et al 1989). This may
suggest that amplification of THRA1 is coincidental and that selection pressure may
be relevant to only to c-erb B2 or another local gene. However it remains possible
that mutations may exist in the THRA1 gene in breast cancer. This thesis
investigates potential co-amplification of THRA1 with c-erb B2, and examines the
zinc finger coding exons ofTHRA1 for functional mutations.
1.13 Other Factors
As previously discussed, nuclear receptors and oncogenes may be involved at a
fundamental level of the oncogenic process, switching on or off target genes which
may contribute to the malignant phenotype. In addition, there are many other
biological indicators of cancer progression. Diverse enzymes are produced by
malignant cells and are implicated in cancer cell invasion and include: collagenases
(Stetler-Stevenson 1990), stromelysins (McDonnel and Matrisian 1990); cathepsin B
(Sloane et al 1990); cathepsin D (Rochefort et al 1990); heparinase (Nakajima et al
1987); and urokinase plasminogen activator (Testa and Quigley 1990). These
enzymes, usually proteases, may play a role in metastatic dissemination of cancer
cells by contributing to basement membrane and connective tissue degradation.
Other important genes are those which code for transcriptional regulators of
proteases, such as the tissue inhibitor of metalloproteases (TIMP) (McDonnel and
Matrisian 1990), oestrogen receptor (Hendry et al 1990), PAI 1, PAI 2 and protease
nexin (Hart and Rehmtulla 1988). A recently discovered serpin, called maspin, may
also be a protease inhibitor (Zou et al 1994). Maspin is produced in mammary
epithelial cells, but is absent in breast cancer cells, involved lymph nodes and distant
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metastasis, suggesting that it may have tumour suppressing activities (Zou et al
1994).
Cathepsin D, an acidic lysosomal protease, is produced and secreted by breast cancer
cells. High concentrations of cathepsin D have been associated with lymph node
metastasis and suggested as a marker of poor prognosis (Brouillet 1990). However,
expression of cathepsin D protease is inducable by oestrogen, may be associated with
prolonged survival in oestrogen receptor positive breast cancers (Henry et al 1990).
Stromelysin 1, 2 and 3 represent a family of related metalloprotease genes, they can
be overexpressed in breast cancer cells (McDonnel and Matrisian 1990). Expression
of stromelysins may not be restricted to cancer cells, indeed stromelysin 3 can be
expressed in fibroblastic cells of tumour stroma immediately surrounding cancer cells
(Basset et al 1994).
Amongst such genes is that coding for urokinase plasminogen activator (uPA) which
is frequently overexpressed and associated with aggressive behaviour in breast cancer
cells (Duffy et al 1988, Janicke et al 1990). Disregulation of uPA, whether directly
by physical alteration to the gene structure or indirectly, via transcriptional
mechanisms may play an important role in the metastasis of the malignant cell.
1.13.1 Urokinase Plasminogen Activator.
Urokinase Plasminogen activator (uPA) is one of a family of plasminogen activators
which includes tissue type plasminogen activator (tPA). Both are involved in the
breakdown of the extracellular matrix and may play a role in the promotion of
cellular dissemination (Sumiyoshi et al 1991). However, analysis of tPA and uPA
concentrations in breast cancer has indicated that it is uPA rather than tPA which is
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involved in lymphatic dissemination (Yamashita et al 1993). Several large studies
have observed an association between the presence of uPA and aggressive behaviour
in breast cancer (Foekens et al 1992, Grondahl-Hansen et al 1993, Janicke et al
1990). The mode of action of uPA has been intensively studied and several
transcriptional control mechanisms have been identified (Saksela and Rifkin 1988).
1.13.2 Biology.
uPA is a serine protease enzyme present in the cytoplasm of epithelial cells. A single
high molecular weight chain forms a proenzyme precursor, which is converted to an
active two chain uPA (chain A and B) by plasmin cleavage of a peptide bond
(Schmitt et al 1992). Conversion to the two chain form may take place after the
binding of the single chain form to its cell surface receptor, which is a highly
glycosylated protein anchored to the plasma membrane (Schmitt et al 1992). This
bound complex is more active than free uPA in degradation of the extracellular
matrix (Hearing et al 1988, Ossowski 1988, Schlechte et al 1989).
Single chain, double chain, and receptor bound uPA are all active forms of the
enzyme, and can convert plasminogen to plasmin, which can degrade proteins of
extracellular tumour stroma (Saksela and Rifkin 1988). uPA can also activate
procollagenase which in turn degrades collagen and basement membrane proteins
(Murphy et al 1992). These abilities suggest that uPA could be involved in the




The gene for uPA is 6,387 nucleotides long and consists of eleven exons separated
by ten introns (Riccio et al 1985). uPA has been localised to the distal third of the
long arm of chromosome 10 (q24-qter)(Tripputi et al 1985). Several promoter or
enhancer regions have been identified in the 5' flanking sequence of the gene
(Cassady et al 1991, Riccio et al 1985). Multiple weak cis-acting (promoter or
enhancer binding) elements are distributed over a large portion (7kb) of the 5'
flanking sequence (Cassady et al 1991). This indicates that transcription of uPA may
be under the influence of many promoter and enhancer elements. Post translational
mechanisms may also regulate the concentration and activity of uPA in breast cancer
cells, perhaps by increased stability ofmRNA (Henderson et al 1992).
1.13.4 Clinical Significance.
Initial indications that uPA may be involved in the carcinogenic process came from
experiments on human ovarian cancer cells, which released uPA into the culture
medium (Astedt et al 1976). Elevated uPA has been reported in affected tissues in
colon (Corasanti et al 1980), lung (Markus et al 1980), prostate (Camiolo et al 1981)
and breast cancers (Duffy et al 1988, Evers et al 1982, Foekens et al 1992, Janicke et
al 1990). In breast cancer the rise in plasminogen activator is solely due to a rise in
uPA and is not associated with the tissue form of plasminogen activator (Layer et al
1987). Immunohistochemical and biochemical studies on breast cancers have shown
that overexpression of uPA occurs in cancer cells but not in the surrounding stroma
(Duffy et al 1988, Foucre et al 1991, Janicke et al 1990), or in normal cells, except
for macrophages (Pyke et al 1993). uPA immunohistochemical staining is generally
localised to the cell membrane and the cytoplasm and is usually present diffusely
throughout affected malignancies(Janicke et al 1990). Metastatic cells appear to
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have a similar concentration of uPA to those in the primary lesion (Janicke et al
1990).
Different frequencies of overexpression and different quantities of uPA have been
observed in breast cancer studies. Expression of uPA has been detected in 28% to
100% of breast cancers using immunohistochemical techniques (Clavel et al 1986,
Janicke et al 1990) for elevated uPA. uPA concentrations measured by ELISA in
cancer cell cytosols have also shown increased uPA concentrations, varying from
four to nineteen times greater than normal breast tissue (Duffy et al 1990, Foucre et
al 1991, Janicke et al 1990, Sumiyoshi et al 1991). Consequently studies which
examined possible associations between elevated uPA and clinical markers of cancer
aggression in breast cancer have found variable or no correlations. Positive
correlations with cancer size and number of axillary nodes with metastasis were
found in one study (Duffy et al 1990) but not in others (Foucre et al 1991, Janicke et
al 1990).
The biological consequences of elevated uPA may therefore depend on other factors
such as the presence of specific inhibitors of uPA within cancer cells and the
concentrations of uPA receptors on the cell surface (Yamashita et al 1993). uPA
activity can be controlled by the inhibitors PAI-1, PAI-2, PAI-3 and protease nexin
(reviewed in Hart and Rehemtulla 1988), and some breast cancers show highly
increased levels of PAI 1 and 2 (Foucre et al 1991). Maximum uPA activity may
also require the presence of uPA specific cell surface receptors (Ossowski et al 1992)
which can be present in increased concentrations in invasive cancers (Del Veccio et
al 1993, Pyke et al 1993). The inhibitory and enhancing affects on uPA by other
factors, means that no clear conclusion about the controlling influences on uPA in
breast cancer is possible. Deregulation may occur in the uPA gene, as well as the
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many other factors that can promote or inhibit its action. Gene amplification, as a
possible mechanism for uPA deregulation, is examined in this thesis using differential
PCR (see section 1.9.6), and related to uPA protein expression measured
immunohistochemically. The potential effects on uPA expression by oestrogen
receptor status and c-erb B2 expression will be explored.
1.14 Aims.
Many important questions in breast cancer progression remain unanswered,
particularly those pertaining to the genetic events which give rise to different
pathologies, and different prognostic outcomes. Models of cancer development could
include one or more initiating events, with diverging or converging pathways of
genetic consequences which may share common disregulatory events. Difficulties
arise in identifying early through to late stage developments in breast cancer. The
early stages of cancer development may be better detected in a screened population,
where cancers may be detected before they become symptomatic. Accordingly this
thesis addresses the following unresolved problems:
1. Critical determination of c-erb B2 gene amplification, using differential PCR, and
overexpression (Chapters 2 and 3).
2. Investigate the relationship between c-erb B2 gene amplification and clinical and
pathological features of breast cancers (Chapter 4).
3. Investigate the relationship between oestrogen receptors and c-erb B2
amplification and overexpression (Chapter 4).
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4. Examine possible allelic imbalance of c-erb B2 in c-erb B2 amplified tissues
(Chapter 5).
5. Examine the THRA1 gene for possible mutations of functional significance
(Chapter 6).








Since the publication of a study linking c-erb B2 to poor prognosis in breast cancer
patients (Slamon et al 1987), many studies have examined c-erb B2 gene
amplification, as measured by Southern or dot blotting (reviewed in Perren 1991;
Singleton and Strickler 1992). However there are major differences between studies
in the association of c-erb B2 disregulation with histopathological features and with
prognosis, therefore its involvement in cancer development and progression is
difficult to determine. It is not clear whether differences in results between studies
have been due to variations in sample selection, experimental technique or to genuine
disparity between populations of biological relevance. It is therefore important to
establish robust and accurate techniques with which to measure gene disregulation.
Of the techniques for measuring gene amplification, Southern and dot blotting suffer
from the disadvantage of requiring microgram quantities ofDNA for analysis. Tissue
morphology is also destroyed in the extraction process. The development of
polymerase chain reaction (PCR) technology has made possible the molecular
analysis of minute quantities of DNA (Saiki et al 1988). The PCR reaction consists
of repeated cycles of heating to over 90°C denaturing target DNA to single strands,
annealing (hybridisation) of specific oligoprimer DNA segments to the target gene
and extension of the remaining DNA segment by thermoactive DNA polymerase,
resulting in precise duplication of the target sequence, illustrated in Figure 9.
However, accurate quantitative measurement of gene copy number is compromised
by the sensitive and exponential nature of the PCR reaction. The concentration of
PCR amplified DNA is defined by the equation x= I(l+E)n, where x is the
concentration of PCR amplified DNA, I is the concentration of target DNA prior to
PCR, E is the average efficiency for each cycle, and n is the number of thermal
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amplification cycles. The efficiency of the reaction can theoretically range from 0 to
1, and can be affected by parameters such as the temperature of annealing,
concentration of primers or template DNA, the formation of secondary DNA
structures, primer-primer bonding or inhibition. The quantity of PCR products can
also vary between duplicate DNA samples using the same concentrations of reagents
and identical cycling parameters (Gilliland et al 1990), due to minor differences in
template/reaction mixture concentrations or minor differences in thermal profiles
between samples. The efficiency of primers binding to the DNA template appears to
be a critical factor in determining the final quantity of PCR product (Sugimoto et al
1993). To overcome this clear drawback of PCR for measurement of gene
amplification, a semi-quantitative estimation of gene copy number using a differential
PCR for DNA in cell lines was developed (Frye et al 1989). Differential PCR
introduces an internal control into each reaction tube i.e. a known single copy gene is
co-amplified with the test gene. The ratio between the intensity of detectable bands
produced from each gene is calculated, which can give an estimation of the test gene
copy number. Differential PCR has been extended to the analysis ofDNA extracted
from fixed, paraffin processed breast cancer tissue (Liu et al 1992, Neubauer et al
1992) however, this technique is not yet fully characterised for clinical samples,
indicating that validation of dPCR is required for each new gene application.
Optimal template DNA preparation is important for PCR analysis. Previous methods
of preparing formalin fixed tissue for PCR have included various procedures such as
dewaxing, proteinase K digestion and phenol/chloroform extraction (Goelz et al
1985, Jackson et al 1990, Shibata et al 1992, Wright and Manos 1990). Methods
employing proteinase digestion of tissues are time consuming (e.g. 5 day incubations,
Jackson et al 1990) and those employing freeze-thaw cycles (Wright and Manos
1990) may partially destroy valuable DNA. Breast cancer tissues in this study were
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Figure 9
An ideogram of the polymerase chain reaction, illustrating specific sequence
amplification. Double stranded template DNA (1) is denatured at 94oC (2), specific
primers anneal to template DNA at 50°C (3), and Taq polymerase extends the DNA
sequence at 72°C, resulting in a duplication of the original sequence. Products
increase at an exponential rate throughout the thermal cycle course (B) until one or























fixed in methacarn, a fixative known to preserve DNA (Doyle and O'Leary 1992,
Jackson et al 1990). However, DNA preparation of methacarn fixed tissue for PCR
has not been fully explored.
This chapter explores the sensitivity of differential PCR in detecting an increased c-
erb B2 gene copy number in cell lines. Differential PCR is a relatively new technique
and factors, such as primer efficiency, reagent concentrations, and DNA template
concentration, are unknown variables within the reaction. The application of dPCR
to fixed, paraffin embedded tissue requires an investigation of optimal DNA
preparation methods. Possible inaccuracies introduced ffom fixed tissue, such as
degraded DNA or possible alteration of the gene copy number of the reference gene
also need to be investigated.
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2.2 MATERIALS AND METHODS
2.2.1 DNA Samples.
2.2.1.1 Test Samples. Breast cancer tissue was obtained fresh at the time of
operation from samples removed for biopsy or mastectomy. Excess fat was trimmed
and selected portions of each cancer were snap frozen in liquid nitrogen and stored at
-70°C; adjacent portions were fixed in methacarn (6:3:1 methanol:chloroform: acetic
acid) overnight at 4°C for subsequent processing in alcohol and xylene by standard
methods and embedded in paraffin blocks. Samples used for optimisation of
experimental protocols varied between experiments due to the limited quantity of
tissue available for study.
2.2.1.2 Control DNA. Control DNA derived from normal human placenta (p258)
was a kind gift of Dr. E. Thompson, MRC Human Genetics Unit, Edinburgh.
Normal human female DNA derived from placental chorionic membrane, was also
obtained commercially (Sigma, UK). Both Sigma and p258 control DNAs would be
expected to have a single copy of c-erb B2. Throughout this thesis the term single
copy is used to mean one gene per haploid genome. It is understood that normal
cells will therefore possess 2 c-erb B2 genes, on the homologous pair of
chromosome 17. Control tissues were also obtained from fresh breast tissue distant
to the lesion site or from non-cancer bearing breasts. These were fixed in methacarn
and processed as above.
2.2.1.3 Cell Lines. Human breast cancer cell lines known to have c-erb B2
amplification were used to calibrate the relationship between differential PCR ratio
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values and gene copy number. The epithelial cell line 21MT2 was obtained from Dr
R. Sager, Dana-Farber Cancer Institute, Boston, MA. and contains a 40 fold
amplification of the c-erb B2 gene (Band et al 1989). The cell line UISO BCA1 was
obtained from Dr R.R Mehta, the University of Illinois, Chicago, IL. and contains a
10 fold increase in the c- erb B2 gene (Sasi et al 1991). MCF7, a cell line derived
from breast carcinoma epithelial cells was obtained from Gibco, U.K. MCF7 is
reported to be hemizygous (Frye et al 1989), i.e. has a "half gene dosage" of c-erb
B2 in the nomenclature adopted here.
Each cell line was cultured from cryo-preserved cell stocks at 37°C in air with 5%
CC>2 added. 21 MT2 was cultured in alpha MEM (Gibco) containing 10% foetal calf
serum, 2mM L-glutamine, ImM sodium pyruvate, 0.1 mM non essential amino acids,
1 pg/ml insulin, 2.8 p.M hydrocortisone, 12.5ng/ml epidermal growth factor and
lOmM HEPES. UISO BCA1 and MCF7 were cultured in GMEM (Gibco), 10%
foetal calf serum and 2mM L-glutamine, with supplementary oestrogen (lOng/ml,
Sigma, U.K.) for MCF7 only.
2.2.2 DNA Preparation and Concentration.
2.2.2.1 Frozen Tissue and cell lines. For DNA preparation from frozen breast
tissue samples, approximately one gram of tissue was removed, chopped and
pulverised while frozen, then immersed in 0.1ml of a digestion buffer, Tris-SDS-
proteinase K, pH 7.5 (see Appendix 2) and incubated for 18h at 37°C. DNA was
extracted by standard phenol/chloroform extraction (Sambrook et al, 1989),
precipitated on addition of 0.1 volume of 5M sodium acetate, and 2 volumes of cold
absolute ethanol (see Appendix 2), washed twice in 70% ethanol and dried under
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vacuum. DNA was reconstituted in 0.01M Tris-EDTA buffer, pH7.6 (see Appendix
2) to a final concentration of lmg/ml.
Cell lines MCF7, UISO BCA1 and 21MT2 were harvested from semi-confluent
monolayer cultures in exponential growth phase by removal of media and addition of
5% Trypsin in phosphate-buffered saline (Gibco,U.K.). After trypsinisation for 5
minutes at 37°C, cells were removed and washed twice in Tris buffered saline (see
Appendix 1). DNA was extracted from the washed cells using digestion buffer as
described above.
All the above DNA concentrations were measured in a Beckman spectrophotometer,
at 260nm extinction in quartz cuvettes.
2.2.2.2 Paraffin embedded tissues. Methods of DNA extraction from paraffin
embedded breast tissue have not been previously standardised for use in quantitative
assessment of gene dosage, therefore three different methods were investigated.
They are fully described in section 2.3.1 of results and are based on: 1. boiling in
water, 2. lysis in Tris-EDTA-Tween buffer containing proteinase K, and 3. boiling in
lysis buffer. For each breast cancer tissue tested four 10pm tissue sections from each
specimen were cut on a Reichert-Jung 2030 microtome and separately transferred to
sterile eppendorf tubes. Frozen sections were cut on a Bright cryostat (Huntingdon,
UK), and transferred to sterile eppendorf tubes on ice. Care was taken to clean the
microtome blade with xylene between samples.
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2.2.3 Differential PCR.
The reaction dynamics of dPCR with primers for c-erb B2 and interferon gamma 150
(IFNG150, single copy reference gene) were tested experimentally. Optimisation of
a number of factors was required before undertaking a large clinical study using this
technique. These included sample preparation (section 2.3.4), PCR amplification
conditions, primer efficiency, dPCR assessment of template DNA degradation, and
investigation of reference gene integrity.
2.2.3.1 Primers and the Polymerase Chain Reaction. Primers used in the
differential PCR were short segments of DNA whose sequences were specific for
either IFNG150, interferon gamma 82bp (EFNG82), interferon beta (IFNB), or c-erb
B2. Nucleotide sequences and chromosomal origin are given in Table 5. The single
copy reference gene selected for the standard dPCR was the interferon gamma 150bp
gene.
2.2.3.2 Standard Differential PCR Reaction. The standard differential PCR was
performed on a Techne PHC3 thermal cycler. Each reaction vial contained five pi of
prepared DNA template suspension, derived from the tissue sections as described in
section 2.8, or from 200ng of DNA extracted from frozen tissue (except where
stated otherwise), 0.25nM of the two primers for each gene (total of InM), 0.2M of
mixed nucleotide bases, dNTPs (Pharmacia, U.K.), 3pCi 32P dCTP, xl Taq
polymerase buffer and one unit of Taq polymerase (Northumbria Biotechnology Ltd,
U.K.). The total volume in each PCR reaction tube was 50pl. Cycling parameters
were one cycle of 94°C for 5 mins, 50°C for 1 min, 70°C for lmin, followed by 30
cycles of94°C for 1 min, 50°C for 1 min, 70°C for 1 min and one cycle of 94°C for
lmin
, 50°C for 1 min, 70 °C for 5 mins.
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Table 5.
The origins and DNA sequences of PCR primers for genes c-erb B2, Interferon
gamma (IFNG150= 150 base pair amplicon), Interferon gamma (IFNG82= 82 base
pair sequence), and Interferon beta (IFNB).




5'- CCT CTG ACG TCC ATC ATC TC-3' 17q21 Frye et al




5*- TCT TTT CTT TCC CGA TAG GT-3' 12q24.1 Frye et al







5'- GTG TCT CCT CCA AAT TGC TC-3' 12q24.1 Neubauer
5'- GCC ACA GGA GCT TCT GAC AC-3' et al(1992)
5'- GCA GAG CCA AAT TGT CTC CT-3' 9p22 Neubauer
5'- GGT CTC CAC ACT CTT TTG GA-3' et al(1992)
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To ascertain the relative quantities of the test gene to the reference gene, a
standardised method of determining the quantity of each PCR product was required.
In all experiments, PCR products were separated by size, in duplicate, on 2% agarose
gels (3:1 Nuseive/Seakem, FMC, UK) at 125V for 2 hours, stained with ethidium
bromide, and photographed. Where dPCR reactions included a radiolabel, 32P
dCTP, visible bands were excised, finely chopped and transferred to separate
scintillation vials, to which 5mls of Optiphase-safe scintillation fluid was added. A
value for the quantity of PCR product was derived from the radioactivity present in
each vial, assessed as counts per minute (CPM) on a Beckman scintillation counter.
CPM values were calculated in duplicate for these test samples in repeat experiments,
to assess intra and inter experimental variation.
2.2.3.3 Measurement of PCR Product. Two methods of measuring PCR
products, UV densitometry and radio-isotope incorporation, were compared.
Standard dPCR was performed incorporating lpCi 32P, using primers for c-erb B2
and IFNG150, on DNA suspensions derived from 16 methacarn fixed breast cancer
tissues, DNA extracted from frozen tissue from sample CR214, and the control DNA
p258.
2.2.3.4 Calculation of Ratio Values. Results from dPCR were expressed as ratio
values. For example, for the UV densitometry method, these were calculated by
dividing the c-erb B2 PCR product value by the IFGN150 reference gene value. For
the radio incorporation method, ratio values were calculated by dividing the
corrected average CPM for c-erb B2 by the average CPM for IFNG150. Corrected
CPM values for each PCR product were obtained from the duplicate gel tracks after
subtracting the average experimental blank (PCR reaction with no template DNA)
and applying a correction factor of 1.25 to compensate for differences in dCTP
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content between IFNG150 (69 C bases) and c-erb B2 (55 C bases). Similar
correction factors were calculated and applied to dPCR involving other combinations
of primer pairs, as shown in Table 6.
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Table 6.
Correction factors applied to PCR products for the determination of dPCR ratio
values. This was necessary in order to make equivalent the number of 32P labelled
dCTP bases within each amplicon. The correction factor was calculated by dividing
the number ofCTP bases in amplicons created by primer set B by the number of CTP
bases in the amplicon created by primer set A. The correction factor was applied to
CPM derived from PCR product from primer set B. Primer sets represented are
interferon gamma 150bp = IFNG150, interferon gamma 82bp = IFNG82, interferon
beta = IFNB, c-erb B2 oncogene = c-erb B2, and urokinase plasminogen activator
(see Chapter 7) = uro.
primer set(A) CI primer set(B) C2 c2/cl
correction factor
EFNG150 69 c-erbB2 55 1.25
IFNG150 69 IFNG82 30 2.3
IFNG150 69 IFNB 54 1.27
IFNG150 69 uro 66 1.04
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2.3 RESULTS.
2.3.1 DNA Preparation from Paraffin Sections.
To establish an optimal method for preparing DNA for the PCR from methacarn-
fixed tissue, three methods were assessed and applied to four 10pm sections from
each of 5 breast cancer specimens. Methacarn fixed and frozen fresh tissue sections
were tested from each cancer. Five microlitre aliquots of each of these preparative
methods was added as DNA template to a standard PCR reaction (section 2.2.3.2)
using primers for c-erb B2 and interferon gamma 150. PCR products were
electrophoresed at 125V for 2h on 2% agarose gels, stained in ethidium bromide and
photographed.
Method 1: Tissue sections were boiled in 0.1ml of sterile water for 10 minutes at
100°C in a boiling water bath. PCR product was not detectable for either fixed or
frozen tissues.
Method 2: Tissue sections were dewaxed in two extractions with one ml of xylene,
washed twice in 70% ethanol, dried under vacuum, then incubated overnight at 37°C
in 0.2ml of a Tris-EDTA-Tween lysis buffer, pH8.5 with added proteinase K (see
Appendix 1), then boiled for 8min in a boiling water bath. Supernatant fluid
contained sufficient template DNA to allow successful PCR amplification from both
fixed and fresh template. However, these supernatant fluids were unstable when
stored at -20°C, and some failed to produce PCR products when thawed and
retested.
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Method 3: Tissue sections were boiled in 0.1ml of lysis buffer (50mM Tris pH8.4,
ImM EDTA, 0.5% Tween 20) for 8 minutes at 100°C in a boiling water bath.
Supernatent fluids, from both fixed and fresh tissue, contained template DNA which
was readily PCR amplified, and produced consistent PCR results. Differential PCR
ratio values were unaffected by multiple freeze thaw cycles (xlO), permitting several
PCR reactions from each specimen preparation. Therefore, this method was used for
all subsequent DNA preparation from tissue sections.
Further testing of specimens prepared by method 3 examined the optimal number of
paraffin sections in each 0.1 ml preparation (1, 2, 3 and 4 10pm sections of breast
cancer CR254), and the volume of supernatant containing template DNA required in
dPCR (5, 10, 20pl per dPCR reaction). A standard dPCR reaction was performed
using primers for c-erb B2 and IFNG150, and ratio values calculated (as in section
2.2.3.2). Differential PCR ratio values obtained for 1, 2, 3, and 4 pm sections were
3.1, 2.5, 2.7, and 2.8 respectively. Five, 10 and 20pl of template DNA produced
ratio values of 3.1, 4.4, and 4 respectively. This indicated that the number of sections
and the volume of supernatant fluid included in each dPCR reaction did not greatly
affect the ratio values obtained by standard dPCR. For all subsequent tests, four
sections per fixed tissue sample were boiled for 8min in lysis buffer and 5pi of
supernatant fluid used in each dPCR.
2.3.2 Comparison of Template DNA Derived from Fixed and Frozen Tissue in
dPCR.
The possible effects of fixation on dPCR ratio values was investigated. Four 10pm
sections of four methacarn-fixed breast cancer tissues, cases CR46, CR53, CR90 and
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CR214, were prepared in lysis buffer (method 3 above). Two hundred ng of DNA
was extracted from a frozen sample of the same tissues and suspended in 5pi of the
0.01M Tris-EDTA buffer. Five pi of each suspension was added to separate vials
and a standard dPCR performed (section 2.2.3.2). Differential PCR ratio values
from frozen and methacarn fixed tissue from the same case varied only slightly (Table
7), indicating that tissue fixation does not distort these ratio values. The high ratio
value derived from frozen DNA in case CR90 was probably due to degraded
template DNA (see below).
2.3.3 Development of Differential PCR and Investigation of Reaction
Efficiencies.
2.3.3.1 Measurement of dPCR Products.
Two methods of measuring dPCR products, UV densitometry and radio-
incorporation, were compared. Standard dPCR was performed on 16 methacarn
fixed breast tissues, 1 DNA from frozen tissue, and one DNA control (p258),
incorporating lpCi 32P, and primers for c-erb B2 and IFNG150. Products were
separated on agarose gels (section 2.2.3.2).
2.3.3.1.1 UV Densitometry. For ultraviolet densitometry, each gel was scanned by
video camera, and the images digitised and stored in a computer file (software
supplied by UVP Products, UK). All subsequent calculations were made from this
stored image. The program automatically deleted a computed background
fluorescence for each gel. A value for the intensity (quantity) of each PCR product
was derived from the peak height and peak area either manually or automatically.
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Table 7
Differential PCR ratio values indicating c-erb B2 gene amplification status in
template DNA derived from frozen or fixed breast tissue specimens.
dPCR ratio value






UV densitometry readily measured strongly stained bands, however tracks containing
faint bands became indistinguishable from the background values, Figure 10. Ratio
values derived from densitometry peaks are given in Table 8. For faint bands,
manual evaluation of peak heights was possible but delimitation of areas under the
curve was subjective, see Figure 10. Also, uneven illumination from the UV
transilluminator occurred, making photographs of the same gel, positioned on
different parts of the transilluminator result in different densitometry peaks, see Table
8.
2.3.3.1.2 Radio-incorporation. One, 3 or 5 p.Ci of 32P dCTP was added to
separate PCR reactions containing template DNA from breast cancer case CR157,
and standard differential PCR performed as previously described. PCR products
were electrophoresed and visible bands were excised and CPM counted as described
in section 2.2.3.2. Duplicate tracks were assessed for intraexperimental variation.
The optimal 32P dCTP concentration was considered to be 3|uCi to minimise
radiation whilst maintaining acceptable label incorporation into nucleotides used in
the dPCR. There was little variability of the ratio values determined by radio
incorporation in duplicate gel tracks, see Table 9.
2.3.3.1.3 Comparison of UV Densitometry and Radio-incorporation. For the
comparison of the two techniques, the differential PCR was performed on DNA from
14 breast cancers and one control DNA (p258), incorporating lpCi 32P radio
labelled dCTP in the standard PCR reaction mixture, section 2.2.3.2. The PCR
products were separated on agarose gels, then stained and photographed for digital
recording for UV densitometry analysis, before bands were excised for scintillation
counting as described above. Ratio values obtained by each method for the same
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Figure 10
Gel photographs and computer overlay of ultraviolet densitometry analysis of PCR
products. The photographs show analysis of two different gel tracks from the same
agarose gel, one which contains densely stained PCR product (A), and one which
contains faintly stained PCR product (B). The lower photographs represent analysis
of the complete gel track, the upper photographs a computer enhanced signal from
the same track. Excessive "background noise" is illustrated in photographs B, where






Comparison of three methods of determining the ratio values of the PCR products of
cerb B2/IFNG150 in 14 fixed and one frozen breast cancer tissues and a control
DNA (p258). Ultraviolet ratio values were calculated from either the peak height
(UV peak) or the area under the peak curve (UV area) ofPCR products detected by
densitometry. The values in parentheses are those from a second densitometric
analysis of the same gel in a different position on the trans illuminator. Ratio values





Specimen UV peak UV area 32P
CR173 2.6 3.1 2.4
CR174 2.7 3.3 2.6
CR175 1.3 NR 1.1
CR176 2.3 2.6 2
CR179 5 NR 3.1
CR180 1.2 1.6 1.2
CR197 2.7 3.24 1.7
CR199 3.3 4.06 1.6
CR202 0.6 0.64 1
CR204 3.9 (2.2) 5.78 (2.37) 2.8
CR205 NR(1.5) NR (1.57) 1.4
CR212 2.3 2.47 2.8
CR213 2.1 2.68 2.5
CR214 3.8 5.8 5.9
CR214dna 4 5 5.2
p258 1.4 1.37 1.2
NR = No result determined.
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Table 9
Differential PCR ratio values for c-erb B2 gene copy number in 6 breast cancer
specimens demonstrating consistency in ratio value calculation from duplicate gel
tracks.
dPCR ratio value








dPCR reaction were compared.
The comparison of ratio values obtained by ultra violet densitometry and by the
radio-incorporation method showed a good correlation, see Table 8. Dissimilar
results were only observed in the PCR products of two samples, CR197 and CR199.
Analysis of PCR products by UV densitometry was also extremely time consuming
and was not used further. Radio incorporation was therefore the method of choice
for quantitation of PCR products and subsequent determination of ratio values
because of its accuracy and consistency.
2.3.3.2 Optimal Concentration of Template DNA in dPCR.
A number of experimental variables were assessed in order to identify factors which
might influence dPCR ratio values. The efficiency and perturbation of the dPCR
reaction with respect to template DNA concentration, was tested in the standard
dPCR incorporating primers for IFNG150 and c-erb B2, in separate vials containing
25, 50, 100, 200, 500, 1,500 or 2,000 ng of control DNA p258, cell line DNA
MCF7, and breast cancer DNA CR90. Ratio values for each test DNA concentration
were calculated as described in section 2.2.3.3.
All concentrations of template DNA tested gave detectable dPCR products from
primers c-erb B2 and IFNG150, but at 25ng, bands were noticeably weaker. The
tolerance of the dPCR for high concentrations of template DNA (lOOng to 2,000ng)
is shown in Figure 11. Ratio values were similar over the range of 100 to 1500 ng
of template DNA. Sample CR90, which produced a high ratio value in a previous
experiment, maintained its high value throughout this range, but showed a reduced,
but still amplified ratio value for 2,000ng. This may indicate that c-erb B2 primers
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Figure 11
Titration of template DNA concentration in differential PCR reactions incorporating
primers for c-erb B2 and IFNG150. Fifty, 100, 200, 500, 1000, 1500 and 2000ng of
template DNA of cell line MCF7 (hemizygous for c-erb B2), control Sigma DNA
(one copy c-erb B2), and breast cancer cr90 (amplified c-erb B2) were tested in a
standard dPCR reaction. Differential PCR ratio values did not vary greatly with
DNA template concentrations between 50 and 1500ng DNA.
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Figure 11 Effect on dPCR ratio values of DNA template
concentration
0 500 1000 1500 2000
DNA concentration (ng)
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are exhausted over the last thermal cycles and IFNG150 primers continue to produce
product with each cycle, thereby reducing the final ratio value. These results indicate
that the PCR primers were not rate limiting, except when template DNA was
>l,500ng.
Attempts to estimate the DNA concentration in the fluid released from paraffin
sections, by spectrophotometry, proved unrewarding.
2.3.3.3 Tolerance of dPCR to Different Concentrations of Taq Polymerase and
dNTPs.
The effect on dPCR ratio values of different concentrations of nucleotides or Taq
polymerase was assessed. 0.25, 0.5, 0.75, 1.0, 2 and 3 units of Taq polymerase were
added to separate reactions incorporating 200ng DNA from control DNA (Sigma)
and cell line UISO BCA1. Ten, 20, 50, 100, 200, and 500 mM of mixed dNTPs
were added to separate reactions incorporating 200ng control DNA (Sigma). Ratio
values for the quantity of gene copies measured for each parameter were calculate as
described in section 2.2.3.3..
Variation in the initial concentrations of Taq polymerase or dNTPs added to the
dPCR reaction indicated that ratio values were not greatly affected for
concentrations between 0.25 and 1 units Taq polymerase and between 20 and
400mM dNTPs, see Figures 12 and 13 respectively. High concentrations of Taq
polymerase may have had an inhibitory effect on PCR amplification, indicated by
reduced total PCR product, possibly due to increased concentration of glycerol
which is present in the enzyme storage buffer. These experiments indicate that minor




Titration of Taq polymerase concentration in a standard dPCR incorporating primers
for c-erb B2 and EFNG 150, for cell line UISO BCA1 and control Sigma DNA.
Figure 13
Titration of dNTP concentration in a standard dPCR, incorporating primers for c-erb
B2 and IFMG150, with cell line DNA UISO BCA1 and control Sigma DNA.
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Figure 12 Titration of Tag polymerase in dPCR
control
UISO BCA1
Figure 13 Titration of dNTP concentration in dPCR
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2.3.3.4 Primer Efficiency of c-erb B2 and IFNG150 in dPCR
The relative efficiencies of the two sets of primers in dPCR reactions were assessed
by titration of the c-erb B2 primers and by monitoring the two relevant PCR
products throughout the progression ofPCR cycles.
125, 250 and 500 pmol of each c-erb B2 primer with 250 pmol of IFNG150 primer
were used in separate PCR reactions containing 200ng control DNA (Sigma) or cell
line DNA UISO BCA1 and ratio values for each primer concentration calculated as
described in section 2.2.3.2. Optimal concentrations of the primer pairs to provide a
ratio value of approximately one for control DNA were considered to be 250pmol,
see Figure 14.
For cycle monitoring, the total volume in each PCR reaction tube was increased to
0.2ml, with primer concentrations of 250 pmol each, and other reagent
concentrations kept as above. Two hundred nanogram of template DNA prepared
from frozen samples of breast cancer cases crl89 or cr342 was used and the standard
dPCR performed as described in section 2.4.2. Samples (20pl) were removed from
PCR reaction tubes on completion of 20, 23, 25, 27, 29, 31, and 35 cycles. Ratio
values were determined for primer pair c-erb B2 and IFNG150 as described below.
Assessment of dPCR product throughout a cycle course showed that ratio values
remained similar for both DNAs tested, Figure 15.




Titration of c-erb B2 primers (125, 250, and 500 pmol) in a standard dPCR reaction
containing 250pmol IFNG150 primer, with cell line DNA UISO BCA1 and control
DNA (Sigma).
Figure 15
Differential PCR ratio values obtained throughout a thermal cycle course for breast
cancer samples cr342 and crl89 in a standard dPCR reaction. PCR product was
sampled at 2 cycle intervals between cycles 20 and 36.
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Figure 14 Titration of c-erb B2 primers in dPCR
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2.3.4 Calibration ofDifferential PCR Ratio Values.
Differential PCR calibration experiments were performed on DNA derived from both
fixed and fresh cell culture preparations in order to determine the relationship
between gene copy number and dPCR ratio value, and to further test the effect of
fixation on dPCR ratio values.
2.3.4.1 Cell Line DNA
For calibration of ratio value with gene copy number, DNA was prepared from cell
lines as described in section 2.2.1.3. DNA extracted from cell line 21MT2 or cell line
UISO BCA1 was mixed with control DNA p258, one c-erb B2 gene copy, in
separate tubes, in proportions which gave a series of known c-erb B2 copy numbers.
The 21MT2 DNA was diluted to produce vials containing c-erb B2 copy numbers of
32, 24, 16, and eight. UISO BCA1 was diluted to give copy numbers of 9, 6, 5, 4,
and three. The standard differential PCR was performed with primers for c-erb B2
and IFNG150, and ratio values determined by radio incorporation as described in
section 2.2.3.2..
The c-erb-B2/IFNG150 ratio values derived from the above DNA solutions of
known c-erb-B2 gene copy number are shown in Figure 16. As defined here, "one
gene copy" corresponds to the normal diploid content of one cell. Increasing gene
copy number resulted in increasing ratio values, values for 1 and 40 gene copy
numbers were 1.66 and 11.46 respectively. A ratio value of 2 apparently
corresponded to approximately 5 copies of the c-erb B2 gene. Therefore each ratio




Relationship between c-erb B2 copy number and differential PCR ratio value. Each
copy was derived by dilution ofDNA from c-erb B2 amplified cell lines 21MT2 or
UISO BCA1 with placental DNA (one copy). Each point on lineM (bold) represents




c-erb B2 copy number
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2.3.4.2 Fixed cell line DNA.
To ascertain if fixation could produce variation in ratio values, pellets of cultured
cells from the tested cell lines were fixed in methacarn. Measured suspensions of 21
MT2 cells were mixed with measured suspensions ofMCF7 cells to give projected c-
erb B2 copy numbers of 6, 4, 2 or 0.5 (MCF7 alone); a control DNA (p258) was
also tested. The cell mixtures were pelleted, fixed in methacarn for 24hrs, then
processed routinely into paraffin blocks. Four 10pm sections were taken from each
block and boiled in lOOp.1 of the lysis buffer (Method 3 section 2.3.1). Five pi of
each of these DNA template preparations was used in separate standard dPCR
reactions, incorporating primers for IFNG150 and c-erb-B2. Ratio values for each
fixed cell mixture were calculated. The placental DNA p258 was used as a control
for the normal copy number of one for both genes.
Differential PCR ratio values increased with increasing c-erb B2 copy number, a ratio
value of 0.4 corresponded to 0.5 copies of c-erb B2 (MCF7) and a ratio value of 1.2
corresponded to approximately 6 copies of c-erb B2, see Table 10. These ratio
values are lower than values expected, according to those found in Figure 16,
however the ratio value obtained for control DNA p258 was within its normal range,
suggesting that the PCR reaction dynamics were similar in both experiments. The
apparently low ratio values and copy numbers in "amplified" mixtures may have been
due to inaccuracies in cell counting, and copy numbers tested were below the
effective sensitivity of the test. Nevertheless, fixation does not appear to artificially
increase dPCR ratio values.
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Table 10.
Differential PCR ratio values obtained from a titration of c-erb B2 gene copy number
in DNA prepared from fixed cell pellets of MCF7 and UISO BCA1 tissue culture
cells. Cells were mixed to give projected c-erb B2 copy numbers of 6,4, and 2. C-
erb B2 copy numbers of 0.5 and 1 are from a fixed cell pellet ofMCF7 and control
DNA (p258) respectively. Ratio values for duplicate experiments are given.
Projected c-erb B2 c-erb B2:IFNG ratio











2.3.5 Factors with Potential to Affect dPCR Ratio Values.
2.3.5.1 Assessment of Template DNA Degradation.
Degraded DNA may have the potential to distort dPCR ratio values, therefore dPCR
with primer pairs IFNG150 and IFNG82 (both specific for the same gene, but
different sequences) was used to investigate possible DNA degradation in methacarn
fixed tissue specimens. The copy number should be the same for both amplicons. If
there was degradation of the initial template DNA, such as may occur during
fixation, the shorter amplicon of IFNG82 would be less likely to be disrupted, and
therefore would appear to give an amplified value in the differential PCR reaction.
2.3.5.1.1 Validation of dPCR using Primers for EFNG150 and IFNG82. The
reaction efficiencies of IFNG150 and EFNG82 were tested in dPCR by titration of
IFNG82 primers with IFNG150 and throughout a thermal cycle course. EFNG82
primer concentrations of 75pmol 125pmol, 175pmol, and 250pmol were titrated
against 250pmol of IFNG150 primer in a standard PCR reaction containing DNA
template from control DNA(p258) and DNA from two normal breast tissue controls.
Cycling parameters and calculation of ratio values were as stated previously for c-erb
B2:IFNG150, section 2.2.3.2 and 3. A correction factor of 2.2 was applied to
IFNG82 CPM to compensate for the smaller number of dCTP bases in its sequence,
see Table 6. Radiation counts obtained for IFNG82 PCR products were divided by
those for EFNG150 to give the final ratio value for this primer pair. Differential PCR
ratio values obtained with different concentrations of IFNG82 primers showed some
variation, but a general trend towards increasing dPCR ratio value with increasing
IFNG82 primer concentration was apparent, Figure 17.
1 00
Figure 17
Titration of IFNG82 primers (82, 125, 160 and 250pmol) in a standard dPCR
reaction containing 250pmol primers for IFNG150 for three control samples p258
(placental), alh490n and alh492n (normal fixed breast tissue).
Figure 18
Differential PCR ratio values for primers IFNG150 and IFNG82 throughout a
thermal cycle course in a standard dPCR. PCR product was sampled at 20, 23, 25,
27, 32 and 35 cycles.
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Figure 17 Titration of IFNG82 primers in dPCR
Figure 18 Differential PCR ratio values for




Primer efficiency was measured by sampling dPCR products throughout the
progression of thermal cycles. The standard dPCR reaction was performed on
control DNA (Sigma) and DNA from two breast cancers, as described above, except
that total reaction volume was 200pl. Twenty pi of the PCR reaction was sampled
at 20, 23, 25, 27, 29, 31 and 35 cycles, and PCR products electrophoresed and ratio
values calculated as described in section 2.2.3.2. Sampling of dPCR products
throughout the course of thermal cycling showed a steady decrease in ratio values
with successive cycles, Figure 18, indicating that reaction efficiencies of these primer
pairs are different.
2.3.5.1.2 Test Samples. Following this calibration, 5pi of prepared DNA
suspension from 52 methacarn-fixed cancer samples and 37 fixed control tissues
were tested in dPCR with primers 250pmol of primers IFNG150 and EFNG82, by the
standard method and ratio values calculated (section 2.3.2). Ratio values ranged
from 0.35 to 1.95 in control tissues and from 1.2 to 5.87 in cancer tissues; the
distribution of these values is shown in Figure 19.
2.3.5.2 Assessment of the Integrity of the Reference gene, EFNG150, using
dPCR with Primers IFNG150 and IFNB.
Differential PCR with primer pairs for IFNG150 and interferon beta (IFNB) assessed
the likelihood of possible deregulation (amplification or loss of an allele) in the
reference gene, as both should remain one copy. Primer efficiency of EFNG150 and




Distribution of differential PCR ratio values for IFNG150 and IFNG82 in 52 breast
cancers and 37 control tissues.
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Figure 19 Distribution of IFNG150:IFNG82 dPCR ratio
values in cancers and controls
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dPCR ratio value
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2.3.5.2.1 Validation of dPCR using primers for IFNG150 and IFNB. IFNB
primers concentrations of 31, 63, 125 and 250pmol were titrated against 250pmol of
IFNG150 primers, containing DNA template derived from one control DNA (p258)
or two DNAs from normal breast tissue, in a standard dPCR reaction as described
2.2.3.2. Ratio values were calculated as described in section 2.2.3.3. A correction
factor of 1.27 was applied to CPM from EFNB, see Table 6. Titration of IFNB
primers in the dPCR indicated an optimal concentration of 125pmol (1:2 dilution) of
each IFNB primer with 250pmol of IFNG150 for subsequent dPCR, Table 11.
2.3.5.2.2 Test samples. Interferon gamma 150 reference gene status was then
assessed in sections from 57 fixed breast cancer tissues and 27 control tissues, using
125pmol of each IFNB primer and 250pmol of each IFNG150 primer in each
standard dPCR reaction. Ratio values for each tissue were calculated as described
above. Ratio values ranged from 0.81 to 1.9 in breast cancers and from 0.4 to 1.7 in
control DNAs. The distribution of ratio values found for each group is shown in
Figure 20. Although the breast cancer group showed on average higher ratio values
than controls, this difference was small (0.5 of a ratio value) and did not suggest
significant disturbance to EFNG150 copy number.
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Table 11
Differential PCR ratio values obtained from a titration of interferon beta (IFNB)
primers with 250pmol interferon gamma 150 (IFNG150) in a standard dPCR
reaction for one normal control DNAs, p258, and two fixed normal breast tissues
ALH480n and ALH482n.
Concentration of IFNB primers (pmol)
Specimen 250 125 63 31
p258 2.87 1.28 0.51 0.37
ALH480n 1.34 0.68 0.38
ALH482n 1.69 0.75 _
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Figure 20
Distribution of differential PCR ratio values for IFNG150 and IFNB in 57 breast
cancers and 27 control tissues.
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Figure 20 Distribution of IFNG150:IFNB dPCR ratio values in
cancers and controls
40




The differential PCR has been proposed as an efficient method of measuring gene
amplification in fixed, paraffin embedded tissues (Neubauer et al 1992). However
detailed investigation of preparative methods for methacarn-fixed breast tissue,
dPCR reaction dynamics, and the relationship between dPCR ratio values and gene
copy number have not been previously reported. Experiments performed in this
chapter investigated each of these parameters and optimised reaction conditions in
order to apply the dPCR technique to clinical breast cancer samples, in a robust,
reproducible manner.
Tissue fixation is thought to degrade DNA and effect molecular arrangement (Doyle
and O'Leary 1992, Jackson et al 1990), and may limit molecular analysis. All breast
cancer tissues in this study were fixed in methacarn, which has been shown to be an
effective fixative for molecular studies (Greer et al 1990). Detailed testing of
template DNA preparation methods produced a simple method of extracting DNA
from methacarn fixed tissues which has significant improvements over previous
methods. The preparation time was short (total approximately 30 min) and
maintained the integrity of the template DNA so that it was resistant to several
ffeeze-thaw cycles. DNA prepared from tissues fixed in methacarn produced similar
results in dPCR to those of DNA prepared from fresh tissue, further indicating its
suitability for this analysis.
Differential PCR is a highly complex and sensitive reaction and dynamics of the
reaction may be effected by minor changes in reaction conditions. The key reaction
in dPCR is thought to be the stability of the binding of primers to template DNA
(Sugimoto et al 1993). For optimum dPCR, the two sets of primers should have
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similar efficiencies (Sugimoto et al 1993), which can be demonstrated by detecting
constant ratio values over a cycle course. This was clearly demonstrated for c-erb
B2 and interferon gamma 150 gene primers (see Figure 15), indicating their validity
in dPCR. This is also reflected in the clear correlation between the ratio values and
gene copy numbers (see below).
In contrast, interferon gamma 150 and 82 gene primers showed dissimilar efficiencies
(see Figure 18), resulting in changing dPCR ratio values with PCR cycle number and
template DNA concentration. These primers appear to be of limited value in dPCR,
yet they have been used to assess degradation of DNA prepared from fixed tissue
(Neubauer et al 1992, Liu et al 1992). Experimentation with fractionated DNA has
indicated that dPCR ratio values can be distorted when the average size of DNA
fragments is less than 200 base pairs (Neubauer et al 1992). This degree of
degradation resulted in IFNG150:IFNG82 ratio values of 3 or greater. On this basis
twenty percent of breast cancers in one study were eliminated from further dPCR
analysis (Liu et al 1992), perhaps creating an experimental bias. In this study, only 5
breast cancers tested in dPCR with primers for IFNG150:IFNG82 had ratio values
over 3, and of these only 2 had amplified c-erb B2 ratio values. This provides
additional evidence that dPCR with IFNG150:IFNG82 is not a robust and valid test.
The measurement ofDNA degradation in fixed tissue samples and its possible effects
on dPCR therefore remain unresolved. It is possible that DNA degradation may be
of only limited significance in most dPCR reactions (Neubauer et al 1992).
The relationship between dPCR ratio values and c-erb B2 gene copy number is not
well documented. Rudimentary associations between cell lines of known c-erb B2
copy number and dPCR determined copy number have indicated a proportional
relationship, but the ratio values obtained in dPCR have not been stated (Frye et al
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1989, Neubauer et al 1992). In other studies, standard curves of c-erb B2
amplifications have been created by adding c-erb B2 amplicons to control DNA to
mimic c-erb B2 amplified DNA (Lonn et al 1992, Lonn et al 1993). A linear
relationship was demonstrated between ratio values and c-erb B2 copy number
within the range of 2-10 copies, but higher amplifications proved difficult to measure
(Lonn et al 1992). Accuracy in this type of assessment may be compromised by
difficulties encountered when measuring the concentration of small DNA fragments.
In this study a titration of c-erb B2 copy number was created using DNA from cell
lines with known c-erb B2 gene amplifications, and mixing this in various proportions
with control DNA to provide different c-erb B2 copy numbers. In agreement with
Lonn et al (1992) a linear relationship was observed with low to medium c-erb B2
copy number, but became non-linear with high amplifications (greater than 32). This
may result, in part, from variation in ratio values obtained in triplicate tests of highly
amplified samples, see Figure 16. Differential PCR in highly amplified samples
produces small amounts of reference gene product, therefore minor changes in
product amount are likely to result in some variation in dPCR ratio values.
However, these ratio values remain within the "highly amplified" range.
Other studies have reported difficulty in assessing the degree of large copy number
amplifications in breast and ovarian cancer tissues (Hruza et al 1993, Lonn et al
1992, Liu et al 1992). One reason for this may be that they used laser densitometry
to measure PCR product, and dense bands representing amplified genes may be
outwith the linear range of the densitometer. Ultraviolet densitometry was assessed
in this study, but demonstrated unacceptable inter-experimental variations in control
values. It was therefore an inappropriate method for measurement of differential
PCR ratio values. The incorporation of radio nucleotides into dPCR amplicons
proved an accurate, numerical method for quantifying PCR product, which was not
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limited by factors such as the sensitivity of densitometry. This enabled a wide range
of c-erb B2 gene amplifications to be detected. Correction factors calculated to
compensate for differences in dCTP bases, see Table 6, which can be labelled with
32P, are important in determining PCR product equivalence. Calibration of dPCR
ratio values with samples of known c-erb B2 gene copy number indicated that dPCR
was not sensitive in detecting gene copy numbers between 2 and 5. However, while
each ratio value was a derived number, proportional to the gene copy number, the
tests outlined in this chapter indicate it is a reliable marker of gene amplification. The
limits of accuracy of gene copy number determined by dPCR may change over the
range of gene amplifications, where normal and low increases in gene copy number
show little variation between duplicate tests, and high amplifications (discussed
above) show greater variation, see Figure 17. For approximately 5 gene copies, ratio
values ranged from 1.7 to 2.2, and suggests that there may be misclassification of
some breast cancers. However, testing in duplicate should minimise this error.
Amplifications of approximately 32 gene copies produced ratio values from 3.9 to
5.1, but even the lowest of these values would still be considered highly amplified.
Confusion has arisen in previous studies of oncogene amplification over the
terminology used to describe an increase in gene copy numbers. The majority of
gene amplification studies, either by Southern or Northern blotting, or by dPCR,
refer to an amplification or increase in gene copy number, as a fold difference, e.g. a
two fold increase, thus equating these to a copy number increase. The calibration of
dPCR ratio values suggested that a ratio value of 2 is equivalent to 5 copies of c-erb
B2. However the accuracy of this calibration is obviously dependent on the accuracy
of the initial determination of gene copy number in the original cell lines, as
determined by Southern blotting. As estimates of gene amplification from Southern
blotting experiments are usually reported as a range, such as 2 to 4, this may
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introduce some initial inaccuracy. I therefore decided to report some dPCR results
as occurring in individual ranges (see Chapter 3) and where comparison with other
studies is required, translated into low medium and high copy number.
A comparative assessment of the dPCR method outlined here, to previous methods
of c-erb B2 gene copy number measurement indicates some major differences in how
gene copy number was assessed and calculated. A complicated algorithm of four
different dPCR reactions was designed to determine c-erb B2 gene copy numbers
(Neubauer et al 1992). This algorithm included a test for DNA degradation,
discussed above, and three dPCRs using primers for three different reference genes
with primers for c-erb B2. Delimiting ratio values for each of these steps were not
stated, and the number of samples which gave a negative result at each step were not
declared. Amplifications appear to have been calculated according to the relationship
of test dPCR ratio values to that of SK BR3, a cell line containing 4-8 copies of c-erb
B2, and normal spleen. Using only these two gene copy references they claim a
sensitivity of detecting twofold increase in gene copy number, clearly this must be
very approximate. My direct assessment of ratio values was based on development
of as complete a knowledge of dPCR reaction dynamics as possible.
In general, my testing indicated that measurement of c-erb B2 copy numbers by
differential PCR is a valid technique for a wide range of experimental situations. Its
strengths lye in the ability to determine c-erb B2 gene amplification in fixed paraffin
embedded tissue, thereby allowing examination of a consecutive series or breast
cancers. One weakness is in identifying cancers with low order gene amplification. I




The Prevalence of c-erb B2 Deregulation in Breast Cancer
115
3.1 INTRODUCTION
Deregulation of the proto-oncogene c-erb B2 has been implicated in the aetiology of
breast cancer (Slamon et al 1987). Although the gene was identified in 1981, (Shih
et al 1981) we still know little of its normal biological function and its role in breast
cancer. C-erb B2 protein shows close homology to epidermal growth hormone
receptor and studies of c-erb B2 activity in rodents and cell lines have suggested a
potential role in growth promotion (Chazin et al 1992, DiFiore et al 1987, Hudziak
et al 1987, Yamamoto et al 1986). A number of possible receptor ligands have been
identified (Holmes et al 1992, Lippman et al 1991), however the possible biological
consequences of their binding to receptor remains unclear. To investigate a potential
role for c-erb B2 in breast cancer it is important to ascertain the prevalence and form
of its deregulation, and at what point of cancer development this could occur.
Recent reviewers have collated the results from over 50 studies of c-erb B2 gene
amplification, mRNA production and protein overexpression (Perren 1991, Singleton
& Strickler 1992). However there were major differences between studies in the
frequency and association of c-erb B2 disregulation with histopathological features
or prognosis, making its exact involvement in cancer development and progression
difficult to determine, see Chapter 1 Tables 1, 2 and 3 . C-erb B2 protein
overexpression, usually measured by immunohistochemistry, has been observed in
15-49% of ductal carcinomas of no special type (DCI NST) (Berger et al 1988, Thor
et al 1989). Messenger RNA overproduction, detected by Northern blotting or in
situ hybridisation techniques, ranged from 23-60% of DCI NST (Rio et al 1987,
Walker et al 1989b), however numbers of cases in these studies tend to be small.
Gene amplification measured by Southern or dot blotting has been observed in 10-
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33% ofDCI NST (Masuda et al 1987, Venter et al 1987). It is not clear whether
these differences were due to variations in sample selection, study size, experimental
technique or genuine biologically relevant disparity between populations.
This chapter extends the use of differential PCR, as assessed and validated in Chapter
2, to determine c-erb B2 gene amplification in a large consecutive series of breast
cancers. Cancer characteristics such as DNA ploidy and cancer cellularity were
examined for their relationship to dPCR ratio values. Deregulation of c- erb B2 is
examined at three possible stages of disfunction; gene amplification, mRNA
production and protein expression. How these events could interrelate and possible
biological effects and consequences on cancer cells are discussed.
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3.2 MATERIALS AND METHODS
3.2.1 Study Set.
The study tissues (314 cases) were collected from primary operable (clinical stage I
and II) breast cancers at routine operations which included mastectomy and
excisional biopsy both for palpable and non palpable lesions. Samples were mainly
restricted to cancers of patients in the age group 50-65, collected between January
1988 and May 1990. Cancer tissues were fixed in methacarn (6:3:1
methanol:chloroform: acetic acid) overnight at 4°C, processed according to routine
methods and embedded in paraffin. Control tissues (43 cases) were obtained from
breast tissue distant to the lesion site or from non-cancer bearing breasts and
processed similarly.
Pathological characterisation was taken from an overall evaluation of material used
for routine diagnosis. I cut, stained and evaluated a 4pm section (H and E stain)
immediately adjacent to sections taken for dPCR (see below). Examples of stained
sections confirmed the nature of the tissue used in the PCR reaction. The cellularity
of each stained section was assessed subjectively for the proportion of the cancer
cellular content. Cellularity was designated as either; l=more than 75% , 2= 25%-
75%, or 3= < 25%. In 26 cases (all breast cancers), samples of the lesion were taken
and stored frozen in liquid nitrogen for RNA analysis.
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3.2,2 Determination of DNA Ploidy by Flow Cytometric Analysis.
Two hundred and thirty five cancers were processed for DNA flow cytometry for
ploidy analysis, according to the method of Hedley et al (1983). Briefly, two 50pm
sections were dewaxed using two changes of xylene and rehydrated. Each tissue
sample was incubated for 30 minutes at 37°C in 0.5% pepsin (Sigma) in 0.9% saline
adjusted to pH 1.5 with 2N HC1, then stained with 0.1% propidium iodide containing
0.004% RNAase. Isolated nuclei were counted and analysed using an EPICS C flow
cytometer (Coulter Electronics Ltd, Hileah, Florida). Ten thousand nuclei were
counted at 480nm excitation and the coefficient of variation calculated using
STATPACK software (Coulter Electronics Ltd). Ploidy was assessed as either
diploid (DNA index DI, between 0.9 and 1.10) or aneuploid (DI >1.10 and <1.90 or
> 2.10). Tetraploids were classified as DI between 1.90 and 2.10 with more than
20% of the cells apparently in G2 plus M phase of the cell cycle. For inclusion the
coefficient ofvariation for the peak value had to be less than 8%.
3.2.3 Detection of c-erb B2 Protein Expression by Immunohistochemistry.
Overexpression of c-erb B2 protein pi 85 in cancer tissues was ascertained using the
rabbit polyclonal antibody , 21N, to this protein (Gullick et al 1987). A separate 4p
m section of each tissue was dried at 56°C then stained in a three stage peroxidase-
antiperoxidase technique (Sternberger et al 1986). The primary antibody, 2IN was
used at a concentration of 3.3pg/ml in 0.1M Tris buffered saline (pH 7.6) containing
5% normal swine serum. Each section was incubated at room temperature for 90
minutes. Endogenous peroxidase was blocked by exposure to 1% hydrogen
peroxide in methanol for 30 minutes before staining. Overexpression of c-erb B2
protein was defined as the presence of brown staining of surface membrane of cancer
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cells. To score positive, more than 10% of cells had to show moderate to strong
staining. Controls included a known positive case and a negative control employing
a pre-incubation of the antibody with its corresponding peptide (lmg ml-1).
3.2.4 Quantification of c-erb B2 niRNA
Messenger RNA was extracted from the frozen samples and analysed by a standard
northern blot method (Thompson et al 1990). Twenty pg of each total tissue RNA
was denatured with formamide and formaldehyde at 55°C for 20 mins and RNA
species separated by electrophoresis on a 1.1% agarose gel. The RNA was
transferred to a nylon filter (Hybond-N, Amersham, UK) by the capillary action of
lOx SSC (1.5M NaCl, 150mM Trisodium Citrate) and covalently fixed to the
membrane filter using a UV transilluminator. To detect c-erb B2 mRNA, the filters
were hybridised with a radio labelled RNA probe #107, a 1.7kb fragment of v-erb B
(Semba et al 1985), according to the method of Church and Gilbert (1984). Filters
were then washed to remove non-specifically attached probe and exposed to pre-
flashed Kodak XAR film at -70°C. Filters were stripped and reprobed with a radio
labelled alpha actin RNA probe (Minty et al 1981) as an internal control for loading.
The degree of hybridisation of each radio labelled probe to the mRNA species was
estimated by reading of the x-ray films by light densitometry. Results were expressed
with respect to hybridisation to the actin probe.
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3.2.5 Measurement of c-erb B2 Gene Copy Number by Differential PCR
3.2.5.1 Sample preparation. DNA for PCR analysis was prepared from fixed
paraffin embedded tissue as described in Chapter 2 (section 2.2.2.4). Control DNA
was derived from normal human placenta (Chapter 2, section 2.2.1.2).
3.2.5.2 Differential PCR. The standard differential PCR reaction was performed
as described in Chapter 2 (section 2.2.3) with primers for DNA sequences specific
for Interferon gamma (IFNG150) and c-erb B2. All specimens were assessed in
duplicate experiments, both as duplicate gel tracks from each PCR tube and in
separate repeat experiments. A negative control, 200ng placental DNA, and a blank
reaction, containing no template DNA, was included in each batch ofPCR reactions.
PCR products were quantified according to the methods described in Chapter 2
(section 2.2.4), and expressed as ratio values.
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3.3 RESULTS
3.3.1 C-erb B2 Amplification and Overexpression in Breast Cancers.
3.3.1.1 Gene amplification determined by differential PCR. 314 breast cancer
specimens and 43 controls were tested for c-erb B2 amplification using primers for c-
erb B2 and IFNG150. Representative differential PCR products from three breast
cancers and a normal placental control DNA are shown in Figure 21. Differential
increase of c-erb B2 products indicating amplification is illustrated, with
corresponding ratio values of 1.3, 2.1, 3.5 (tracks 1-3) and 1.1 for control placental
DNA (track 5). Template DNAs for PCR in tracks 3 and 4 were derived from fixed
and fresh tissue from the same cancer, and demonstrate a similar ratio value, 3.5 and
3.6 respectively.
The ratio values obtained using primers for c-erb B2 and IFNG150 from both normal
(n=43) and cancer tissues (n=314) are shown in Figure 22. The ratio values for
normal tissues fell consistently between 0.6 and 1.9 (mean 1.2, S.D. 0.36). Ratio
values of 2 or above were therefore considered to signify c-erb B2 gene
amplification. A value of 2 corresponds to approximately 5 gene copies (see Figure
16, Chapter 2), and indicates that dPCR, in its present form , is unsuitable for exact
specification of those cases with low copy number (<5). For some analyses gene
amplifications were classified as low-medium copy number (ratio values 2-3
corresponding to approximately 5-10 gene copies) and high copy number (ratio
values greater than 3, corresponding to greater than 10 copies). Duplicate
experiments gave consistent results for cancers without gene amplification and those
with gene amplifications of low-medium and high copy number.
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Figure 21
Differential PCR products from IFNG150 (150bp) and c-erb B2 (98bp) size
separated on a 2% agarose gel. Lanes are: A BRL molecular weight marker V; 1,2
and 3 three different cancers; 4 DNA prepared from frozen tissue from the same
cancer as track 3; 5 normal control DNA(p258). Differential PCR ratio values for
tracks 1-5 are 1.3, 2.1, 3.5, 3.6 and 1.1 respectively. Tracks 2,3 and 4 all show clear
amplification of c- erb B2 product.
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Figure 21









Distribution of differential PCR ratio values for c-erb B2 in 314 cancer tissues and 43
normal control tissues. Figures in columns are expressed as percent of cancers or
percent ofnormal controls.
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Figure 22 Distribution of c-erb B2 dPCR ratio values
for breast cancers and controls
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Cancer tissues had ratio values ranging from 0.6 to 19.2, Figure 22, indicating copy
numbers throughout my calibration range (1 to 40). Fifty six percent of the total
study set (n=177) had dPCR ratio values of 2 or above. For 41 in situ cancers the
ratio values ranged from 1.0 to 8, with ratio values >=2 in 28 (68%), of which 17
(41%) were of low-medium and 11 (27%) were of high copy number. For 273
invasive breast cancers, the ratio values ranged from 0.6 to 19.2, with ratio values
>= 2 in 149 (54%), corresponding to low-medium copy number in 93 (33%) and
high copy number in 56 (21%). The difference in frequency of c- erb B2 gene
amplification between in situ and invasive cancers was not significant, X2=2.73 p=
0.10, Table 12.
3.3.1.2 Tissue localisation of c-erb B2 amplification. In order to confirm that
gene amplifications were present in cancer cells but not in normal breast tissue dPCR
ratio values were compared between cancer and normal tissue from the same tissue
section. Localisation of c-erb B2 gene amplification was examined in a small number
(n=3) of cancers in which normal tissue and cancer tissue were present in discrete
portions within one paraffin section. This allowed dissection of the section into
normal and invasive portions, and in one case an additional separate in situ cancer
portion. For each component part, three 10pm sections were cut from each block
and sub-divided using fresh sterile instruments. Portions of sections not taken for
PCR were stained with haematoxylin and eosin to determine the accuracy of
subdivision. Template DNA was prepared, (Chapter 2 section 2.2.2), and differential
PCR performed, (Chapter 2 section 2.2.3).
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Table 12
C-erb B2 amplification and cancer type. Cancers with dPCR ratio values of 2 or
more were considered amplified. The difference in amplification frequency between
in situ and invasive cancers was not significant, X2 = 2.73 p= 0.10.
c-erb B2 amplification
amplified non amplified
in situ 28 13
invasive 149 124
Table 13
Differential PCR analysis of c-erb B2 gene amplification in normal and cancer tissue
from three breast cancer cases.
dPCR ratio value
Case Normal Invasive In situ
CR80 2.13 2.55
CR832 1.71 2.22 5.75
CR868 1.1 1.46
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Differential PCR ratio values from dissected paraffin sections of three cancers are
given in Table 13. No other cases with c-erb B2 gene amplification were suitable for
dissection. Specimen CR832 has a higher degree of amplification in its in situ
component than in invasive or normal parts. The high value for normal tissue from
CR80 is possibly due to some contamination with cancer cells.
3.3.2 Cancer Characteristics which may Affect dPCR Ratio Values.
Differential PCR ratio values may be affected by a number of intrinsic features of
breast cancers. Technical factors were discussed in Chapter 2, however biological
factors such as DNA ploidy and cancer cellularity also have the potential to disturb
dPCR ratio values.
3.3.2.1 DNA Ploidy. Satisfactory analysis of DNA ploidy by flow cytometry was
obtained from 235 cancers. 112 had a diploid phenotype, and 123 were aneuploid or
tetraploid. The frequency of amplification of c-erb B2 in specimens assessed by flow
cytometry was found to be highest in cancers which were diploid (61%), with lower
percentages of aneuploid (47%) and tetraploid (49%) cancers being amplified. These
differences, however, were not statistically significant, X2 = 3.43, p0.50> p >0.10.
3.3.2.2 Cancer Cellularity. A second potentially confounding factor was the
dilutional effect ofnormal cells present within the cancer tissue, perhaps reducing the
detection frequency of amplification. The proportion of amplified and non-amplified
cases of invasive cancer ranked according to section cancer cellularity is shown in
Figure 23. Amplification was found in each of the groups, including those specimens
where cancer cells constituted less than 25% of total cellularity.
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3.3.3 Relationship of c-erb B2 gene amplification to 2ene function.
The biological effect of c-erb B2 gene amplification may be mediated via normal
gene functions which involve the transcription of the gene to mRNA and translation
to the receptor protein. It was therefore important to examine expression of c-erb
B2 mRNA and receptor protein, and assess the inter-relationships between these and
gene amplification.
3.3.3.1 Protein overexpression assessed by immunohistochemistry.
Immunohistochemistry for c-erb B2 overexpression was performed on 328 breast
cancer specimens. Overexpression of c-erb B2 was detected in 16 of 44 (36%) of
carcinoma in situ, and in 36 of 284 (13%) invasive carcinomas, representing a
significant difference, X2 = 15.89, p= <0.001. In cases where in situ and invasive
forms of cancer were present on the same slide no detectable differences in the
staining pattern between them was observed. Staining was concentrated on epithelial
cell membranes and stained cells were present evenly throughout the cancer (Figure
24), except in one cancer where focal staining of cancer cells was observed.
Overexpression was not observed in normal epithelial or stromal cells.
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Figure 23
Relationship between cancer cellularity and frequency of c-erb B2 amplification in
277 breast cancers. Cancer cellularity was assessed visually as >75% cancer cells =1,
25-75% cancer cells =2, < 25% =3. Specimens with a dPCR ratio value less than
two are represented by dark columns, specimens considered to be amplified (dPCR
ratio value of 2 or above) are represented by light columns.
Figure 25
















Figure 23 C-erb B2 amplification and cancer cellularity
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Photograph of a comedo type in situ carcinoma (A) and an invasive ductal carcinoma
of no special type (B) stained with c-erb B2 specific polyclonal antibody, 2 IN.
Cancer B shows fixation retraction of tissue. Staining, indicated by strong brown





3.3.3.2 Comparative evaluation of protein overexpression and gene
amplification. A case comparison of gene amplification determined by dPCR with
protein expression determined by immunohistochemistry is shown in Table 14. Forty
two of 51 immunopositive cases (82%) had gene amplification (with ratio values
ranging from 2.0 to 19.2). There were 9 cases where differential PCR did not detect
gene amplification in the presence of protein overexpression. However 135 of 263
immunonegative cases (51%) had PCR-detectable amplification of c-erb B2 gene,
and this included 46 cases with ratio values >3, indicating a relatively high copy
number. The range of differential PCR values was similar between the
immunopositive and immunonegative groups (Figure 25), and applied to both in situ
and invasive cancers. Of the 14 samples assessed by immunohistochemistry but not
available for PCR, 1 was immuno-positive.
3.3.3.3 mRNA overexpression and c-erb B2 gene amplification and protein
overexpression. Overexpression of c-erb B2 mRNA was identified by the presence
of a positive hybridisation signal. The expression of c-erb B2 mRNA in normal
tissue was not detectable by northern blotting techniques. Increased levels of c-erb
B2 mRNA were found in 11 of 26 cases (42%). Correlation of the c-erb B2 mRNA
values with gene amplification and overexpression status is shown in Table 15. All
cases with positive immunohistochemistry contained elevated levels of c-erb B2
mRNA. Furthermore four of nineteen cases negative for immunohistochemistry also
had elevated levels ofmRNA; gene amplification determined by dPCR was present in
two of these cases.
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Table 14
Comparison of c-erb B2 protein overexpression measured by immunohistochemistry
and c-erb B2 gene amplification measured by dPCR in 314 breast cancers, for an




No amplification 9 128
Table 15
Association of increased c-erb B2 mRNA expression with protein overexpression
and gene amplification. All cancers with protein overexpression show elevated levels
of mRNA. Four of 19 cases which were negative for protein overexpression have




mRNA positive negative positive negative
Amplified 4 0 2 10
Non-amplified 3 0 2 5
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3.4 DISCUSSION
In this study c-erb B2 gene amplification was detected by dPCR in 55% of invasive
ductal carcinomas (Table 12), a considerably higher percentage than previous reports
employing other methods of detection of c-erb B2 gene amplification in breast
cancers (Singleton & Strickler 1992). Most cases of gene amplification in both in
situ and invasive cancers in this study, were in the lower range of amplification
number. Amplification was often present without detectable c-erb B2 protein
expression, but was rarely absent when protein overexpression was present. An
accurate determination of gene amplification and its relationship to gene expression is
important for a valid interpretation of the potential role and mechanisms of
deregulation of c-erb B2 in breast cancer.
In this study the overall frequency of c-erb B2 gene amplification was high, with 56%
of the total study set having increased gene copies. In another ten major studies of
breast cancer, each assessing 100 or more cancer cases by Southern blotting, the
frequency of detection of c-erb B2 gene amplification was consistently between 17%
and 23% of the total study sets (reviewed in Singleton and Strickler 1992).
However, in other studies, also using Southern blotting (Venter et al 1987, Andersen
et al 1994) the percentage of cancers showing c-erb B2 amplification has been 33 to
70%. The direct comparison of amplification frequencies obtained by dPCR
presented here and those in other studies is complicated by the incomplete
knowledge of the relative sensitivities of the techniques and by differences in criteria
and nomenclature used in assessment of increased gene copy number (see Chapter 2
for a discussion of gene copy nomenclature). Only one study of the relative
sensitivity of dPCR or Southern blotting for detection of c-erb B2 gene amplification
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has been reported (Hruza et al 1993). They found dPCR to provide reliable
estimates of the numbers of extra copies in cases of gene amplification, similar to
values obtained by blotting. They, along with other studies, also found that dPCR
detected a higher percentage of cancers with gene amplification than Southern
blotting methods (Hruza et al 1993, Imyanitov et al 1992, Slamon et al 1989, Zhang
et al 1989). While other studies using Southern blotting have claimed to be able to
detect very low levels of gene amplification, such as only two gene copies (Berns et
al 1992, Borg et al 1991, Tavassoli et al 1989), these studies have lacked some
validation requirements, such as the full range of values observed, the experimental
variation in duplicate tests, cancer cellularity differences, and a control group of
normal tissues. The dPCR as performed here would appear to lack the sensitivity to
identify very low copy number increases of two to four copies.
In this study, the majority (61%) of c-erb B2 amplifications apparently involved only
low to medium increases in gene copy number, of between five to ten copies, see
3.3.1.1. In another study, a similar percentage of amplified cancers also had low
increases in gene copies (Borg et al 1991). It is not known if the number of gene
copies is relevant to the behaviour of the cancer cell. Although it is generally
assumed that c-erb B2 is expressed in proportion to the gene copy number, this has
not been satisfactorily established, and is discussed below. Gene amplification may
merely indicate a breakdown in cellular repair or control mechanisms. If so
amplification of c-erb B2 would be a very frequent "random" event, perhaps
maintained in the clonal population due to a selective growth advantage.
In this study, there were no clear differences between the frequencies of c-erb b2
amplification in in situ and invasive cancers, 68 and 54% respectively. Studies of c-
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erb B2 amplification in in situ cancers have been restricted to dPCR, because their
small size precludes Southern blotting analysis. Therefore the dPCR offers a great
advantage in analysis of cancer progression involving in situ cancers. In another
dPCR study of in situ and invasive cancers (Lui et al 1992), c-erb B2 amplification
was detected in 48 and 21% respectively; however that study had a restricted study
series and introduced a complex algorithm for dPCR calculations which excluded
certain cases, as discussed in Chapter 2. Nevertheless, c-erb B2 amplification
appears to be common in cancer types showing both invasive and non-invasive (in
situ) phenotypes. It is therefore not valid to postulate c-erb B2 amplification as a
marker for aggressive cancers. This is supported by studies relating case survival
with the presence of c-erb B2 amplification (Ali et al 1988).
In this study, c-erb B2 amplification was often present without a detectable
overexpression of c-erb B2 protein in the cancer cells. However, c-erb B2
amplification was rarely absent when protein overexpression was present. It is
possible that the immunohistochemical methods employed in this study failed to
adequately detect some overexpressing cancers. As mentioned above, the majority
of cases in this study had low to medium amplifications whereas the antibody used
will only detect expression in cells with at least 12 copies of c-erb B2 (Gusterson
1992). Detection of overexpression of c-erb B2 protein by immunohistochemistry is
subject to considerable variation between studies (Singleton & Strickler,1993), due
in part to differences in the primary antibodies, fixation methods, study set
composition and criteria for assessment of staining.
There was a strong correlation between the presence of overexpression and
amplification, eighty percent of immunopositive cancers had c-erb B2 gene
amplification. Amplification was therefore rarely absent when overexpression was
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present. Interestingly, there was a wide range of gene copy numbers in
immunopositive cancers, see Figure 25. So some cases with strong immunostaining
showed only a low increase in c-erb B2 gene copy number. It is possible that some
enhancement of transcription and translation of the c-erb B2 gene occurs in some
instances. Increased c-erb B2 mRNA levels, due to elevated amounts of a
transcription factor, were observed in cancer cell lines with no detectable gene
amplification (Hollywood and Hurst 1993). Other limitations of simple
immunohistochemistry as a measure of deregulated gene activity have been
recognised (Anderson 1992, Wynford-Thomas 1992). Detection of abnormal gene
activity through in situ hybridisation methods (Kallionemi et al 1992, Smith et al
1993) may reveal more about the heterogeneity and degree of gene deregulation
within cancer cell populations.
This variety of biological events and consequences suggest that a more realistic
model to evaluate c-erb B2 deregulation in breast cancer must encompass a greater
number of circumstances than (simply) gene amplification alone, and consider the
interaction of other biological processes, see Chapter 8.
The presence of c-erb B2 amplification was not more apparent in aneuploid cancers.
This indicates that the amplification was not a non-specific process associated with
ploidy disturbances. This confirms the findings of previous studies (Lonn et al 1993,
Ro et al 1989). An unexpectedly high frequency of amplification was found in
cancers with a low cellularity of cancer cell to total cell numbers, see Figure 23.
Testing of normal breast tissue did not produce any amplified c-erb B2 ratio values
suggesting that some small cancers have high copy numbers of the c-erb B2 gene.
Small cancers are not generally available for Southern blotting, due to insufficient
tissue for DNA preparation, and were not included in another dPCR study (Lui et al
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1992), therefore their amplification status has not been previously assessed. Cancer
cellularity is only rarely taken into consideration in cancer gene studies (Slamon et al
1989). I performed a limited study on the localisation of gene amplifications within
portions of a cancer containing separate invasive, in situ and normal elements which
indicated that amplification levels are not always constant within a cancer.
A finding of "amplified" was based on a ratio value of 2 or above, as this was always
above values obtained for control samples. Raising the cut-off point to a ratio value
of 2.5 would reduce the number of cancers with "amplified" c-erb B2, but not
change the relationships of c-erb B2 disregulations mentioned above. It is likely that
the approximations and experimental variation inherent to other DNA analyses,
including Southern or dot blotting techniques would also affect the precise
amplification values obtained by those methods. The significance of c-erb B2
amplification may be merely that it is deregulated, not the exact number of gene
copies.
Despite the problems of comparability, the dPCR technique has major potential to
give a valid but different perspective of gene disregulation and cancer progression.
To do this, I compared gene disregulation to factors such as cancer size, oestrogen




C-erb B2 Deregulation in Breast Cancer:
Correlation with Cancer Characteristics.
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4.1 INTRODUCTION.
Identification of the molecular events associated with progression in breast cancer is
important to our understanding of the disease and for development of effective
clinical treatments. The complexity of these associations is evident from the absence
of any clear trends in the large number of studies to date. Some other cancers, such
as colon cancer, are known to accumulate molecular disregulations as cancer
progresses from adenoma to invasive carcinoma (Fearon and Vogelstein 1990). A
similar accumulation of molecular events may occur in breast cancer, however the
wide variety of histopathological forms and ill-defined precursor lesions have
hampered their recognition. The likely progession from hyperplasia to in situ to an
invasive cancer is widely accepted (Crisp et al 1993, Page et al 1982, Rosen et al
1980), but the scientific evidence to support this is difficult to acquire.
My study of cancers derived from mammographically screened breast cancers may
provide a selection of cancers "caught" at an earlier stage of development than those
detected symptomatically, and could therefore provide vital clues to early genetic
events. Histopathological and biochemical features of breast cancer indicate
considerable disease heterogeneity and are currently used in the estimation of cancer
behaviour and as an aid to appropriate clinical treatment. Heterogeneity is illustrated
by differences in features such as histological type, histological grade, lymph node
metastasis and oestrogen receptor concentration (Perren 1991). Some of these
features have an obvious chronological relationship with cancer progression, such as
cancer size and lymph node metastasis, which usually increase over time. However
oestrogen receptor status and cancer grade have a less well defined relationship with
progression. In order to investigate the role of c-erb B2 deregulation in cancer
progression, it is first necessary to consider the relationship between these other
1 43
features within the subgroups of the study set to provide a potential "framework" of
cancer progression. Breast cancer type is determined by the pattern of cancer cell
growth. Breast cancers commonly originate from epithelial cells which form the
breast parenchymal units or lobular units (Bodian 1993). In situ carcinomas consist
of cancerous cells which are still contained within the breast ducts and have not
invaded surrounding stromal tissue. The presence of in situ carcinoma in many
invasive lesions is suggestive of this being a precursor of invasive cancers (Black et al
1972, Page et al 1982, Rosen et al 1980). Special type cancers are invasive but
generally of good prognosis (Dixon et al 1985), and may indicate that these
histological types of cancer are less aggressive. These include tubular carcinomas,
lobular carcinomas and mucinous carcinomas (Page and Anderson 1987). By far the
most frequent type of breast cancer is invasive ductal carcinoma of no special type.
These cancers show a more disorganised pattern of growth and exhibit considerable
heterogeneity, but may still contain elements of in situ and or special type patterns of
growth (Page and Anderson 1987).
Cancer grade is an important indicator of aggression or prognosis (Elston 1987).
This method of classifying cancers, developed by Bloom and Richardson (1957),
measures cancer cell differentiation status by assessing the presence of tubules
formed by cancer cells, the extent of nuclear pleomorphism, and the number of
mitoses present within a high-power microscopic field (Elston 1987).
Lymph nodes are commonly sampled at time of operation and histological
examination is used as an indicator of cancer spread. The presence of cancer cells
within the adjacent draining lymph nodes is likely to be the first indication of
metastases, and is a clear indicator of poor prognosis (Clark et al 1991). The number
of nodes involved and extent of node invasion may signify the stage of progression,
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or chronological age of the cancer (Tubiana and Koscielny 1991). Terminal lesions
are usually due to distant metastasis which may follow invasion of the lymph nodes
(Burst and Ingold 1993). However, although lymphatic invasion does indicate one
sort of progression, it may not be directly responsible for blood spread to bone, lungs
etc (Burst and Ingold 1993). It is conceivable that cancers which metastasise to the
lymph nodes are different to those which metastasise via the blood.
Oestrogen receptor (ER) concentration is measured in all suitable cancers for clinical
treatment purposes. The presence of ER above 20 fmol/mg protein indicates that
treatment with anti-oestrogens may inhibit tumour growth (Hawkins et al 1981).
The exact role of ER in cancer progression is not clear, however the absence of ER
in invasive cancers is an indicator ofpoor prognosis (Bernstein and Ross 1993). The
functional role of oestrogen receptor in breast cancer remains unclear, but is likely to
be multifactorial and involve the promotion of gene transcription (Dubik et al 1992,
Hulka et al 1994). The presence of oestrogen receptors is thought to negatively
correlate with c-erb B2 overexpression in cancer cells (Russell and Hung 1992), and
suggests that oestrogen receptors may have a functional or regulatory relationship
with c-erb B2.
This chapter aims to explore the inter-relationships between histopathological and
biochemical features and biological measures of genetic deregulation in cancers from
screened and symptomatic breast cancers and identify possible stages of progression
in which deregulation of c-erb B2 may occur.
1 45
4.2 MATERIALS AND METHODS
4.2.1 Definitions of Breast Cancer Source
The study set consisted of breast cancers obtained, in a consecutive manner, from
female patients the majority ofwhom were aged between 50 and 65. Cancers which
presented symptomatically were referred to as never screened. Cancers which were
detected by mammography were predominantly from new attenders to a prevalence
round of the UK National Screening program during 1988-1990, and were referred
to as newly screened. A small group of cancers were identified in women who
attended or participated in a previous mammographic screening program (Roberts et
al 1984) 1978-1988, and were referred to as previously screened.
4.2.2 Definitions of Breast Cancer Characteristics
Cancer size at the time of operation was noted for invasive cancers as the diameter of
the lesion on macroscopic tissue examination. In situ cancers were not measured.
Large inoperable cancers were allocated a nominal size of 51mm because accurate
determination of size was not possible from their wedge biopsies. Lymph node
status was noted in invasive cancers, as either positive or negative for the presence of
malignant cells, following the histological examination of lymph node biopsies taken
concurrently at surgery. Some breast cancers greater than 50mm in diameter did not
have node samples taken as these formed part of a separate treatment trial (E.
Anderson, Dept. Surgery, Univ. Edinburgh).
The histopathological type of all cancers were classified according the criteria of
Page and Anderson (1987). The major cancer types identified in this study set are
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illustrated in Figure 26 A-E, and listed in Table 16. Invasive cancers were graded for
nuclear pleomorphism, tubule formation and mitotic rate, according to a modification
(Elston 1987) of the method of Bloom and Richardson (1957). Each of these
elements is given a score of 1 to 3, and summation of these gives a grading score:
grade I (best prognosis) scores between 3 and 5, grade II 6 or 7, and grade III (worst
prognosis) 8 or 9. In situ cancers were not graded.
4.2.3 Definition of Oestrogen Receptor Status.
Oestrogen receptors were measured by a radio-ligand binding assay using dextran
coated charcoal according to the method ofHawkins et al (1981). The concentration
of oestrogen receptors in each cancer sample was then expressed relative to the
protein concentration in each sample. Values of >20fmol/mg protein have been
defined as the minimum concentration of receptors necessary for clinical treatment
with anti-estrogens (Hawkins et al 1981), and were therefore considered receptor
positive.
4.2.4 Genetic and Biochemical Features of the Study Set
Methods for determination of DNA ploidy, c-erb B2 overexpression, c-erb B2
amplification and cancer cellularity were described in Chapter 3.
4.2.5 Data Analysis
Data points (field values) were entered into a Paradox for Windows database
(Borland Ltd, USA). For each cancer the following fields were recorded: laboratory
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number; date of birth; name; pathology reference number; screening status; lymph
node status; cancer size; histopathological type; cancer grade; oestrogen receptor
concentration; DNA ploidy status; c-erb B2 immunohistochemistry; and c-erb B2
amplification. Univariate analysis of field values for each of these groups were
computed by Paradox software (Borland Ltd), and X2 analysis of contingency tables
applied to test significance. Results were formulated as frequencies or percentages
of field values in comparisons between groups and were expressed graphically.
Multivariate analysis was performed using logistic regression with analyses of
deviance and the asymptotic chi-squared distribution for the log-likelihood to
compare nested models. All multivariate analyses were implemented using computer
software EGRET by Dr.F.Alexander.
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Figure 26 A-E
Photomicrographs illustrating the main histopathological types of breast cancer:
A In situ ductal carcinoma. Cancer cell are contained within the duct, and can
form different histopathological patterns, such as comedo (illustrated here), solid or
micropapillary types.
B Invasive ductal carcinoma of no special type. This is the most common type
ofbreast cancer. Cancer cells have invaded the normal tissue surrounding ducts and
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Figure 26 C-E
C Tubular carcinoma. Invasive carcinoma which forms tube like structures
through normal breast tissues. Cancer cells are well differentiated and the epithelial
tissue shows a high percentage ofglands.
D Lobular carcinoma. Invasive carcinoma which forms chains of cells, usually in
single file.
E Medullary carcinoma. Invasive carcinoma formed from solid sheets of large



















^ ^ 4 t v1A % (r % c * „
•. <? i 41 "•-?/ V • • • W> **,v .? ' . f , „ »t>
' '
. ' .?- v > , i ') t I (i ^ *
' ***** * -:h> •
j| */v % , > - ..-
'
♦ " % • //' ^ • »'
.?>•&
<iN;• /
'✓ /> J ; / % & 0
h i ' " '. / \* ' »
<
ert tp . "L
- «• / • -vrj, ,/r': *•
•.
. »■
J#. ' '. Av &<?
=
-. il* . ^.-i"4'
■' '
■' '• ', ;j ;
a . />
'
t' a* J #1




ft \c ' %:* -sw *• *»







,s • « } >.
- •' '>% '<*•
■■ ■ M
m**rn -




This table lists the major histopathological types of breast cancer. The major
classifications are in situ and invasive carcinomas, with subdivisions created by
distinct pathologies within each group. The most common type of cancer is invasive
ductal carcinoma of no special type.
Histopathological cancer type
In situ carcinomas - Lobular
- Ductal - comedo
- non comedo micropapillary
cribriform
Invasive carcinomas - Ductal of no special type







4.3.1 Characterisation of Breast Cancers
All cancers were classified according to histopathological type. In situ cancers, of
ductal (n=42) and lobular origin (n=2), represented 14% of the study group.
Seventy-four percent (n=244) of the study group were invasive ductal carcinoma of
no special type. Of the special type cancers, lobular (n=20) and tubular (n=12)
cancers were the most frequent, 6% and 4% respectively. Other special types
medullary, and mucinous occurred infrequently, and together represented the
remaining 2% of the total population. Two hundred and 51 invasive cancers were
graded for nuclear pleomorphism, tubule formation and mitotic rate: grade I, n=64,
grade II, n=143, and grade III (worst prognosis), n =44. Lymph node status was
noted in 266 invasive cancers as either positive (n= 92) or negative (n= 174) for
presence ofmalignant cells on histopathological examination.
4.3.2 Screenin2 Status and Cancer Characteristics
The study set consisted of 334 breast cancers, of which 173 were never screened,
111 were newly screened and 44 were previously screened. Six cases had no
screening status noted. Cancer characteristics were compared between cancers from
the screening groups (previous and newly screened) and those in the never screened
groups in order to ascertain if cancers in these groups could represent different
stages of cancer development.
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Screen detected (both previously and newly screened groups) invasive cancers show
a significant trend towards smaller cancer size than never screened cancers, Figure
27, X2= 42.46, p<0.001. Thus 86% of the cancers in the l-10mm size group are in
the screening groups. This was not surprising as small cancers are less likely to be
symptomatic. Only slightly reduced percentages of cancers >3Omm in diameter
occurred in the screening groups, suggesting the presence of some cancers which
may have been symptomatic at time of detection. The excess of small cancers,
although reduced, remained on analysis of ductal carcinoma of no special type only,
X2= 38.23, p<0.001.
Lymph node invasion was present in each of the screening categories, with the
highest frequency occurring in the previously screened group (41%), followed by
never screened (34%) and newly screened (25%). These differences were not
significant, X2= 4.93, p<0.10.
The distribution of cancer type was different between the newly, previously screened
and never screened groups, X2= 13.74, p<0.01, Table 17. Invasive ductal
carcinoma of no special type was the most frequent cancer type in each of the
groups. Special type cancers, tubular and lobular, as well as in situ cancers were
more frequent in the newly screened and previously screened groups than in the
never screened group.
Grade I cancers were more frequent in the newly screened group (35%), than in the
never screened group (22%), with grade III cancers showing the reverse trend, X2 =
11.4, p<0.025, Figure 28. However, this difference was influenced by the presence
of special type cancers in the screen detected cancers, and the test lost significance
when DCINST alone were analysed, X2= 8.11, p<0.10.
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Figure 27
Distribution of cancer size (diameter in mm) for each screening group, previously
screened, newly screened, and never screened. Cancer sizes have been grouped in
10mm size categories. Results are expressed as percentage of screening group.
Figure 28
Distribution of histopathological grade for each screening group, previously
screened, newly screened, and never screened. Results are expressed as percentage
of screening group.
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Histopathologic^ cancer types found in each of the screening groups, previously,
newly and never, expressed as percentages of each group.
Table 17
Cancer type previously newly never
in situ 20 17 9
Invasive
No special type 68 65 82
Special type 12 18 9
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Oestrogen receptor concentrations were divided into three groups <20frnol/mg
protein, 20-200fmol/mg protein, and >200fmol/mg protein. An arbitrary value of
>200ffnol was chosen for more detailed assessment of oestrogen receptor
associations. Newly screened group cancers were more likely to be oestrogen
receptor positive (>= 20fmol/mg of protein), however the previously screened group
show a higher percentage of ER negative cancers (37%) than either newly or never
screened cancers, X2= 6.18, p<0.05.
Never screened cancers had a greater frequency of abnormal DNA ploidy,
aneuploidy (38%) and tetraploidy (21%), X2= 10.5, p<0.05, Figure 29.
4.3.2.1 Summary of Cancer Characteristics of Screening Groups.
Differences in the distribution of cancer size, type and grade were observed between
screen detected and never screened cancer groups. No difference in distribution of
lymph node metastases, histopathological grade and oestrogen receptor status were
observed. The frequency of some of these features, particularly histopathological
type and grade, oestrogen receptor status, and DNA ploidy status can be influenced
by the "length bias" inherent of the prevalence screen, in which a proportion of
cancers are slow growing and indolent. Multivariate analysis (restricted to women
aged 50-65) indicated that only cancer size and lymph node were chronological
factors which changed over the time period of the screening program.
Some characteristics of the previously screened group were different to the newly
screened group and indicated the presence of high grade, oestrogen receptor
negative, and lymph node negative cancers, see Figure 28 and section 4.3.2. This
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group was considered too small for statistical analysis, but suggests that interval or
incidence cancers can have aggressive characteristics.
4.3.3 Inter Relationships between Histopathological and Biochemical Features
of Breast Cancer.
The inter relationships between histopathological and biochemical features of breast
cancer are complex. Cancer size and lymph node metastases are known as
chronological features of breast cancer, and associations with other cancer features
may provide an approximate "framework" of the particular features of cancers in the
stages of progression.
Small cancers were correlated with lymph node negativity X2=12.64, p<0.01 (Figure
30), low grade (grades I, X2= 21.75, p<0.01, Figure 31), and less disturbance to
DNA ploidy X2= 21.16, p<0.01 (Figure 32) but not with oestrogen receptor status
X2 = 6.71, p<0.10 (Figure 33). Conversely large cancers were more likely to be high
grade (grade III), lymph node positive, and oestrogen receptor negative.
Disturbances to DNA ploidy did not appear to increase with cancer size in cancers
over 20mm (Figure 32).
Lymph node involvement was present in several histopathological cancer types, but
was not significantly different between ductal carcinomas of no special type and
special type cancers, X2= 3.16, p<0.10. Lymph node metastases were not
associated with cancer grade X2 0.48, p=0.50, oestrogen receptor concentrations, X
2= 0.2, p=0.5, or DNA ploidy disturbances X2= 0.26, p=0.5.
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Figure 29
Distribution of DNA ploidy status for each screening group, previously screened,
newly screened, and never screened, expressed as a percentage of screening group.
DIP = Diploid, AN = Aneuploid, TET = Tetraploid.
Figure 30
The association between lymph node status and cancer size (diameter in mm) in
invasive cancers, expressed as a percentage of cancer size. Cancers were classified
as node negative where there was no evidence of metastasis to the axillary lymph
nodes, or node positive where cancer cells were present within the lymph node
tissue. Lymph node positivity increases in a linear fashion with cancer size.
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The distribution of histopathological grade with cancer size (diameter in mm),
expressed as a percentage of size group. Cancer sizes have been grouped in 10mm
categories. Grade I cancers decrease in frequency with increasing cncer size, and
conversely grade HI cancers increase in frequency with increasing size.
Figure 32
Distribution of DNA ploidy status with cancer size (diameter in mm), expressed as
percentage of size group. Cancer sizes have been grouped in 10mm categories. DIP
= Diploid, AN = Aneuploid, TET = Tetraploid.
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Figure 31 Cancer Size and Cancer Grade
1-10 11-20 21-30 31-40 >40
cancer size (mm)
1-10 11-20 21-30 31-40 >40
Cancer size
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Other associations between biological characteristics may also be important for
interpretation of cancer features in progression. Highly significant differences in
cancer grade (X2 = 27.1, p<0.001) and DNA ploidy (X2= 24.91, p<0.001) were
found between special type and no special type invasive cancers. Special type
cancers were usually of low grade (grade I, Table 18), and showed less disturbance
to DNA ploidy (Table 19).
Cancers which were negative for oestrogen receptor status (<20fmol/mg protein)
correlated strongly with grade III cancers, X2= 32.57, p<0.001 (Figure 34).
Relationships between these features help to provide a framework of chronological
and biological features in cancer progression.
4.3.4 C-erb B2 Overexpression and Histopathological and Biological
Characteristics of Breast Cancer.
In univariate analysis c-erb B2 expression was found to vary with cancer type, cancer
grade and oestrogen receptor status, but was independent of lymph node status,
screening status and DNA ploidy disturbances. Initial examination of expression in
screen detected groups indicated that expression was more frequent in newly and
previously screened groups, 16% and 23% respectively, than in the never screened
groups (14%), Figure 35, but this was not a significant difference, X2= 2.03, p<0.50,
> 0.10. C-erb B2 overexpression was more frequent in cancers over 21mm in size,
however the frequency did not increase with further increasing size, Figure 36,
thereby resulting in a negative correlation, X2= 7.53, p<0.50. This low frequency of
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Figure 33
Distribution of oestrogen receptor status and cancer size (diameter in mm),
expressed as percentage of size group. Cancer sizes have been grouped in 10mm
categories. Cancers with <20fmol/mg oestrogen receptor (oestrogen receptor
negative) increased in frequency with increasing cancer size.
Figure 34
The distribution of histopathological cancer grade with oestrogen receptor status,
expressed as a percentage of cancer grade. Oestrogen receptor concentrations <20
finol/mg protein were considered negative. The frequency of oestrogen receptor
negative cancers increase with increasing cancer grade.
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Figure 33 Oestrogen Receptor Status and Cancer Size
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Table 18
Frequency of invasive cancer types with histopathological cancer grade.
Table 18
Cancer Grade
Cancer type I II III
No special type 42 180 42
Special type 22 16 2
Table 19
The frequency ofhistopathological cancer type with DNA ploidy status.
Table 19
Ploidy status
Cancer type Diploid Aneuploid Tetraploid
in situ 20 6 4
Invasive
No special type 77 63 40
Special type 20 5 5
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Figure 35
C-erb B2 expression and screening status, expressed as percentages of screening
group, previously screened, newly screened, and never screened. C-erb B2
expression is expressed as; Positive= c-erb B2 protein overexpression, Negative= no
c-erb B2 protein overexpression.
Figure 36
C-erb B2 expression and cancer size (diameter in mm), expressed as percentage of
cancer size. C-erb B2 expression is expressed as; Positive= c-erb B2 protein


























c-erb B2 expression in cancers <10mm was not due to the high frequency of special
type cancers (commonly small and c-erbB2 negative). There was no correlation
between lymph node status and c-erb B2 expression, X2= 0.04 , p=0.5.
The highest frequency of c-erb B2 overexpression was detected in in situ cancers
(38%) with a lower percentage in invasive cancers (15%), described in Chapter 3,
X2= 19.46, p<0.001. In invasive cancers c-erb B2 overexpression was found
predominantly in ductal carcinomas of no special type, with only one special type, a
medullary, positive.
Significant associations were found between c-erb B2 overexpression and high
cancer grade, X2= 10.17, p <0.025 (Figure 37), and oestrogen receptor negative
cancers, X2= 54.37, p<0.001 (Figure 38). No grade I cancers showed
overexpression, whereas grade II and grade III had 13% and 16% of overexpression
respectively.
These results suggest that the frequency of c-erb B2 expression does not change with
any of the chronological features of breast cancer, but is strongly associated with
biological characteristics such as histopathological type and oestrogen receptor
status. On multivariate analysis the significant association of expression with high
grade was not independent of oestrogen status.
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Figure 37
C-erb B2 expression and histopathological grade, expressed as percentage of cancer
grade. C-erb B2 expression is expressed as Positive= c-erb B2 protein
overexpression, Negative= no c-erb B2 protein overexpression. The frequency of
cancers overexpressing c-erb B2 increases with increasing cancer grade.
Figure 38
C-erb B2 expression and oestrogen receptor concentration, expressed as percentage
of oestrogen receptor (ER) group. Oestrogen receptors are categorised as
<20fmol/mg protein, 20-200 frnol/mg protein, and >200frnol/mg protein. C-erb B2
expression is expressed as; Positive= c-erb B2 protein overexpression, Negative^ no
c-erb B2 protein overexpression. The frequency of c-erb B2 expression decreases
with increasing oestrogen receptor concentration.
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4.3.5 C-erb B2 Amplification and Histopathological and Biological
Characteristics of Breast Cancer.
In univariate analysis, c-erb B2 amplification was found to vary with oestrogen
receptor status and showed minor differences in distribution with cancer type, DNA
ploidy and cancer size. The frequency of c-erb B2 amplification was independent of
lymph node status, screening status and cancer grade. C-erb B2 gene amplifications
were present in 55% of the cancers in the never screened group, and in 52% and
61% of previous and newly screened respectively, Figure 39, these differences in
frequency were not significant, X2= 1.03, p=0.50.
There was no significant correlation between the presence of gene amplification and
cancer size, X2= 6.97, p<0.10. Similar percentages of cancers with c-erb B2
amplification were detected in four groups 10mm in size ranging from 11 to >40 mm
(46% to 58%). Cancers of 10mm or less in diameter appeared more likely to be
amplified (71%, Figure 40), but this was not statistically significant. Frequencies of
c-erb B2 amplification for lymph node positive (54)% and negative cancers (55%)
were similar, X2= 0.03, p=0.5.
C-erb B2 gene amplification was present 55% of invasive cancers and 65% of in situ
cancers, see Chapter 3. Amplification was present in lobular (80%), tubular (58%),
medullary (67%), and DCI no special type (52%). C-erb B2 did not correlate with
cancer grade, and was present in 49%, 54% and 45% of grades I, II, and III
respectively, X2=1.03, p>0.50. A significant correlation between ER concentration
and c-erb B2 amplification was observed, Figure 41, X2 = 10.47, p - < 0.01. On
multivariate analysis this association was not independent of c-erb B2 expression.
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Figure 39
C-erb B2 gene amplification and screening status, expressed as a percentage of
screening group, previously screened, newly screened, and never screened. C-erb B2
amplified cancers = dPCR ratio values of 2 or above, non amplified cancers = dPCR
ratio values <2.
Figure 40
C-erb B2 gene amplification and cancer size (diameter in mm), expressed as
percentage of size group. C-erb B2 amplified cancers = dPCR ratio values of 2 or
above, non amplified cancers = dPCR ratio values <2. Cancer sizes have been
grouped in 10mm categories.
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C-erb B2 gene amplification and oestrogen receptor status, expressed as percentage
of oestrogen status group, <20finol/mg protein, 20-200 finol/mg protein, and
>200finol/mg protein.. C-erb B2 amplified cancers = dPCR ratio values of 2 or
above, non amplified cancers = dPCR ratio values <2.
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C-erb B2 gene amplification was most frequent in diploid cancers (60%) with
frequencies of 52% and 51% in aneuploid and tetraploid cancers respectively, these
differences were not significant, X= 3.06, p = <0.50 >0.10.
These results suggest that the frequency of c-erb B2 gene amplification does not
change with chronological features and does not appear to be associated with
biological cancer features investigated in this study.
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4.4 DISCUSSION
Data presented within this chapter provide valuable insights into the biological and
chronological features of breast cancers which formed part of a breast screening
program. The relationships between various features is important in the
identification of markers of cancer progression, and the evaluation of molecular
events. As yet, no invariant markers have been identified. This is probably due to
the considerable heterogeneity of breast cancer disease and to the fact that
examinations of cancer tissues usually represents only a single "time frame". As
screen detected cancers may represent a different phase in cancer chronology from
symptomatic cancers, I attempted to identify those cancer features which differed in
distribution between these sets and how these could be related to cancer progression.
The contribution of c-erb B2 deregulation to breast cancer progression was assessed
using this "framework" of characteristics.
The importance of comparing cancers which have been detected mammographically
with those detected symptomatically cannot be overstated, as this is the only means
at present to obtain breast cancers at different stages of chronology. Early lesions of
the breast are not well characterised (Cardiff 1988), and the critical molecular events
in oncogenesis have not been identified or related to histopathology or cancer
features assessed in this chapter. Current theories of breast cancer progression
suggest that cancers arise following the transition of normal breast cells to
hyperplasia, to in situ, to invasive, to metastatic carcinoma (Cardiff 1988). Other
features, such as cancer size, cancer grade, lymph node status, oestrogen receptor
status, and DNA ploidy are also likely to change with this cancer progression
(Tubiana and Kosceilny 1991), each being an indicator of tissue differentiation,
metastasis or DNA damage. However the exact relationship of these features to
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progression is ill-defined. In addition, by the time an in situ or invasive cancer is
clinically detected it is likely to contain a number of molecular disregulations, not all
ofwhich may be of direct relevance to cancer progression.
4.4.1 Screening Status and Cancer Characteristics.
Cancers detected by mammographic screening are usually non-symptomatic, and
should represent a chronologically earlier population of cancers than those presenting
symptomatically (Miller 1992), although this may represent only a relatively short
period in relation to the complete history of the cancer. In agreement with other
studies (Anderson et al 1991), the mammographically screened cancer sets in this
study contained a higher proportion of small cancers, and in situ and special type
cancers. Differences in the detection of cancer types may not necessarily indicate
different stages of progression, however some current theories suggest that special
type cancers could progress to invasive ductal carcinoma of no special type (Cardiff
1988, Tubiana and Koscielny 1991). The occasional co-existence of different
morphological forms within the same cancer would support this suggestion, however
evidence of true progression remains circumstantial. It is likely that the only feature,
apart from cancer type, which changes significantly over this "window" of cancer
progression is cancer size. Similarly lymph node involvement was strongly correlated
with larger cancer on multivariate analysis.
Few clear differences in cancer grade, DNA ploidy, lymph node status and oestrogen
receptor status were observed between the sets. This may be partly due to the nature
of the newly screened set. These cancers were detected during the prevalence screen
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and included some cancers at a relatively advanced, but sub-symptomatic stage, as
illustrated by the presence of some cancers greater than 40mm in size. The
previously screened set was too small for full analysis ofbreast cancer characteristics,
however a small number of cancers within this group had an unexpected combination
of features. The previously screened set had a higher proportion of grade III cancers
than either of the other sets, and these cancers were largely negative for oestrogen
receptors and lymph node involvement. This suggests that they are rapidly growing ,
poorly differentiated cancers, features not normally associated with an early stage of
progression. Unfortunately the exact time interval between a clear mammographic
screen and detection of the cancer was not available. The newly screened and
previously screened groups therefore appear to represent slightly different sets of
breast cancer.
Overall these results indicate that screening does detect some cancers at an earlier
stage of progression, however there remains considerable heterogeneity within each
set. Therefore, other potential markers of cancer progression remain important.
4.4.2 Histopathological and Biochemical Features of Breast Cancer and
Cancer Progression.
Cancer features can be classified according to "good" or "bad" characteristics
indicated by the data analysed in this study, see Table 20, and a simplistic
hypothetical "framework" of features relating to cancer progression suggested. Early
stages of cancer progression may be associated with low grade, oestrogen receptor
positivity, in situ or special type cancers, small size and lymph node negativity.
Whereas late stages of cancer progression may be associated with high grade, large
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size, oestrogen receptor negativity, ductal carcinomas of no special type and lymph
node positivity.
Cancer features have been positioned in Table 20 according to their relative
associations found in this study. Assessment of screening groups with size and
lymph node status established them as chronological factors (section 4.4.1). Both
histopathological grade and DNA ploidy status were significantly correlated with
cancer size, suggesting breast cancer cells become more poorly differentiated and
show more disturbance to DNA ploidy with cancer progression, indicated by cancer
size. An association between cancer grade and progression has been observed by
others (Tubiana and Koscielny 1991), although it is unclear how many cancers will
remain at the same grade throughout their "life". The speed at which transition
occurs between grades could be very variable (Tubiana and Koscielny 1991), a
conclusion supported in this study by the finding of some large cancers of low grade
(Table 31). Changes to DNA ploidy are also thought to increase with cancer
progression (Bacus et al 1990). In this study small cancers were clearly more
frequently diploid, but aneuploid and tetraploid cancers did not increase in frequency
in cancers over 20mm in size, suggesting that the relationship between DNA ploidy
and progression indicated by cancer size may only apply over a relatively short size
range.
The percentage of lymph node positive cancers increased with cancer size, indicating
that the larger, growing cancers have more cells which are able to grow in the nodes.
However, positive lymph nodes were not strongly associated with other markers of
aggression such as changes in DNA ploidy, cancer grade, oestrogen receptor
negativity, and did not vary greatly with screening status. A model proposed by
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Tubiana and Koscielny (1991) suggested that there was a continual progression from
an initial lack of involvement of lymph nodes to the involvement of one or two nodes
as the primary cancer volume increases. While the number of involved nodes may be
important in an assessment of cancer prognosis, lymph node sampling and assessment
was not extensive or complete in the surgical operations where my samples
originated (usually three of potentially >20 nodes).
Whilst oestrogen receptor concentration was not significantly associated with many
indicators of progression, a strong correlation between low oestrogen receptor
concentration and high cancer grade would indicate that loss of oestrogen receptor is
associated with "late" stage disease. This has been confirmed in other studies, which
also found correlation with aggressive breast cancer (Schroeter et al 1992, Slamon et
al 1989, Tsuda et al 1989). However oestrogen receptor expression may be
controlled by several mechanisms (Piva et al 1988, Piva et al 1993, Kameko et al
1993) and should be regarded as a biological marker rather than a chronological
marker of progression.
4.4.3 Overexpression of c-erb B2 and Cancer Progression.
The high frequency of disregulation of c-erb B2 suggests that it may play a role in the
aetiology of breast cancer. However, it is not clear at what point(s) of progression
the disregulation of c- erb B2 may occur, or what its contribution to the disregulated
phenotype may be. A model of cancer progression involving c-erb B2 in breast
cancer has been proposed by Alfred et al (1992). They proposed that c- erb B2
expression is an early or initiating event in some cancers, particularly comedo type in
situ cancers, only a proportion of which progress to invasive carcinomas, or that c-
erb B2 expression is reduced on transition from in situ to invasive carcinoma. In
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addition, they suggest that many invasive cancers progress to invasive ("de novo")
without a significant in situ stage and without c-erb B2 expression. This model is
based on histopathological features of breast cancer, and does not fully discuss the
potential effect of factors which may alter the expression of the gene.
In this study of c-erb B2 expression was associated with both "early" and "late" stage
cancer characteristics. C-erb B2 overexpression has not been detected in putative
pre-neoplastic lesions (Allred et al 1992, Gusterson et al 1988, De Potter et al 1989)
but appears to be associated with in situ or invasive types of cancer. In agreement
with several other studies (Allred et al 1992, Barnes et al 1992, Gusterson et al 1988,
De Potter et al 1989), I found that c-erb B2 overexpression was significantly
associated with certain cancer types, with the highest frequency being detected in in
situ cancers, see Chapter 3 Table 12. This may suggest that c-erb B2 expression is a
marker of the transition between these stages of development in some breast cancers,
providing that the cancer type changes with progression. Because the frequency of
c-erb B2 overexpression did not appear to vary with screening status, lymph node
status, DNA ploidy disturbance, or cancer size, this suggests that c-erb B2
expression can be an early, stable event.
In apparent contradiction to the results discussed above, c-erb B2 expression was
also significantly associated with high cancer grade and oestrogen receptor
negativity, both potential markers of late stage disease. This has been observed in
other studies (Russell and Hung 1992, Todd et al 1992), and may indicate a
functional relationship between c-erb B2 and oestrogen receptor. Oestrogen
receptor functions as a nuclear receptor involved in transcriptional regulation of
target genes (King 1992), and may have the potential to down regulate the
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expression of c-erb B2. This has been shown to occur in vitro, where c-erb B2
expression in breast cancer cell lines can be down-regulated by oestrogen receptor
complexed with oestradiol (Russell and Hung 1992, Todd et al 1992). Results here
indicate that this also occurs in vivo, indicating that c-erb B2 expression is not
related to late stage disease but has a biological association with oestrogen receptor.
These associations indicate that expression of c-erb B2 may be an early event,
however its biological effect on cancer progression remains unclear.
4.4.4 C-erb B2 gene Amplification and Cancer Progression.
C-erb B2 expression is closely associated with c-erb B2 gene amplification, see
Chapter 3, but it remains unclear whether these events are separate disregulations or
causally related. A high percentage of cancers in this study had c-erb B 2 gene
amplification in the absence of overexpression, but as discussed above, c-erb B2
expression can be regulated by other factors, therefore the relationship between these
events and to cancer progression is difficult to establish. C-erb B2 gene amplification
has been proposed in some studies as a late event (Kraus et al 1987), but this was
based on the observation that expression was more frequent especially in in situ
cancers.
In contrast, results in this study suggest that c-erb B2 amplification may be an "early"
genetic event that is maintained during cancer progression and does not greatly
change in frequency between screening groups. Its common presence in all cancer
types, including special types, which are almost universally negative for c-erb B2
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overexpression, suggests that it may be associated with a fundamental change in the
normal breast epithelial cell. Indeed c-erb B2 gene amplification is more frequent in
in situ cancers than invasive cancers, see Chapter 3. C-erb B2 gene amplification
was independent of cancer size, lymph node status, cancer grade, and disturbance to
DNA ploidy. A weak negative correlation with oestrogen receptor was found, but
this was not independent of c-erb B2 expression. This lack of association with "late"
stage markers also supports an early role for gene amplification. This finding
contrasts with other studies of amplified genes, where amplification ofEGFR and n-
myc were associated with late stage (III and IV) cancer (Brodeur et al 1984,
Ekstrand et al 1991, Ranzani et al 1990).
The mechanisms of c-erb B2 gene amplification are poorly understood, but are
unlikely to be due to purely random chromosomal disruption. Changes in DNA
ploidy generally indicate progressive cellular disregulation, cancer cells are thought
to become tetraploid during cancer development, then lose extra chromosomes in a
random fashion over time to become aneuploid (Bacus et al 1990). In this study
there was no association of c-erb B2 gene amplification with increasing DNA ploidy
disturbances, this concurs with a large study (Borg et al 1991), and suggests that
gene amplifications are due to stable changes in chromosome structure, not
detectable by DNA ploidy analysis.
4.4.5 Conclusions
Cancer size and lymph node status have been identified as chronological markers of
breast cancer and a hypothetical framework of cancer characteristics in relation to
cancer progression is proposed. While it is clear that the role of c-erb B2 in the
progression of breast cancer is complex, disregulation of c-erb B2 does appear in
188
relatively early cancers. Amplification does not appear to increase or decrease with
features of late stage disease, and may suggest that it is a relatively stable event. C-
erb B2 overexpression also occurs in "early" cancers, but expression may be
temporal and depend on transcriptional control mechanisms. However not all
cancers have detectable c-erb B2 deregulation, therefore alternative pathways of
cancer progression which do not involve c-erb B2 disregulation exist.
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CHAPTER 5
Possible Allelic Imbalance of c-erb B2 in Breast Cancer.
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5.1 INTRODUCTION
The high frequency of c-erb B2 disregulation in breast cancer, especially gene
amplification, suggests that it represents a specific event, selected for in the process
of breast carcinogenesis. The precise chromosomal location and extent of c-erb B2
amplification in cancer tissues is still unclear. Amplifications of greater than 40
copies of c-erb B2 have been reported (Ali et al 1988, Berns et al 1992, Tavassoli et
al 1989) but most breast cancers harbour less than 10 extra copies of c-erb B2
(Chapter 3, Borg et al 1991). A biological selection pressure for c-erb B2
amplification may exist in breast cancer, but very high gene copy number may also
indicate an amplification mechanism which is "jammed on". In situ hybridisation
studies have suggested that c-erb B2 amplifications are present at more than one
chromosomal location and that the copy number is variable between cells (Smith et al
1993), but it is not known whether c-erb B2 amplifications are present on
chromosome 17q, in homogeneously stained regions within other chromosomes, or
as extra-chromosomal DNA forming double minutes.
It is not known whether one or both alleles are involved in c- erb B2 amplification
and whether amplification is a random process, equally as likely to affect each allele.
Investigation of possible associations between gene amplification and genotype, and
analysis of relative allele intensity may provide some clues to processes involved in
gene amplification. Amplifications may arise from either deregulated DNA
replication mechanisms or deregulated gene transcriptional mechanisms (Stark et al
1989), see Chapter 1. Gene overexpression prior to gene amplification has been
proposed as a key factor in gene amplification of the multiple drug resistance gene 1
in cell lines (Shen et al 1988) and of c-erb B2 in breast cancers (Kraus et al 1987).
This may involve disregulation of gene expression, in which increased or altered
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transcription may lead to a malfunction of normal DNA replication resulting in re-
replication of newly replicated DNA in S phase of the cell cycle (Stark 1989). This
process could involve gene promoters, or suppressers, which may act upon both
alleles of c-erb B2, assuming that the transcriptional control regions of each allele are
the same. Uneven recombination followed by amplification could also result in
amplification of both alleles in one cell lineage, accompanied by complete loss in
another. Alternatively, preferential amplification of one allele could suggest a genetic
predisposition associated with that allele. Predisposition could result from a
functional difference associated with a polymorphism or a genetic linkage to another
relevant DNA sequence. Purely random amplification mechanisms would effect
either or both alleles.
Several oncogenes have shown allelic imbalance in various cancer types, such as c-
Ha-ras in breast cancer and L-myc in bone and soft tissue sarcomas (Honda et al
1988, Kato et al 1990). It has been suggested that a higher frequency of rare alleles
in cancers than in the normal population may indicate a predisposition to
carcinogenesis associated with that allele (Honda et al 1988, Kato et al 1990).
However, this remains only a possibility and has not been experimentally confirmed.
Genes which show allele imbalance in breast cancer are infrequently amplified,
therefore any potential relationships have not been identified. Other oncogenes, such
as c-myc (Riou et al 1984, Riou et al 1987), which can be amplified in breast cancer
have not been investigated for allele specific amplification.
A restriction fragment polymorphism of c-erb B2 permits the analysis of the
genotype and of the relative intensities of c-erb B2 alleles in breast cancer DNA. The
polymorphism is present in the general population, and has a polymorphism
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information content of 0.3, that is 30% of the population will be heterozygous at this
locus. The polymorphic site is formed by a single base pair insertion within intron 3
of the gene which creates an additional Mbol restriction site, and is detected on
restriction digestion of a 1.1 kb PCR amplified DNA sequence spanning the
polymorphic site (Hall et al 1990a).
This study aimed to;
1) Determine the allele frequencies and allelotypes for the c- erb B2 polymorphism
in c-erb B2 amplified and non-amplified breast cancers and in control DNAs.
2) Assess relative band intensities in heterozygous patients and controls to identify
whether one or two alleles have been amplified.
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5.2 MATERIALS AND METHODS
5.2.1 Tissues
Breast cancer tissues were obtained at routine surgical operations, as described in
Chapter 3. Each tissue was snap frozen and stored at -70°C. Samples were
restricted to cancers of sufficient size to provide tissue for DNA extraction. These
varied from 7mm to 80mm in diameter. In situ cancers were not measured. Most of
the cancers were invasive of no special type (DCINST), 5 were in situ carcinomas, 4
were invasive lobular, 2 were invasive tubular and one was mucinous. Control tissue
was obtained from non involved colon tissue from colon cancer patients. Tissue
DNA was prepared by standard methods (Sambrook et al 1988) and resuspended to
a final concentration of lmg/ml. Histopathological characterisation of the tissues
was performed on fixed tissue taken adjacent to the frozen portion. As described in
Chapter 3, the proportion of "contamination" by normal stromal cells was assessed
subjectively in these fixed tissues.
Any c-erb B2 amplification was determined by differential polymerase chain reaction
on DNA from fixed tissues and DNA ploidy changes were assessed by flow
cytometry. Both methods are described in Chapter 3.
5.2.2 Allele Analysis
For each specimen a 1.1 kb fragment of the c-erb B2 gene was amplified using
specific primers spanning the polymorphic site: sense 5'CTG GAA TGG GAA GCA
3' and antisense 5'GCC AGC AAA GAA ATC TTA GAC GT 3' (Hall et al 1990a),
with 200ng of template DNA, 250pmol of each primer, 200mM dNTPs (Pharmacia),
lx reaction buffer (Bioline, UK), and 0.5 unit Taq polymerase (Bioline, UK) in each
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tube for a PCR reaction. Cycling was performed on a Hybaid Omnigene thermal
cycler incorporating parameters of one cycle of 94°C for 5 mins, 55°C for 1 min,
72°C for 1 min 30 sec, followed by 30 cycles of 94°C for 1 min, 55°C for lmin, 72°C
for 1 min 30 sec, and one cycle of 94°C for one min, 55°C for 1 min and 72°C for 5
mins. Each PCR product was digested twice with 3 units of restriction enzyme Pvu
II (Sigma, UK) at 37°C for 3 hours. Buffer concentrations of Tris HC1 and NaCl
were altered to give a final concentration of 50mM Tris HC1 pH 7.9 and lOOmM
NaCl. Samples were then digested twice with 3 units ofMbo I (Sigma) at 37°C for a
further 3 hours, to digest the PCR products into the allelic bands of 520 or 500 bp.
The Pvu II restriction was necessary to pre-digest a constant band of 550 bp, which
would appear with Mbo I digestion alone, and would confuse identification of the
Mbo 1 allelic bands.
Restriction fragments were separated by size through a 1.8% Metaphor agarose gel
(FMC products, UK) for 2 hours at 125V, stained by ethidium bromide, visualised in
ultra violet light, and photographed. Each specimen was tested in duplicate
experiments. A molecular weight marker (1.1 kb ladder) was run in an adjacent gel
track to each sample. Allelotypes and relative band intensity were assessed visually,
and scored independently by myself and another scientist (Dr V.J. Bubb, Dept.
Pathology, Edinburgh).
5.2.3 Population Analysis
Allele frequencies for each group were calculated and genotype distribution for
amplified, non amplified and controls were tested for goodness of fit with the Hardy-
Weinberg equilibrium. The Hardy-Weinberg theorem is used to calculate the
frequencies of homozygotes and heterozygotes within a population. The theorem is
based on the principle that in the absence of migration, mutation, and selection, gene
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frequencies remain constant in a large population. Expected genotype distribution is
calculated from the observed allele frequencies using the equation p2 + 2pq + q2 =1,
where p and q represent the frequency of each allele. Deviations from this
equilibrium are calculated using a chi-squared test on observed and expected
frequencies. Two by two contingency tables and chi-squared statistics were used to
assess differences in allele frequencies between groups.
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5.3 RESULTS
5.3.1 Allele analysis and Frequencies.
A 1.1 kb fragment of c-erb B2 was PCR amplified and digested from 70 breast
cancers and 34 controls. Digestion with Mbo I and Pvu II resulted in one or two
allelic bands of 520bp (Al) and 500bp (A2), and two constant bands of 330bp and
220bp, as illustrated in Figure 42. All digests with Mbo I and Pvu II were complete,
with no evidence of residual PCR product after gel electrophoresis of digested
product.
The distribution of genotypes for amplified, non-amplified and control tissues are
shown in Table 21. Allele frequencies determined from the distribution of genotypes
within each group were not significantly different between "total" cancers and
controls. Nor were there significant differences in allele frequencies between
amplified and non amplified cancers, Table 22, X2= 2.01 , p= 0.2-0.10.
5.3.3 Genotype Distribution.
Chi-squared analysis of observed genotype distribution for each group did not
deviate significantly from expected frequencies, Table 21. Further analysis of
genotype distribution in the amplified cancer group using the allele frequencies of the
normal and non amplified groups, Tables 23 A and B, demonstrated a deviation from
the Hardy Weinberg equilibrium. These differences were statistically significant
when non amplified allele frequencies were used in the equation, X2 = 9.12,




Photograph illustrating a restriction fragment length polymorphism contained within
intron 3 of c-erb B2. Breast cancer DNA in tracks 1-6 represent anMbo I and Pvu
II restriction digest of a 1. lkb PCR amplified sequence of c-erb B2. Allelic bands are
indicated at 520bp (Al) and 500bp (A2), constant bands of 330bp (CI) and 220bp
(C2) are indicated. Track 1 shows a homozygous A2 DNA, track 2 shows a
homozygous Al DNA, and tracks 3, 4, 5, 6 are show heterozygous DNA. Allelic






Genotype distribution of breast cancers groups with (Amplified) and without (Non-
Amp) c-erb B2 gene amplification, and a normal control group (Control). Allele
frequencies were determined from observed genotypes (O) for each group (p = Al, q
= A2), and the expected genotype frequencies (E) calculated according to the Hardy-
Weinberg equilibrium (p2+2pq+q2=l). Chi-squared statistics were performed for
each group and p values given
Allele
Genotypes Frequencies
Group n O/E Al/Al A1/A2 A2/A2 p a
Amplified 34 O 15 12 7 0.62 0.38
E 13 16 5










X2-0.64, = >0.2 <0.5
Control 37 O 20 11 6 0.69 0.31




Observed allele frequencies (A1 and A2) for c-erb B2 amplified and non amplified
breast cancers. Allele frequencies were compared in a two by two contingency table.
Chi-squared statistics showed that allele frequencies were not significantly different
between c-erb B2 amplified and non amplified cancers.
Allele A1 (p) Allele A2 (q) total
Amplified 42 26 68
Non-amplified 55 21 76
total 97 47 144
X2= 2.01, p= 0.1-0.2
Table 23
Distribution of c-erb B2 genotypes in c-erb B2 amplified cancers. Expected values
according to the Hardy-Weinberg equilibrium were calculated using allele
frequencies of A. = nonamplified cancers, and B = normal controls. Chi-squared




Al/Al A1/A2 A2/A2 X2 ^
observed 15 12 7 9.12
expected 17 14 3 p=<.01
B
Genotypes
Al/Al A1/A2 A2/A2 X2
observed 15 12 7 5.99
expected 16 15 3 p=.05-.01
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Distribution of genotypes with changes ofDNA ploidy are shown in Table 24. The
c-erb B2 genotype distribution in cancers which were diploid and tetraploid showed
no deviation from Hardy-Weinberg equilibrium, however a reduced frequency of
heterozygotes was observed for aneuploid cancers which approached significance.
Study numbers were too small to subdivide each ploidy group by amplification
status.
5.3.4 Allele amplification.
Heterozygotes were assessed for allele band intensity, and scored as even intensity
(e), more intense allele 1 (Al), or more intense allele 2 (A2), Table 25. All control
heterozygotes had even intensity bands. Thirty one percent of heterozygous non-
amplified cancers showed uneven band intensity, equally distributed between Al and
A2. However, 58% of heterozygous amplified cancers showed uneven band
intensity, with 5 of 7 of the most intense bands being A2.
Case numbers were too small for any clear assessment of possible associations
between genotype distribution and clinical characteristics, such as screening status,
cancer type, cancer grade, lymph node involvement and oestrogen receptor status.
Eleven of the study cases overexpressed c-erb B2 and all but one of these had gene
amplification. Deviation of genotype distribution from the Hardy-Weinberg
equilibrium was observed in c-erb B2 overexpressing cancers, and approached




Distribution of c-erb B2 genotypes with DNA ploidy status, diploid, tetraploid and
aneuploid. Allele frequencies were calculated for each group (p and q), and expected
values determined according to the Hardy-Weinberg equilibrium and are given in
parenthesis. Chi squared statistics were performed on observed and expected values,
and p values given.
Genotype
DNA Ploidv Al/Al A1/A2 A2/A2 A1 fpt A2 (a) X2
Diploid 9(10) U(10 ) 2(2) 0.66 0.34 0.2
ns
Tetraploid 10 (9) 5 (7) 2 (1) 0.73 0.26 1.68
ns
Aneuploid 12 (10) 5 (10) 5 (2) 0.66 0.34 7.4
p=<0.05
Table 25
Allele analysis of c-erb B2 polymorphic bands in heterozygous breast cancers and
controls. The relative intensity of allelic bands on agarose gels was assessed visually,
and recorded as A1 or A2 where the respective allele was most intense, or E, where
heterozygous bands were of equal intensity. Only breast cancer cases showed
uneven band intensities.
Group Heterozygote band intensity
A1 E A2
Amplified 2 5 5
Not amplified 2 9 2
Control 0 11 0
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5.4 DISCUSSION
Analysis of frequency and distribution of c-erb B2 has identified differences in
genotype distribution between cancers with and without c-erb B2 gene amplification.
Allele A2, the 500 bp Mbo 1 allelic band, may occur more frequently in c-erb B2
amplified cancers, than in non-amplified cancers or normal colon tissue. Where
cancer tissue DNA was heterozygous at the c-erb B2 locus in c-erb B2 amplified
cancers, allele A2 formed a disproportionately high percentage of the alleles
amplified. These findings may indicate a bias in allele amplification.
The allele frequency and genotype distribution of the Mbo I site c-erb B2
polymorphism for the control population in this study were both similar to those
published for a normal American population (Hall et al 1990a). Allele frequencies
can differ between populations physically isolated from one another and between
different ethnic groups (Chakraborty 1990, Devlin et al 1993) and genotypes can
deviate from the Hardy-Weinberg equilibrium (Sullivan et al 1992), complicating the
interpretation ofgenotype distribution. However, it appears that allele frequencies at
the c-erb B2 locus are stable, at least for those with European ancestry, and that the
genotype distribution is not subject to selection pressure within the normal
population.
In this study, allele frequencies were similar for control and cancer populations.
However when cancers were analysed in c- erb B2 amplified and non amplified
groups a difference in allele frequency was apparent, but did not reach significance.
Analysis of a larger study set may resolve this trend, which indicated that allele A2
may be more frequent in c-erb B2 amplified cancers. Disturbances to allele
frequency have been reported in cancer populations, including oncogenes L-myc and
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c-Ha-ras, and may indicate that there is an association of specific alleles with
initiation or progression of cancer (Champeme et al 1992, Kato et al 1990,
Kawashima et al 1992, Lidereau et al 1986). Possible reasons for an excess of rare
alleles in a population include population "bottlenecks", the presence of slightly
deleterious mutations or hidden sub-divisions within populations (Chakraborty
1990). Hidden sub-divisions may become apparent when the rare alleles are
associated with factors which become phenotypic, such as the development of
cancer.
Selection pressure may also be apparent in the distribution of genotypes within a
population. The distribution of genotype in the amplified cancer group deviated
significantly from those expected according to the Hardy-Weinberg equilibrium,
suggesting that a selection pressure may apply to this cancer group. It is possible
that the selection pressure may be linked to gene amplification, as other cancer
features are heterogeneous within this group. C-erb B2 amplified cancers showed an
increase in A2 homozygotes and a reduction in A1/A2 heterozygotes, suggesting a
potential bias associated with amplification. This bias for c-erb B2 genotype
distributions may extend to cancers which overexpressed c-erb B2 protein, but case
numbers were not sufficiently large for satisfactory analysis.
Deviations from the expected genotype frequencies have been reported in both
normal populations and those with cancer (Doering et al 1992, Sullivan et al 1992,
Mittanack et al 1993). This usually takes the form of an increased frequency of
heterozygotes, such as that observed for the HLA-DQ alpha locus in a normal Asian
population (Sullivan et al 1992), or sickle cell anaemia (Simpson et al 1991). In
contrast the c-erb B2 polymorphism in c-erb B2 amplified cancers shows a reduction
in heterozygotes and increase in homozygotes. The biological basis for selection
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pressure usually involves change of gene product function, and at the sickle cell
anaemia locus results in heterozygote vigour, but in many other cases is unknown.
Polymorphisms or mutations which can alter the normal function of a gene product
are usually contained within coding exons of the gene. However, the c-erb b2
polymorphism studied here is contained within an intron (Hall et al 1990a). This
does not necessarily mean that this polymorphism cannot effect the gene product as
some intronic sequences can have regulatory functions (Kawashima et al 1992).
However, a direct functional relationship between genotype and gene amplification is
unlikely as c-erb B2 gene amplifications are present in all genotypes. Other
oncogenes prone to gene amplification, such as N-myc, can also show a non-random
distribution of genotypes, and like c-erb B2, this polymorphism is also contained
within an intron (Waber et al 1991). Genetic linkage to another gene of relevance to
gene amplification could be another reason for genotype distribution disturbance.
A major finding of this study is that one or both alleles can be amplified. This
suggests that there may be more than one mechanism of gene amplification or that
different post-amplification events occur. Current theories of how genes become
amplified favour a gene recombination event followed by unequal distribution of the
recombined DNA into two daughter cells (Stark 1989), one containing gene
amplification the other, gene loss (Stark 1989), repetition of the process during
subsequent cell cycles could result in multiple gene copies involving both alleles.
Mechanisms which amplify single alleles may include amplification after allele loss or
allele duplication, a mechanism demonstrated in vitro for the c-Ha-ras gene in
nitrosomethylurea induced mammary adenocarcinoma (Aldaz et al 1992). Gene
overexpression may play a role in these mechanisms (Kraus et al 1987, Shen et al
1988), but experimental evidence in vivo has not been obtained.
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Examination of the relative intensities of heterozygous c-erb B2 amplified cancers
provided further indication of specific allele involvement. One allele was more
frequently amplified than both (see Table 25), with a bias towards allele A2. These
results indicate that there is a possible association between c-erb B2 allele A2 and c-
erb B2 gene amplification. However the exact mechanism(s) of c-erb B2 gene
amplification are not clear, and further experimentation is necessary to resolve this.
A potentially confounding factor pertinent to both genotype distribution and allele
specific amplification is the presence of loss of heterozygosity at 17q, previously
reported in up to 60% of breast cancers (Cropp et al 1990, Devilee et al 1989). This
could partly explain a reduced frequency of A1/A2 heterozygotes and an increased
frequency of Al and A2 homozygotes. If this does occur then this would suggest
that allele loss occurs more frequently in c-erb B2 amplified cancers and could be
related to the amplification process. Such allele losses may be indicated by a
deviation of genotype distribution, as allele frequencies would not deviate from
normal if the losses were random (equivalent numbers ofAl and A2 alleles would be
lost).
An indication of chromosome (therefore allele) loss may be obtained from the
analysis of genotype distribution with DNA ploidy change. Aneuploid cancers
deviate from the Hardy-Weinberg equilibrium and show a reduction in A1/A2
heterozygotes, and an increase in Al and A2 homozygotes over those expected.
This indicates that some random loss of chromosome 17 DNA may occur, but due to
the relatively crude nature of DNA ploidy analysis more specific analysis is not
possible. Due to the small size of the study set it was not possible to determine
whether the genotype deviation found for c-erb B2 amplified cancers was
independent of aneuploidy. However, analysis of DNA ploidy and c-erb B2 gene
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amplification (Chapter 4) indicates that aneuploidy is not positively associated with
amplification, and diploid cancers are more frequently amplified.
These results clearly indicate that allele specific amplification is worthy of further
analysis. Deviation to the expected c-erb B2 genotype distribution in c-erb B2
amplified cancers may indicate a biological basis for amplification mechanisms, either
as increased susceptibility or by linkage to another relevant DNA sequence. I have
shown that c-erb B2 gene amplification may not be a single or straightforward
mechanism, and that different mechanisms or post amplification events occur. Allele
loss may be implicated in the amplification process. This is an important area of
research as very little is known of the mechanisms of gene amplification which is a
common event in breast cancer.
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CHAPTER 6
THRA1 - a co-conspiritor?
209
6.1 INTRODUCTION
Chapter 3 established that c-erb B2 was frequently disregulated in breast cancer, with
a high percentage of cancers containing c-erb B2 gene amplifications. DNA
amplifications encompassing c- erb B2 on chromosome 17 appear to be variable in
size, and may include other important genes nearby (Keith et al 1993). The extent
and type of any chromosome 17 DNA amplification within individual breast cancers
with c-erb B2 gene amplification is often not known, but may include genes such as
the thyroid hormone receptor gene (THRA1), retinoic acid receptor, and
topoisomerase II, which have been mapped to 17ql3-q21 (Mattei et al 1988, Tsai-
Pflugfelder et al 1988, Weinberger et al, 1986). Indeed all four of these genes have
been shown to be co-amplified with c-erb B2 in a small number of breast cancers
(Keith et al 1993), indicating that amplicon involving c-erb B2 can include several
genes. Amplification ofTHRA1 gene has been reported in 23-64% of breast cancers
with c-erb B2 amplification, but not in breast cancers without c-erb B2 amplification
(Futreal et al 1992, Tavassoli et al 1989, Tsuda et al 1989). Furthermore, this region
of chromosome 17 is of extreme interest in breast cancer as one of the genes
responsible for familial breast cancer BRCA1 localised at 17ql2-q21 (Hall et al
1990b, Miki et al 1994, Narod et al 1991).
THRA1 is of particular interest as its oncogene, v-erb A, along with v-erb B, is
present on the avian erythroblastosis virus (Graf and Beug 1983). V-erb A alone
does not appear to transform cells, but when co-transfected with v-erb B, enhances
the transforming ability of v-erb B (Frykberg et al 1983, Graf and Beug 1983, Kahn
et al 1986). V-erb A does contain several mutations likely to effect the functioning
of the receptor (Sap et al 1989), including a missence mutation in the zinc finger
DNA binding domain (Bonde et al 1991). These mutations may alter the binding
210
specificity and abrogate the receptors capacity to bind thyroxine (Bonde et al 1991,
Damm et al 1989). No mutations have been found in its cellular counterpart (Futreal
et al 1994).
The normal product of THRA1 is the thyroid hormone receptor (TR), a member of
the steroid receptor family (Sap et al 1986), which when bound with ligand can act as
a transcription factor (reviewed in King 1992). The transcriptional specificity of
THRA1 is dictated by the binding affinity of the receptor protein to the steroid
response elements (SRE) within the target gene promoter (King 1992). The SRE
usually consists of two hexameric DNA base sequences, which may be separated by
three variable nucleotide bases within the promoter region of the target gene (King
1992). These sites are recognised by the zinc finger regions of the receptor, which in
THRA1 are coded by exons 4 and 5 of the gene (Laudet et al 1991). The amino acid
sequence of these zinc fingers is critical for binding the specific target sequences, as
only a single amino acid change, Gly-Ala, could convert the receptor into a molecule
which would recognise oestrogen rather than thyroxine response elements (Glass et
al 1990).
The similarity of oestrogen receptor (ER) and TR in target DNA binding, for both
the amino acid sequence of their zinc fingers and the steroid response elements in
target genes, suggests that there may be some possible interrelationship between their
functions. Mutations in either of these elements could result in an altered THRA1
receptor specificity, which could have the potential to mimic ER specificity. This
may be of relevance to cancers with amplified c-erb B2, as one function of oestrogen
receptor may be to down regulate the expression of c-erb B2 (Chapter 4, Antoniotti
et al 1994, Russell and Hung 1990). Co-amplification of THRA1 may indicate the
potential for increased transcription of the receptor, which could potentially effect
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the relationship between c-erb B2 amplification and c-erb B2 expression. The DNA
binding sequence (zinc fingers) of THRA1 is therefore worthy of investigation. A
hypothesis pertaining to possible relationships between THRA1, ER and c-erb B2 is
outlined in Figure 43.
The aims of this chapter were to:
1) Establish the extent of co-amplification of TH0RA1 and c-erb B2 using differential
PCR.
2) Investigate the DNA sequences coding for the zinc fingers of THRA1 for




Ideogram illustrating potential transcriptional control mechanisms of c-erb B2. C-erb
B2 gene transcription can be initiated by promoter molecules, possibly in conjunction
with enhancer elements. Transcription of c-erb B2 may be blocked, either directly or
indirectly, by oestrogen complexed with oestrogen receptor. The thyroid hormone
receptor (THRA1) with or without thyroxine, due to close homology with oestrogen
binding specificity (zinc fingers), may also be able to block c-erb B2 transcription.














6.2 MATERIALS AND METHODS
6.2.1 Breast Cancer Study Set.
The status of THRA1 was examined in 90 breast cancers, a random subset of the
study set previously described in Chapter 3 (section 3.2.1), and in 24 control DNAs
derived from normal colon tissue. Template DNA was prepared from frozen tissue
and or fixed paraffin embedded tissue according to methods outlined in Chapter 2
(section 2.2.2).
6.2.2 Primers and the Differential Polymerase Chain Reaction
Primers were designed using "Primer" software v0.5 (Whitehead Institute, USA)
from the THRA1 DNA sequence published by Laudet et al 1991. DNA sequence
was available only for exons 1 to 10, and included only limited flanking intronic
sequence. Primers were designed to amplify exons 4 and 5, which represent two zinc
finger coding sequences (Laudet et al 1991), and are listed in Table 26.
Primer sets for each exon were first tested individually for specific product in a
standard PCR reaction (Chapter 2), but using variable buffer concentrations and
annealing temperatures. Primers for exon 4 and exon 5 were then tested for
efficiency in the standard differential PCR (Chapter 2, section 2.2.3.2), and ratio
values calculated according to methods outlined in Chapter 2 (section 2.2.4).
Correction factors of xl.06 and xl.8 were applied to average cpm of exon 4 and
IFNG150 in dPCR for exons 4 and 5 respectively.
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Table 26.
Primer sequences designed using "Primer" software (Whitehead Institute, USA) for
PCR amplification of DNA sequences of exons 4 and 5 of THRA1. The primer
sequence, gene location according to base pair numbers of Laudet et al (1991), and
PCR product size (in base pairs) are given. PCR product sizes for primer




Exon primer primer sequence location
4 A1 forward CTT TGG GCA AAT TGC TTC AT 301-320
A2 reverse CTT TGG GCA AAT TGC TTC AT 449-429
4 B1 forward CCC AGG GTA TAT CCC TAG TT 306-325
B2 reverse ATC TCA CCA AGC TTC CAT AC 431-411
4 C2 reverse ATT GCT TCA TCA TCT CAC CAA GC 439-420
D1 forward TTG GTT CAG GAA GGG GAA G 197-215
D2 reverse TCT ATT CCC TCC ACC TGG G 431-413
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2.2.2 Single Stranded Conformational Polymorphism (SSCP) Analysis.
DNA from breast cancers and control tissues were examined for mutations or variant
sequences in exons 4 and 5 by SSCP. For each sample, 200ng of DNA was PCR
amplified in xl reaction buffer (BCL or Bioline) containing 5mmol MgCl2 (exon 4)
or 1.5mmol MgCl2 (exon 5), 200mmol dNTPs, 250pmol primers B1 and B2 (exon
4), or D1 and D2 (exon 5), and 1 unit Taq polymerase (BCL or Bioline). 5% of
DMSO was added to PCR reactions for exon 4. Cycling parameters were one cycle
of 94°C for 4min, 55°C for lmin, 72°C for lmin, 28 cycles of 94°C for lmin, 55°C
for lmin, 72°C for lmin, and one cycle of 94°C for lmin, 55°C for 1 min, 72°C for 5
mins. PCR products were extracted once in an equal volume of chloroform: isoamyl
alcohol (24:1) and denatured in 0.3MNaOH, ImM EDTA at 50°C for 5mins. 7.5 pi
of stop loading buffer (Appendix 1) was added to 15pi of denatured PCR product
prior to loading on 6% nondenaturing polyacrylamide gel (MDE, AT Biochem Inc.)
(see Appendix 1). Each sample was electrophoresed at 20W per gel for either 2 hrs
at 20°C or 4.5hrs at 4°C. For gels electrophoresed at 4°C glycerol was omitted from
the acrylamide gel solution. To visualise single stranded product bands the gels were
stained using Biorad silver staining reagents and protocols, see Appendix 2. After
staining the gels were fixed twice in methanol:acetic acid for 5mins and dried under
vacuum, then laminated. Band patterns were assessed visually.
6.2.3 Sequencing ofDNA with Variant SSCP Bands.
Variant sequences found by SSCP analysis were sequenced using two different
techniques: Cycle sequencing and Sequenase sequencing. Template preparation,
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resulting in single stranded template for sequencing, consisted of either Dynabeads
preparation (Dynal, Norway) or cloning into plasmid vector, pGEM 7z f+.
6.2.3.1 Dynabead Preparation of DNA Template for Sequencing. Dynabeads
are superparamagnetic polystyrene beads with streptavadin covalently attached to the
bead surface. The beads will bind to biotinylated PCR product, only one strand of
which is biotinylated. When the DNA is denatured, the single stranded biotinylated
sequence remains attached to the bead and can be magnetically separated from the
non-biotinylated strand, thereby providing pure single stranded template for
sequencing.
DNA for sequencing was PCR amplified as previously described using a biotinylated
primer D1 (Cruachem Ltd, Glasgow). PCR products were extracted with an equal
volume of chloroforrmisoamyl alcohol (24:1) to remove residual paraffin oil. PCR
products were purified on either a Wizard DNA clean up column (Promega, UK Ltd)
or G50 sephadex columns (BCL, UK Ltd) according to the manufacturer's
instructions.
Twenty microlitres of Dynabeads were washed twice in 5mM Tris pH7.6, ImM
EDTA and 1M NaCl (wash solution), and added to 40jul of purified DNA product
and left at room temperature for 15 mins. The Dynabead bound PCR products were
separated from the supernatant fluid using a magnet and washed twice in lOOpl of
wash solution. DNA attached to the beads was denatured by suspension in 8pl of
0.1M NaOH and incubated at room temperature for 10 minutes. After magnetic
separation, the supernatant containing the antisense strand was removed.
Denaturation was repeated once. The biotinylated strand attached to the Dynabeads
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was resuspended in lOpl of double distilled water, this preparation was used directly
in sequencing reactions.
The non-biotinylated strand collected in the denature supernatant described above
was precipitated in 0.1 volume 5M sodium acetate and 4 volumes of ethanol at -20°C
overnight. The DNA precipitate was spun for lOmins at 12,000g, washed once in
70% ethanol and dried under vacuum. The final DNA pellet was resuspended in lOp
1 of double distilled water and used directly in sequencing experiments.
6.2.3.2 Preparation of Sequencing Template by Cloning into pGEM 7Z f +.
High concentrations ofpure DNA template can be prepared by ligating a blunt ended
DNA fragment into a linearised plasmid vector, transforming E. coli (Escherichia
coli) cells, and preparing plasmid DNA from the resulting cultures.
Exon 5 DNA was amplified in a standard PCR reaction. The products were
extracted once in an equal volume of chloroform:isoamylalcohol (24:1) and PCR
precipitated in 0.1 volume 5M sodium acetate and 2 volumes ethanol at -20°C
overnight. The DNA precipitate was spun for lOmins at 12,000g, washed once in
70% ethanol and dried under vacuum. Blunt ends were formed by digestion at 30°C
for 15 minutes with 3 units Klenow enzyme (BRL, UK Ltd), xl blue palette buffer
(Sigma, UK Ltd), and 2nm dNTPs in a total volume of 20pi. The reaction was
stopped by addition of lpl 0.5M EDTA, pH8. The blunt ended template DNA was
extracted once in 20pl phenol, and once in 20pi 24:1 chloroform:isoamyl alcohol
before purification on a G50 sephadex column, according to the manufacturer's
instructions (Appendix 2). Two pg of plasmid pGEM 7Z f+ was linearised by
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digestion with 9 units of Smal in a total volume of 20pl at 25°C overnight, followed
by purification on a G50 sephadex column.
Ligation. The concentrations of prepared insert and vector were estimated by
comparison with standards on agarose containing 0.5ng/ml of ethidium bromide.
Vector concentration was estimated as 15ng/pil and both crl27 and crl64 contained
approximately lOng/pl. Four ligation reactions were performed. crl27 and crl64
were both ligated at 10:1 and 3:1 insert to vector ratios, and two control reactions
were pGEM with no insert, and pGEM with no insert and no ligase. Ligation
reactions contained approximately 200ng of total DNA (insert and vector), xl T4
ligase buffer, and 2.5 units T4 ligase in a total volume of 20pl. All ligation reactions
were incubated at 16°C overnight.
Transformation. Library efficient DH5 alpha cells (E. coli) (20pi) were mixed with
lpl of a 1:5 dilution of ligated samples or controls, and incubated on ice for 30
minutes. Bacterial cells were heat shocked for 40 seconds at 42°C then placed on
ice. 80pi of SOC (see Appendix 1) was added to the cells and incubated at 37°C for
1 hour shaking at 225 rpm. Transformed cells were cultured on L-amp (see
Appendix 1) plates coated with lOOpl of lOOmM EPTG (isopropyl-B-
thiogalactopyranoside, Promega UK Ltd) and 20pl 50mg/ml X-gal (Promega UK
Ltd), overnight at 37°C. White coloured colonies of transformed cells containing
exon 5 insert were picked and grown in L-broth containing 50pg/ml of ampicillin and
incubated overnight at 37°C shaking at 225 rpm.
Plasmid DNA containing exon 5 insert was prepared from 3mls of bacterial culture
using the Wizard miniprep protocol (Appendix 2). The purified plasmid DNA was
finally resuspended in 50pl ddw, this was used directly in sequencing reactions. The
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presence of insert DNA was established by electrophoresis after digestion of a 4pi
aliquot of plasmid DNA with 3 units ofPvu II at 37°C for 2 hours.
6.2.4 DNA Sequencing
Sequencing reactions were performed on template DNA prepared using Dynabeads
or by cloning, described above, using two different sequencing protocols.
6.2.4.1 Sequencing using Sequenase. DNA template was sequenced using
Sequenase™ Version 2.0 DNA sequencing kit (United States Biochemical, Ohio).
0.5pmol primer D1 or D2 was annealed to the appropriate strand of template DNA
in xl sequenase buffer at 65°C for 2 minutes, cooling to < 35°C over 30 minutes.
Alternatively Dynabead prepared DNA template was heated to 94°C for 5 minutes
and immediately cooled on ice. The sequence was then labelled on addition of lpl of
DDT (dithiothreitol), 2pl labelling mix containing dNTPs, 5pCi S35 dATP and 1 unit
of sequenase enzyme and incubated at room temperature for 3 minutes. The reaction
was terminated by adding 3.5pi of the labelled reaction to 2.5pi of each of 4
termination mixes, each containing a different dideoxy nucleotide base (ddATP,
ddGTP, ddCTP, or ddTTP). These reactions were incubated at 40°C for 3 minutes
and stopped on addition of 4pl of stop solution (Appendix 1).
6.2.4.2 Cycle Sequencing. Cycle sequencing, using Cyclist DNA sequencing kit
(Stratagene, USA), was performed on single stranded template DNA prepared by the
Dynabead method. For each reaction a master mix of 7pl DNA template, lpmol
primer D2, 4pl sequencing buffer (BRL), lOpCi S35 and 2 units of Taq polymerase
(BRL) and lOpl H20 was prepared. Reactions containing 3pi of each
dideoxynucleotide (ddATP, ddGTP, ddCTP, or ddTTP) and 7pl of master mix were
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denatured at 95°C for 5 minutes followed by 30 cycles of 95°C for 30 sec, 55°C for
30sec, and 72°C for 60sec in a Techne PHC4 thermal cycler. The reactions were
stopped by the addition of 5pi of stop mix.
6.2.5 Polvacrvlamide Gel Electrophoresis
Sets of samples prepared by either of the 2 methods described above were heat
denatured at 94°C for 3 minutes, and 3 pi was loaded per track on a 6% denaturing
polyacrylamide gel (see Appendix 2) and electrophoresed for 1 or 2 hours at 70W.
Gels were fixed in 10% methanol 10% acetic acid for 10 minutes, then heat dried
under vacuum for 2 hours. Dried gels were exposed to X-Omat x-ray film overnight
and developed automatically in a X2 Hyperprocessor (Amersham UK). The DNA
sequence was assessed visually.
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6.3 RESULTS
6.3.1 PCR of THRA1, Exons 4 and 5.
Exon 4. Exon 4 primer sets A1/A2, B1/B2, A1/B2, B1/B2, Bl/Al, A1/C2 and
B1/C2 (see Table 26) were tested in dPCR reactions containing 200ng control
placental DNA (Sigma, UK Ltd). Reaction buffers varied according to buffer
concentration (0.5mM, ImM, 1.5mM, 2.5mM or 5mM MgCl2) and annealing
temperatures (50°C, 53°C, 56°C and 60°C).
PCR with primers A1/A2 failed to produce detectable product at any annealing
temperature and MgCl2 concentration combination. Therefore a second set of
primers, B1/B2, was designed and the experiment repeated. Low concentration of
product was produced from control placental DNA (Sigma) with these primers at an
annealing temperature of 54°C, and MgCl2 concentrations of 2.5 and 5mM.
Amplification efficiency was not improved by the use of primers combinations
A1/B2, B1/A2, A1/C2 or B1/C2. Examination of each primer concentration showed
that B2 appeared xlO less concentrated than Bl, although spectrophotometric
readings supplied had indicated similar concentrations. After the concentration ofB2
was increased ten fold, PCR produced an acceptable concentration of product. All
further experiments were conducted with ten fold primer B2.
Exon 5. Primers for exon 5 (D1/D2) were tested in a standard PCR containing
200ng of control placental DNA (Sigma), and produced high concentration of
product at an annealing temperature of 55°C and ImM MgCl2 concentration in the
reaction buffer. PCR of template derived from fixed tissue was not as efficient as
DNA derived from frozen tissue.
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6.3.2 Quantitation of THRA1 Gene Copy Number by dPCR.
Exon 4. The efficiencies of primers B1/B2 (exon 4) and IFNG150 were tested in
dPCR using control placental DNA (Sigma) and breast cancer crlll as DNA
template. A dPCR was performed using 50pmol, lOOpmol, 200pmol, 250pmol, and
500pmols of primers B1 and B2(exon 4), with 250pmol of IFNG150 in the standard
PCR reaction, at an annealing temperature of 55°C and PCR product measured as
described in Chapter 2. Increasing concentrations of primers B1 and B2 did not
effect dPCR ratio values obtained, indicating abnormal reaction kinetics. Because of
this finding and the problems encountered with primer concentrations (above) I
decided to concentrate on exon 5 for dPCR.
Exon 5. Primer efficiencies ofD1/D2 (exon 5) were tested in a dPCR using 200ng
of control DNA (Sigma) and crl 11 as DNA template. A dPCR was performed using
50pmol, lOOpmol, 150pmol, 250pmol and 500pmol of D1/D2 primers with 250pmol
IFNG150 primers in a standard reaction at an annealing temperature of 55°C. Ratio
values obtained increased with increasing D1/D2 primer concentrations, (Figure 44),
therefore an equimolar concentration of primers for D1/D2 and IFNG150 was
chosen for further experiments.
To further test primer efficiency dPCR was performed on control DNAs (Sigma and
p258) and cancer crlll in a standard reaction containing primers for TH5 and
IFNG150, and PCR product was sampled at 23, 26, 30 and 35 cycles and ratio
values calculated. The results indicate that the reaction efficiencies of the primer sets
were similar, (Figure 45), although control DNAs (Sigma and p258) showed a trend
towards lower ratio values with increasing cycle number. Attempts to "spike" PCR
225
Figure 44
Titration of THRA1 exon 5 primer (TH5) concentration in differential PCR with
250pmol of IFNG150 (reference gene) primers. DNA template were control DNAs
Sigma and p258 and one cancer DNA crl 11. Results were expressed are dPCR ratio
values and show that as TH5 primer concentrations increase, dPCR ratio values also
increase.
Figure 45
Differential PCR cycle course using equimolar concentrations of TH5 and IFNG150
primers in a standard dPCR reaction. PCR product was sampled at cycle numbers










Figure 44 Titration of TH5 primers in dPCR
Figure 45 Differential PCR ratio values throughout a thermal
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of control DNA with THRA1 PCR product failed to produce "amplified" ratio
values.
THRA1 dPCR in breast cancers. Thirty nine breast cancers, 28 c-erb B2 amplified
and 11 non-amplified, were tested for THRA1 gene copy number in a standard dPCR
reaction containing 200ng template DNA. The range of ratio values found for
amplified cancers (0.56-1.82) was similar to those found for non amplified cancers
(0.69-1.38). Repeat tests found poor consistency in the ratio values found for
individual samples.
6.3.3 SSCP
Exon 4. 64 breast cancers (25 c-erb B2 amplified, 31 nonamplified and 8 not
known), and 11 control DNAs were assessed for mutations in exon 4 by SSCP
analysis. Gel electrophoresis at 20°C produced 3-4 bands, and 2 bands at 4°C, which
were normally present in all samples, and are illustrated in Figure 46. Analysis was
complicated in some samples by the presence of non-specific PCR amplified
fragments, which made interpretation of these gels difficult. However, when present,
non specific bands were numerous and were unlikely to be mistaken for a mutant
band. Nevertheless , it is possible that non-specific bands may have concealed a real
mutant band. Attempts to improve the quantity ofPCR product in order to increase
the signal on SSCP analysis by changing reaction pH and buffering conditions,
resulted in more non-specific fragments. Of the cases tested 49 were free ofmultiple




SSCP analysis of exon 4 of THRA1 of PCR amplified sequence from breast cancer
DNA. Photographs show the resulting SSCP bands after electrophoresis of a 149bp
PCR amplicon on 6% MDE polyacrylamide gel. Electrophoresis was performed at
20°C (A) and 4°C (B). All cancers show similar patterns of bands, (A) tracks and















Exon 5. Exon 5 was assessed for potential mutations in 90 breast cancers, (34 c-erb
B2 amplified, 36 non amplified, and 18 not known) and 24 control DNAs. Gel
electrophoresis at 20°C usually produced 4 major bands, illustrated in Figure 47. A
single variant band was detected in 7 cancers and 2 controls, illustrated in Figure 48.
This band was of equal intensity to the other major bands and was not present, even
faintly, in any of the other cancers or controls. SSCP analysis at 4°C failed to detect
any additional variant bands.
Clinical and biological features of 7 cancers producing a variant band are listed in
Table 27. Cancer diameter ranged in size from 20mm to 50mm. All were negative
for c-erb B2 expression, but 4 were c-erb B2 amplified. Oestrogen receptors ranged
from 0 to 344frnol/mg protein, but were generally low with 5 below 50 fmol/mg
protein. All cancers with abnormal THRA1 bands were from the non-screened
group.
6.3.4 DNA Sequence of SSCP Variants.
Samples which produced a variant band on SSCP analysis, (crl 11, crl27, crl64, and
cr569 and 1 colon control, nl8) were sequenced to identify the location and type of
variant.
6.3.4.1 Dynabead preparation and Sequenase and Cycle sequencing. DNA
prepared from breast cancer samples crl 11, crl27, crl48, cr216 and normal controls
nl8 and placental DNA (Sigma) using Wizard or G50 purification methods (see
Appendix 2), produced only a partial sequence of exon 5 when sequenced using
Sequenase or Cycle sequencing techniques.
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Figure 47
SSCP analysis of exon 5 of THRA1 of PCR amplified sequence from breast cancer
DNA. Photographs show the resulting SSCP bands after electrophoresis of a 253bp
PCR amplicon on 6% MDE polyacrylamide gel. Electrophoresis was performed at
20°C (A) and 4°C (B). At 4oC all cancers showed similar patterns of SSCP bands,
(B) tracks 1-4. Electrophoresis at 20°C revealed one varient band (indicated by
arrow), illustrated in (A) track 1. Tracks (A) 1-4 were breast cancer cases, and







SSCP analysis of exon 5 DNA at 20°C. Tracks 1-3 represent three different breast
cancers all containing a single varient band (indicated by arrow). Tracks 4and 5, and
6 and 7 represent two control DNAs with matched colon cancer DNA, all of which
exhibit the varient band. Tracks 8 and 9 contain breast cancer DNA, and tracks 10-
13 contain control DNA, none ofwhich exhibit the varient band. Marker 1 (Mkl) is






SSCP analysis detected a variant DNA sequence in seven breast cancers.
Histopathological and biochemical features (described in Chapter 4) of these cancers
are given in this table. DCI NST = ductal carcinoma of no special type, MCI =
special type invasive cancer (mucinous). Cancer grade (I, II, or III) was determined
according to the method of Elston (1987). DNA ploidy was defined as DIP =
diploid, AN = aneuploid, and TET = tetraploid. Lymph node status defined positive
















The DNA sequence of a 60 base pair section at the 3' end of the PCR fragment,
consisting of part of intron 5 up to the start of exon 5 was identified, but contained
no variant DNA sequence. The 148bp sequence ofDNA coding for the exon and 27
bases of intron 4 were unreadable due to "stops" where bands were present in all four
tracks.
Attempts to solve this problem included alteration of the annealing temperatures,
termination temperature, and reaction times of labelling and termination reactions,
and addition of DMSO to annealing and termination reactions. None of these
alterations produced any improvement on the length of readable sequence. Similar
problems were encountered when the reverse strand was sequenced. In an attempt
to increase specificity and reduce possible secondary structure cycle sequencing was
performed on crl27 and crl64. The higher temperatures involved in the PCR cycles
failed to reduce the possible impact of secondary structure and no additional
sequence could be read.
6.3.4.2 Plasmid cloning and Sequenase sequencing. PCR amplified DNA of
exon 5 from breast cancers crl27 and crl64 was cloned into pGEM 7f+ and
transformed DH5 alpha cells (E. coli) prior to sequencing. White colonies were
present in all ligation reactions (3:1 and 10:1 insert:vector), signifying the presence
of transformed DH5 alpha cells. Control plates of pGEM plus ligase only produced
blue colonies, pGEM minus ligase produced no colonies. Five white colonies,
containing plasmid and insert DNA, from each ligation reaction of crl27 and crl64
were cultured overnight, and plasmid DNA prepared. Restriction digestion of
plasmid DNA with Pvu II showed the presence of insert DNA but two different
patterns of bands, illustrated in Figure 49.
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Figure 49
A. Diagram of plasmid vector pGEM 7f+, showing the Sma I cloning site, and Pvu
II restriction sites, which were used to check for correct insert DNA.
B DNA prepared from four different transformed colonies are shown in tracks 1-4,
and represent DNA inserts from PCR reactions from breast cancer cases crl27
(tracks 1-2) and crl64 (tracks 3-4). Tracks 1-3 show the expected restriction
fragments from the correct exon 5 insert. Track 4 represents an unknown insert
fragment. Track 5 shows Pvu II restriction of pGEM 7f+ without insert DNA.
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The plasmids containing DNA inserts were sequenced using both forward and
reverse primers D1 and D2. A complete sequence was obtained from 6 of the 10
selected colonies, four ofwhich had a sequence indistinguishable from the published
sequence, Figure 50. Two clones produced a totally different sequence when the
reverse primer D2 was used in sequencing, however no sequence was detected with
the forward primer, Dl, indicating that these were non-specific PCR products.
A single base transition from C to T was identified in a single clone of both CR127
and CR164, Figure 50. The transition occurs within the coding sequence of the
second zinc finger of THRA1, and converts GCC to GCT, Figure 51. Both these
triplets code for arginine, therefore this variant is silent. Other clones of crl27 and
crl64 contained the normal DNA sequence, indicating that these cancers were
heterozygous at this locus.
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Figure 50
DNA sequence of exon 5 of THRA1 from two different breast cancers, each
exhibiting a varient band on SSCP analysis.
I Sense strand sequence for breast cancers crl27 and crl64. This sequence does
not deviate from normal.
II Antisense strand sequence for two clones of crl27. The normal sequence is
shown in crl27 A, and the varient sequence is shown in crl27 B. The single base
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Figure 51
Enlargement of DNA sequence in Figure 49 II, showing the single base transition




cr 127 A cr127 B
A T C GAT
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6.4 DISCUSSION
There are currently no convincing data that THRA1 plays a role in human breast
carcinogenesis. In experimental systems co-transfection of v-erb B and v-erb A
indicates that v-erb A has a synergystic effect on cancer cell growth (Frykberg et al
1983, Kahn et al 1986, Graf and Beug 1983). Mutations play an important role in
the transforming capabilities of v-erb A, and mutations can alter the binding
specificity and the ability of the gene to promote transcription (Bonde et al 1989,
Damm et al 1989, Sap et al 1989). Several mutations, associated with generalised
thyroid hormone resistance disorder, have been identified in c-erb A beta (Parrilla et
al 1991), however no mutations have so far been identified in c-erb A alpha
(THRA1) (Futreal et al 1994). Similarly, co-amplification of THRA1 has not been
observed in the absence of amplification of c-erb B2 (Futreal et al 1992, Tavassoli et
al 1989, Tsuda et al 1989). Nor have previous attempts to measure transcription in
breast cancer tissue proved successful (Tavassoli et al 1989), though this study may
have been limited by technical factors such insensitivity, a short half life of the
nuclear receptor, or that THRA1 mRNA is naturally present at low copy numbers (5-
10 copies per cell) in many adult tissues (Sap et al 1986).
In this chapter I addressed the postulate that co-amplification of THRA1 could be of
relevance to the biology of breast cancer and that mutations within the zinc finger
coding sequences of THRA1 could change the specificity of the receptor, possibly
mimicking the specificity of oestrogen receptor. Amplification of THRA1 was not
demonstrated for technical reasons, but no significant mutations in the critical exon
4-5 (Zinc finger) region of the gene were found . The only abnormality detected in
this region turned out to be a polymorphism involving a conservative base change.
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This polymorphism was not detected in a previous study (Futreal et al 1994),
possibly due to the low frequency of this allele and that only 20 breast cancers were
investigated. It remains possible that mutations in other parts of the gene , not
examined here, could influence the normal function of the receptor protein (Koenig
et al 1989).
Hence, although the power of this study was limited, the data are against THRA1
playing a major role in breast carcinogenesis. THRA1 receptor protein would appear
to have normal binding specificity and that the single base pair change found in exon
5 represents an infrequent polymorphism. It remains possible that co-amplification of








Analysis of c-erb B2 gene expression and amplification with various cancer
characteristics in chapters 3 and 4 has suggested that deregulation can occur at an
early stage of progression. Deregulation of c-erb b2 has also been associated some
cancer characteristics associated with late stage disease and aggression in breast
cancer (Borresen et al 1990, Borg et al 1990), a major indicator of this being the
dissemination of cancer cells to lymph nodes and metastasis to other organs (Tubiana
and Koscielny 1991). There is no evidence for the direct involvement of c-erb B2 in
cancer cell dissemination, although co-expression of c-erb B2 and urokinase
plasminogen activator (uPA) has been reported in a small number of breast cancers
(Del Vecchio et al 1993). This observation has not been tested in a large, well
characterised cancer set.
Overexpression of the serine protease, urokinase plasminogen activator (uPA) in
epithelial cells has been linked to aggressive behaviour in breast cancer (Duffy et al
1988, Janicke et al 1990). The biochemical action of the enzyme may promote
metastasis by degradation of collagen in the tumour's extracellular stroma (Wilhelm
et al 1988). The conversion of plasminogen to plasmin by uPA is thought to be a
critical step in this degradation (Liotta et al 1981). Plasminogen activators may have
functions other than matrix degradation and could include the promotion of
expression ofgrowth factors/receptors (Mizoguchi et al 1990).
Previous studies of breast cancers by immunohistochemistry using a monoclonal
antibody directed against human uPA have shown overexpression of uPA in all 115
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cancers tested (Janicke et al 1990). Analysis of uPA antigen by ELISA, in the
cytosolic fraction of these cancers indicated that they contained, on average, 11 times
more uPA than normal breast tissue (Janicke et al 1990). High concentrations of
uPA in breast cancer tissue may be an independent prognostic factor in predicting
early relapse (Duffy et al 1990, Foekens et al 1992, Grondahl-Hansen et al, 1993,
Janicke et al 1990).
The mechanisms of overexpression of uPA in breast cancer are not clear and may
involve deregulated promoter or suppressor activity, or fundamental DNA changes
such as gene amplification. The regulation of the concentration of uPA in the
cytoplasm of cells is complex. It can be influenced by a number of cell signals such
as hormones (Mira-y-Lopez et al 1983), phorbol esters (Stopelli et al 1986), growth
factors (Rorth et al 1990), and cytokines (Neidbala et al 1992). Another possible
mechanism for overexpression is gene amplification. Overexpression associated with
gene amplification has been demonstrated in breast cancer for some oncogenes, such
as c-erb B2 and c-myc (Riou et al 1984, Riou et al 1987, Slamon et al 1987, Slamon
et al 1989), although these genes can be deregulated by more than one mechanism.
This chapter examines the expression of urokinase plasminogen activator and its
relationship to clinical features of a breast cancer population, in particular whether
possible associations between c-erb B2 deregulation and uPA protein expression
could occur. I developed a new differential PCR to determine whether
overexpression of uPA could be due, in some cases, to uPA gene amplification.
Analysis of this gene also provides the opportunity to assess dPCR in a further gene,
using the same source material as the initial development of the method in Chapter 2
and 3.
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7.2 MATERIALS AND METHODS.
7.2.1 Breast Cancer Study Set.
Samples of tissue were collected from 134 breast cancers, a random subset of the
population previously described in Chapter 3. All were primary cancers, which had
not been included in neo-adjuvant treatment studies (Anderson et al 1991). Tissues
were fixed and processed according to methods outlined in Chapter 2, section 2.2.1.
Control tissue was obtained from breast tissue distant from the lesion site or from
non-cancer bearing breasts. For cancers, histological type, grade, and node status
were assessed according to criteria described in Chapter 4 (section 4.2),and cancer
cellularity and ploidy status were determined according to methods described in
Chapter 3 (sections 3.2.1 and 3.2.2).
Oestrogen receptors were measured according to the method described in Chapter 4
(section 4.2), from tissue that had been collected, frozen and then stored at -196°C at
the time of operation. The concentration of oestrogen receptors in each cancer
sample was expressed as a concentration of protein, with values of >20fmol/mg
protein considered positive for oestrogen receptor as this was a concentration
regarded as clinically significant for treatment with anti-oestrogens (Hawkins et al
1981).
7.2.2 Immunohistochemistry.
Expression of uPA protein was examined with a murine monoclonal antibody, #394,
specific for human urokinase plasminogen activator (American Diagnostica Inc. New
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York, NY). Four micron paraffin sections of all cancers were dried at 56°C
overnight. The sections were dewaxed in xylene and rehydrated to water.
Endogenous peroxidase was blocked by exposure to 1% hydrogen peroxide in
methanol for 15 minutes before staining. The sections were washed in Tris-buffered
saline (TBS pH7.6), followed by a 10 minute incubation with normal rabbit serum
(Scottish Antibody Production Unit, Carluke, UK) diluted 1:5 with TBS. The
primary antibody was applied at a 1:100 dilution in normal rabbit serum in TBS and
incubated at room temperature for 30 minutes. Normal rabbit serum was used in
place of the primary antibody as a negative control. An ABComplex method was
carried out according to manufacturers instructions (Dako K355). The sections were
lightly counterstained in haematoxylin. To score positive, indicating uPA expression
cancer cells had to show weak, moderate or strong brown staining of cytoplasm
above normal stromal components of the tissue section, excluding macrophages. A
positive control, a cancer previously identified as showing strong staining with #394,
and a negative control were incorporated in each set of sections for staining. Some
variation in staining intensity was noted in control sections. A fall in titre from 1:100
to 1:10 during overnight storage after reconstitution of the lyophilised preparation
was observed in 3 separate batches of #394, and hence fresh dilutions of #394 were
prepared for each batch of slides.
Immunohistochemistry results were assessed for associations with other cancer
characteristics such as histopathological type, grade, lymph node status and ER
status, and presented in a tabular format. Results were tested for significance by X2
analysis of contingency tables. Urokinase expression was also examined for
associations with c-erb B2 expression and amplification which were previously
assessed in Chapter 3.
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7.2.3 Primers and the Differential Polymerase Chain Reaction
Primers for differential PCR for uPA were designed from the human uPA gene
sequence published elsewhere (Riccio et al 1985), using "Primer" software
(Whitehead Institute, USA). The primer sequence for the sense strand was 5'
CAGTTTACCCTCACCCTGGA 3' (1631- 1650bp), and the antisense strand 5'
AGCCAACTGTTGTAGGGGTG 3' (1757-1738 bp). PCR using these primers
yields all lbp product from the intron 2-exon 3 boundary of the published sequence.
The single copy reference gene used in dPCR was a 150bp sequence of human
interferon gamma (Frye et al, 1989).
Fixed paraffin breast tissues were prepared for dPCR according to the method
described in Chapter 2 (section 2.8.1). Differential PCR was performed using the
standard protocol described in Chapter 2, section 2.2.3.2 using 0.25nmol each of the
two primers for uPA (described above) and IFNG150. Differential PCR ratio values
were calculated according to methods outlined in Chapter 2, section 2.2.4. For uPA
a correction factor of 1.04 was applied to compensate for differences in dCTP
content between amplicons IFNG150 (69 C bases) and uPA (66 C bases).
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7.3 RESULTS
7.3.1 Detection of urokinase plasminogen activator expression by
immunohistochemistrv.
Immunohistochemistry for expression of uPA protein was performed on 134 breast
cancer specimens. Overexpression of uPA was identified by the presence of a brown
reaction product in cancer cells and the absence of this stain in normal tissue.
Overexpression of uPA protein was observed in 40 of 113 (35%) invasive cancers
and in 4 of 21 (19%) in situ cancers, (total cancers 33%). Staining was concentrated
in the cytoplasm of the cancer cells, and usually present evenly throughout the cancer
cell population in each positive tissue, illustrated in Figure 52. Staining of the cell
membrane was present in some positive cancers, however this was always in
association with cytoplasmic staining. In some cases weak staining was observed in
normal stroma and infiltrating lymphocytes, but this was always in association with
positively stained cancer cells. Strong staining was observed in cells identified as
macrophages in a small number of cases; if present only in macrophages, samples
were considered negative.
Table 28 summarises the association between uPA protein overexpression and
features of the cancers studied. uPA expression was more common in invasive
cancers , and within that group was more frequent in oestrogen receptor positive
cancers, although neither trend was significant, X2= 0.19, p>0.5. "Positive" staining
was present in similar proportions in each of the ploidy groups, diploid (36%),
aneuploid (43%) and tetraploid (38%), X2~ 0.22, p>0.5. There was no correlation
ofuPA expression with size of cancer, XI = 4.38, p=>0.1,<0.5 ,or node status,
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Figure 52.
Photomicrograph of four micron section of an in situ carcinoma (A) and an invasive
ductal carcinoma of no special type (B). Both photographs illustrate strong positive
anti uPA staining in the cytoplasm of cancer cells. Normal stromal cells do not stain.
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Clinical features of the study population with uPA immunohistochemistry. Invasive
cancer types are DCI = ductal carcinoma of no special type, LCI = lobular
carcinoma, TCI = tubular carcinoma, and OTH = other special types
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Table 28
Number of cases Percentage with positive
immunohistochemistry
Invasive cancers 113 35
In situ cancers 21 19
Invasive cancers only
Oestrogen receptor status
< 20fmol/mg protein 32 41








1 - 10 10 50
11-20 38 24


















X2 = 0.74, p=>0.10, <0.50. Grade I cancers showed a lower frequency of
overexpression (24%) than grade II or III (38% each), but these differences were
also not significant, X2= 1.12, p>0.5. Overexpression was not confined to any
particular histological type of cancer, but noteworthy was the high proportion in
lobular carcinomas (7 of 14), and overexpression was also present in some tubular
carcinomas (2 of 10). Frequency of overexpression in each type of cancer is shown
in Table 28.
Overexpression of uPA was significantly associated with overexpression of c-erb B2,
X2 =6.47, p=0.01 , but not with c-erb B2 gene amplification, X2 =2.15, p=>0.10,
<0.5, Table 29.
7.3.2 Validation of dPCR for Detection of uPA Gene Copy Number.
The relative efficiencies of primers sets for uPA and EFNG150 were tested in
differential PCR. Optimal primer concentration was tested using 83, 125, 250 and
312pmol of urokinase primers with 250pmol of EFNG150 primers in a standard
differential PCR on 2 normal fixed breast tissues and a placental control DNA.
Differential PCR ratio values increased with increasing uPA primer concentration,
Figure 53, and equimolar concentrations gave an approximate ratio value of 1 for
each DNA. This concentration was used for all subsequent experiments.
A positive control was not available for uPA amplification, therefore a standard PCR
reaction containing 200ng of placental DNA as template, was "spiked" with 1, 2, 4,
8, 16 and 32pi of uPA PCR product (lxl0~6 dilution) to provide an artificially
increased uPA template. Measurement of the concentration ofPCR product used for
258
"spiking" was attempted using standard spectrophotometry, fluorometry, and
ethidium bromide staining methods.
Primer efficiency for uPA with IFNG150 was tested on control DNA and control
DNA spiked with uPA product in a dPCR cycle course experiment, in which PCR
product was sampled at 23, 25, 27, 29, 31 and 35 cycles. Ratio values tended to
increase or decrease with increasing cycle numbers for the positive or negative
controls respectively, Figure 54. This indicated some variation in primer efficiency
but the differential between the two controls remained distinct.
The dPCR ratio values for positive "control" DNA in the standard dPCR for uPA are
shown in Figure 55. Increasing quantities of "spiked" uPA product resulted in
increased dPCR ratio values, indicating that the technique can detect increased uPA
templates. Attempts to measure the concentration of uPA PCR product added to
"spiked" reactions were unsuccessful due to the difficulty in measuring small DNA
fragments in low concentration.
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Table 29
Association between urokinase plasminogen activator (uPA) expression and c-erb B2


























Titration ofuPA primer concentration with 250pmol IFNG150 primers in a standard
dPCR reaction. Differential PCR ratio values increase with increased uPA primer
concentrations for normal breast tissue DNAs alh488n, alh490n and cell line DNA
MCF7.
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Figure 53 Titration of uPA primers in a standard dPCR
reaction
concentration of uPA primers
262
Figure 54
Differential PCR cycle course using equimolar concentrations of uPA and IFNG150
primers in a standard dPCR reaction. PCR product was sampled at cycle numbers
23, 25, 27, 30 and 35, and the results expressed as ratio values. Results indicate that
the ratio value does not change with increasing cycle number for both the negative
control (Sigma DNA) or the positive control.
Figure 55
Differential PCR ratio values obtained from control DNA (Sigma, UK Ltd) "spiked"
with 1, 2, 4, 8, 16, and 32pl of urokinase PCR product to produce DNA templates
which represent increases copy number of uPA gene. In a standard dPCR reaction
ratio values increase with increasing uPA gene copy number.
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Figure 54 Differential PCR ratio values for uPA
throghout a thermal cycle course
23 25 27 29 31 35
PCR cycle
Figure 55 Effect on dPCR ratio values of additional
uPA template with control DNA
2 4 8 16
ul of uPA template (10-6)
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7.3.3 Assessment of uPA Gene Copy Number in Breast Cancer.
Differential PCR ratio values were obtained for 134 cancer specimens and 33 control
tissues, Figure 56, and range from 0.52 to 1.54 (mean 0.9) in control tissues and 0.41
to 1.83 (mean 1.1) in cancer tissues. Figure 57 shows representative dPCR products
obtained from three cancer specimens and a normal DNA control (derived from
human placenta). Ratio values of 2 or above have been considered to signify gene
amplification with the oncogene c-erb B2, see Chapter 2. There was no clear
difference in range of values between invasive cancers (0.41-1.83) and in situ cancers
(0.7-1.55). The distribution of ratio values was similar for immunohistochemistry-
positive and -negative cancers, Figure 58. Cancers shown to be overexpressing uPA
protein are distributed evenly over the range of dPCR values, indicating that cancers
which overexpress uPA are not associated with high dPCR values. Differential PCR
values were not influenced by specimen cellularity or DNA ploidy.
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Figure 56
Range ofdPCR ratio values found for 134 breast cancers and 33 control tissues.
Figure 58
Range of dPCR ratio values obtained in a standard dPCR reaction for breast cancers
which are either immunohistochemistry positive or negative cancers.
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Figure 58 Distribution of uPA dPCR ratio values for uPA
immunohistochemistry - negative and -positive cancers




Differential PCR products from three different breast cancers (Tracks A and B and
C) and one control placental DNA (Track D), separated on 2% 3:1 Nuseive/Seakem
agarose gel. Track E contains the experimental negative control (PCR reaction
minus template DNA). PCR products for IFNG (reference gene) and uPA are
indicated at 150bp and lllbp respectively
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Figure 57





The studies on uPA amplification presented above lead to two principle conclusions.
First, the methods used - essentially the same as those devised for c-erb B2 in
Chapter 2- produce a profoundly different result, for this unrelated gene. This gives
further support for the power of this method in measuring gene amplification.
Second, there was no evidence that uPA was amplified, and although
immunohistochemistry showed overexpression in 33% of cases (including "early"
ones), that was not related to uPA amplification
Differential PCR with primers for uPA and IFNG150 was validated using normal
control DNA and DNA "spiked" with uPA product, and showed that, although there
was some difference in primer efficiency, dPCR could detect uPA gene amplification
if present in cancer DNA. This method of "spiking" control DNA with PCR product
has been used to calibrate other dPCR studies (Lonn et al 1993), but its sensitivity in
detecting gene copy number remains unproven as concentrations of small DNA
fragments are difficult to measure accurately. Amounts of uPA added to "spiked"
controls were selected for their similarity to those amounts of c-erb B2 PCR product
required to "spike" normal control DNA to produce an amplified dPCR ratio value
(data not shown), and suggests that uPA template added to dPCR was of the correct
order.
Although no difference was detected between the ranges of dPCR ratio values for
cancers and controls, cancers had a higher mean dPCR value. This could reflect a
low level of chromosomal instability, yet there was no association between "high"
dPCR values and abnormalities ofDNA ploidy. Furthermore, cases overexpressing
uPA protein were not solely restricted to those with dPCR ratio values at the upper
270
end of the normal range, indicating that overexpression was not due to minor
chromosomal deregulation. The possibility that gene overexpression can lead to
gene amplification has been suggested (Shen et al 1986, Kraus et al 1987) but has not
been confirmed experimentally and seems unlikely to be true for the uPA gene.
The associations found between uPA and cancer aggression in some studies is
commonly thought to be mediated by the breakdown of the extracellular matrix
thereby facilitating cancer cell dissemination (Duffy et al 1990, Janicke et al 1990). I
found uPA expression to be common in invasive lobular cancers. These cancers
characteristically infiltrate through stromal elements as individual units in linear array,
and uPA may play some part in this process. However, both invasive tubular
carcinomas and in situ cancers also expressed uPA, yet these histological types are
recognised for cell cohesion, differentiation and lack of metastasis (Bellamy et al
1993, Dixon et al 1985). This, and the presence of uPA in small, low grade, lymph
node negative cancers suggests that overexpression of uPA can be an "early" event
and that additional factors are required for the development of invasion resulting in a
poorer prognosis. The presence of uPA in the cytoplasm is probably only one of
several possible factors involved in cancer cell dissemination. Examination of lung
carcinoma cell lines have indicated that functionally active, receptor bound, uPA is
essential for tissue invasion (Bruckner at al 1992). Studies of uPA overexpression
combined with assessment of cell surface receptors (uPAR) may illuminate the
significance of overexpressing uPA, especially in cancers which have a favourable
outcome.
Assessing the mechanisms accounting for overexpression of uPA in breast cancer is
likely to be complex, and may involve factors which affect transcription, translation
and posttranscriptional processing. Increased levels of specific uPA inhibitors, PAI-
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1, PAI-2 and protease nexin, in breast cancer cells have been shown to regulate
cytoplasmic concentration of uPA (Hart and Rehmtulla 1988). Post-transcriptional
activation mechanisms ofuPA may also be disregulated in cancer cells, resulting in an
increase in stability and or processing of nuclear uPA transcripts (Henderson et al
1992). Immunohistochemistry is a convenient method for demonstrating
disregulated gene expression and detection frequency is usually high, in the order of
88% to 100% of breast cancers (Janicke et al 1990, Sumiyoshi et al 1991).
However, this study detected overexpression of uPA in only 33% of breast cancers, a
frequency similar to another immunohistochemical study of breast cancer, although
that study was based on frozen sections (Visscher et al 1990). This recorded
disparity in frequency of positivity is a cause for concern, but could be due to criteria
for scoring positivity, differences in immunohistochemical protocols and affinity of
antibodies, or all of these. Present requirement for staining above that of normal
stroma was an excluding factor in only 6 cases and is unlikely to be a major factor
influencing the frequency of positivity. The instability of the antibody used here is a
major factor causing concern and has been noted in other laboratories (M. Walch,
personal communication) for unidentified reasons, this instability may reduce the
sensitivity of detecting uPA protein. If the sensitivity is reduced then the uPA
expression detected here may represent cancers with particularly high levels of uPA.
There are alternative antibodies available for uPA which also detect high frequencies
of expression in ELISA (Grondahl-Hansen et al 1993) but present experience
suggests caution before drawing conclusions from immunohistochemistry alone.
Other features of our cancer population, such as size and ploidy, show no particular
associations with uPA expression. The trends toward elevated uPA expression in
grade II or III cancers and in negative lymph node status cancers observed above,
were noted previously (Foekens et al 1992, Grondhal-Hansen et al 1993). However
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in the majority of studies uPA expression did not vary according to classical
prognostic factors, such as histopathological grade, lymph node status, oestrogen
receptor status or cancer size, but remained significantly associated with shorter
disease free and overall survival (Duffy et al 1990, Foekens et al 1992, Foucre et al
1991, Janicke et al 1990).
Correlations of biochemical and immunohistochemical procedures generally have
indicated that measured concentrations of uPA protein correlate with the strength of
immunostaining, although individual cases can show major discrepancies (Janicke et
al 1990). This suggests that the relationship between immunohistochemical staining
and detection of uPA protein in breast cancers is not strictly quantitative.
Furthermore, the results of biochemical studies may be confounded by the presence
of uPA-rich macrophages (Pyke et al 1993), indicating that a combination of
immunohistochemistry and ELISA would be more informative than either technique
alone. Comparability between studies is further confounded by differences in the
experimental strategy and antibodies employed (Duffy et al 1988, Foekens et al 1992,
Grondahl-Hansen et al 1993, Janicke et al 1990, Visscher et al 1990). The
concentrations of uPA in the cytoplasm of cancer cells is known to be affected by
growth factors, phorbol esters, cytokines and hormones (Butler et al 1979,
Katzenellembogen et al 1984, Neidbala et al 1992, Rorth et al 1990, Stopelli et al,
1986). Studies of cell lines have shown that oestrogen complexed with its receptor
can induce uPA synthesis (Katzenellenbogen et al 1984). I found no significant
difference in the frequency of uPA protein overexpression in oestrogen receptor-
positive and -negative cancers, suggesting that oestrogen is not a major influence in
the complex regulatory mechanisms ofuPA production.
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uPA expression may also be associated with growth factor activity in breast cancer
cells (Naldini et al 1992). Overexpression of c-erb B2, a member of the epidermal
growth factor receptor family, has been observed in cancers which also overexpress
uPA (Del Vecchio et al 1993). While that study examined only 22 breast cancers, a
limited number of cases, my study confirms and extends this association. This may
merely reflect the presence of two similar but unconnected markers of aggression in
invasive cancer tissues, or it may reflect some biological linkage between these two
genes. In vitro studies have shown that uPA expression can be increased by
epidermal growth factor (EGF) (Neidbala et al 1990). C-erb B2 cannot bind EGF
directly (Dougall et al 1994), but may be able to participate in the binding complex
by forming a heterodimer with epidermal growth factor receptor (Dougall et al
1993). A direct effect of c-erb B2 activation could be mediated by an increase in
cAMP activity (Dougall et al 1994) as uPA has an upstream sequence of DNA
similar to corresponding regions of other cAMP regulated genes (von der Ahe et al
1988). Furthermore uPA protein has a partial amino acid sequence homology to
EGF, in the region which binds to EGFR (Appella et al 1987) although the ability for
uPA to bind to the receptor has not been shown. These possible interrelationships
need to be clarified to evaluate biological relevance.
In summary, this study has provided evidence that uPA is overexpressed in at least
some breast cancers which may relate to gene deregulation, though not to gene






The role of the gene c-erb B2 in breast cancer has been under active investigation
since the initial association of c-erb B2 gene amplification with aggressive behaviour
in breast cancer (Slamon et al 1987). Several important questions remain and some
were addressed in this thesis: what are possible causes or controls of deregulation of
c-erb B2, how are the processes of disregulation interrelated, and at what stage(s)
of cancer progression may c-erb B2 exert an influence?
I modified and extended the differential PCR technique for the detection of
amplification of relevant genes, including c-erb B2, and uPA. This allowed an
examination of the complex relationships between gene amplification,
overexpression, and other features of breast cancers, and an examination of c-erb B2
polymorphisms in amplified cancers. Novel findings included aspects of disregulation
of c-erb B2 in breast cancer and its possible effects on the biology of breast cancer. I
will attempt to relate these findings to some general theories of breast cancer and
genetic disregulation.
Current theories on breast cancer aetiology and progression are based mainly on
morphological features of the disease, which suggest an initial in situ phase
progressing to invasive forms (Cardiff 1988, Tubianna and Kocielny 1992), as
discussed in Chapter 4. Numerous gene disregulations have now been identified in
breast cancer but evaluation of their potential significance in disease progression is
complicated by the lack of clear morphological markers of the stages in breast
cancer. However, some familial cancers have now been shown to have disregulation
ofBRCA1 and BRCA2 (Wooster et al 1994, Miki et al 1994). While it is possible
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that such genes may also be disregulated in sporadic breast cancers, it is likely that a
more complex pattern of accumulated disregulations occurs in elderly women.
Other "candidate" genes for disregulation include tumour suppressor genes which
may show a loss of function, or oncogenes which can gain function, with such
disregulation, leading to neoplasia. C-erb B2 oncogene codes for a cell membrane
receptor which shows close homology to the epidermal growth factor receptor. It
can act as a dominant transforming gene in cultured mammary and other cells
(DiFiore et al 1987, Pierce et al 1991), and in transgenic mouse mammary tissue
(Muller et al 1988). Although c-erb B2 gene is frequently reported to be either
amplified and/or overexpressed in human breast cancer tissue, its role in breast
cancer initiation or progression is not yet clear.
8.2 Possible Mechanisms of c-erb B2 Gene Amplification.
Gene amplifications are thought to be rare in normal epithelial cells (Tlsty et al
1990), however transformed cells demonstrate greater genetic instability and can
contain regions ofDNA amplification involving several genes (Stark and Wahl 1984,
Keith et al 1993). Genetic instability may occur in some cancers in a non-specific
fashion, and include point mutations, deletions, translocations and amplification.
Telomere shortening has been suggested as a cause of genetic instability (Shay et al
1993, Odagiri et al 1994). As the frequency of c-erb B2 amplification is thought to
be the highest of the known oncogenes in breast cancer (Press 1990), it is possible
that some specific mechanisms are also involved.
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It has been suggested that increased gene expression may lead to amplification of that
gene. For example, an in vitro study of the multiple drug resistance gene showed it
was amplified after its expression was increased by treatment with cytotoxic drugs
(Shen et al 1986). However, many other genes, such as urokinase plasminogen
activator are known to become overexpressed but are not subsequently amplified
(see Chapter 7). Nevertheless, this model was suggested for c-erb B2 gene
amplification (Kraus et al 1987) based on the observations that overexpression was
more frequent than amplification, and that amplification was usually accompanied by
gene expression. As discussed above, the high frequency of c-erb B2 gene
amplification, often without accompanying overexpression, in all types of cancers
makes this mechanism only a circumstantial possibility, dependent on expression
being a variable factor.
The exact sites of c-erb B2 amplification within the genome of affected cells is not
known, therefore giving no clue as to possible mechanisms. It is known from in situ
hybridization studies that c-erb B2 amplification occurs at multiple sites (Smith et al
1994), but differentiation between episomal and chromosomal locations was not
possible. More information is known about other genes. Amplifications of n-myc
gene in neuroblastomas are present as repeated amplicons within sections of DNA,
known as homogeneously stained regions, on different chromosomes; with the
retention of the single copy gene at the resident site (Arnler et al 1992).
Amplifications of multiple drug resistance gene are present as small circular DNA
episomes, which amplify further to form visible structures, known as double minutes
(Schoenlein et al 1992). These two possible amplification sites could be linked in
some way, for example episomal DNA could be incorporated into the genome.
Cytogenetic studies of breast cancer tissue have indicated the presence of
homogenously stained regions but not double minutes; however analysis indicated
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that c-erb B2 amplifications were not localised to the stained regions (Saint-Ruf et al
1990).
This study is the first to demonstrate that either one or both alleles of c-erb B2 can be
amplified (Chapter 5). This suggests that amplification can arise by different
mechanisms. The models of DNA amplification which involve replication of the
affected gene (see Chapter 1.6.4) may be more likely to involve only one allele than
both, assuming initiation of amplification is a random error within a chromosome.
The models of DNA amplification which involve segregation of DNA fragments
during cell division may be more likely to involve both alleles in the resulting
amplicon. Interpretation of allele frequencies and genotype distribution is
complicated by possible allele loss, which can occur at loci in the c-erb B2 region in
over 50% of breast cancers, and may be more frequent in cancers with c-erb B2
amplification (Futreal et al 1992). It is therefore apparent that the mechanism of c-
erb B2 amplification in breast cancer is not yet defined, although investigation of
allele frequencies is a useful tool for further study.
It is thought that gene amplifications in sporadic cancers arise by chance over time,
and are not repaired by normal DNA repair mechanisms. Once present, these
amplifications could be selected for, in some manner, if the amplicon was functional
and provided an indirect or direct cellular growth advantage. Both selection
pressures and faulty DNA repair mechanisms may contribute to the incidence and
maintainance of the high frequency of c-erb B2 gene amplification observed in this
study. Deregulated DNA repair mechanisms might not be specific to c-erb B2 and
could accompany multiple sites ofDNA amplification. However, groups of cancers
with c-erb B2 amplification do not appear to have higher frequencies of amplification
of other oncogenes, located distant from c-erb B2. For example, analysis of breast
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cancers for c-myc, c-erb B2 and int-2 and other amplifications found a very low rate
of co-amplification of other oncogenes in c-erb B2 amplified cancers (Berns et al
1992, Zhou et al 1989). It is therefore possible that positive selection pressure exist
for the presence of c-erb B2 amplification. These selection pressures could be
indirect or direct.
Indirect selection pressure could be applied to a gene closely linked and co-amplified
with c-erb B2. Breast cancers have been shown to harbour amplification units
encompassing c-erb B2, THRA1, retinoic acid receptor and topoisomerase Hot
(Keith et al 1993), with some expression of topoisomerase Ila. The latter three
genes all have products known to be involved in gene transcription, signalling and
repair respectively. They could hence provide an indirect selection pressure if
present as functional amplicons.
Examples of this kind of indirect selection pressure do exist for other oncogenes.
The oncogene int-2 is amplified in some breast cancers (Tsuda et al 1989) and the
int-2 amplification unit on chromosome llql3 usually includes other genes, such as
bcl-2, which can also be amplified independently of int-2 (Theillet et al 1990, Saint-
Ruf et al 1991a). These other genes in the int-2 region are thought to be of
significance in cancer progression, with the int-2 gene of lesser direct relevance
(Brada 1992).
A direct selection pressure for the presence of c-erb B2 amplification could involve
the expression of its growth factor receptor product, giving a direct advantage to cell
growth after expression from a functional amplicon. The overexpression of c-erb B2
protein in breast tissue has been associated with an increased rate of proliferation of
the cancerous breast epithelial cells, as measured by thymidine incorporation (Barnes
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et al 1991) or S phase fractionation (O'Reilly et al 1991). This association was
strong in in situ cancers, particularly of the comedo type, but only weak in invasive
cancers (Barnes et al 1991, O'Reilly et al 1991). Taken as a whole, this data could
indicate that the c-erb B2 protein can directly influence cancer cell growth, possibly
providing a positive selection derived from the amplification. However there is a
long chain of events implicit in this concept, with numerous likely qualifications, of
which little is known.
Functional oncogene amplifications are only thought to occur in tissues where these
genes are expressed at some point during normal development (DePinho et al 1991).
C-erb B2 protein is thought to be present in low concentrations on the membrane of
normal adult breast epithelial cells and is also expressed in the embryo during its
normal development (Dougall et al 1994). It may have a role in normal cell
differentiation and morphogenesis (Dougall et al 1994). The possible relationships
between amplification, functional expression and oncogenesis may therefore occur
over a long period.
In this study, c-erb B2 gene amplification was a common event and it was clearly
detected in some cancers without an accompanying gene product overexpression. In
a few cancers, gene overexpression occurred in the absence of amplification. Other
studies have suggested that c-erb B2 amplification is not a frequent event (20 to 25%
of breast cancers) and is nearly always accompanied by overexpression (Walker et al
1989b, Uehara et al 1990). It is therefore possible that my techniques used to
measure amplification are more sensitive than previous studies. The considerable
effort validating the parameters of my techniques indicated that the results are
broadly correct, indicating that c-erb B2 disregulation may be more common than
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previously recognised. Similarly, the use of new monoclonal antibodies (not used in
this study) has led to an increase in detection of cancers overexpressing c-erb B2
gene product (Poller et al 1992). The study of the screened cancers suggested that c-
erb B2 amplification occurred in all cancer histopathological types, including those
with "early" features. Taken together, these indications that c-erb B2 amplification is
an early and common event suggest that the gene may either be involved early in the
oncogenic process, or that it is a secondary event conferring a growth advantage.
Recent in situ hybridisation studies have indicated that transcriptional regulation may
influence the relationship between c-erb B2 amplification and its expression in cells of
an individual cancer (Smith et al 1994). The finding of a few cancers with
overexpression, but no amplification in this study, also suggests that cellular
mechanisms for increasing expression may operate alone. It is possible that these
mechanisms could also operate in amplified cancers but this speculation has not been
tested.
8.3 Expression of c-erb B2.
Although gene amplification is an important marker of gene disregulation, gene
expression is more likely to exert a biological effect on the cancer cell. There may be
an important role for mechanisms which control gene transcription, including the
action of factors called promoters, enhancers or suppressors. These usually bind to a
sequence of DNA upstream from the relevant gene. This upstream sequence is
designated the promoter region, and both promoters and suppressors usually bind
within this region. Other factors known as enhancers may also bind within gene
introns, but few relevant studies are available.
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The promoter region of c-erb B2 gene may contain sites for multiple mechanisms of
transcriptional initiation (Tal et al 1987). However, few promoter factor molecules
specific for c-erb B2 have been identified. Cell derived DNA binding proteins OB2-1
and HPBF have been shown in vitro to bind specifically to c-erb B2 promoter region,
resulting in an upregulation of mitogenesis and c-erb B2 expression (Hollywood and
Hurst 1993, Sarkar et al 1994). These promoters may themselves be subject to
disregulation. Indeed HPBF was only detectable in cytoplasmic extracts from
malignant cells (Sarkar et al 1994).
More studies have examined the role of suppressors, due to the recognition that
oestrogen receptor may be involved in this type of action in breast cancers.
Oestrogen receptor is thought to be involved in the transcriptional control of c-erb
B2 gene (Russell and Hung 1992, Antoniotti et al 1994), but specific response
elements (receptor binding sequences) have not been identified within the promoter
region of c-erb B2. A particularly strong association between oestrogen receptor
status and c-erb B2 expression was observed in this study set (Chapter 4), where the
absence of oestrogen receptor correlated with the overexpression of c-erb B2 in
nearly all cases, as found in other recent studies of similar study sets (Schroeter et al
1992, Schonborn et al 1994). This concurs with other in vitro studies, which have
found that breast cancer cells containing oestrogen receptors stimulated by oestradiol
also had a marked downregulation of c-erb B2 expression (Russell and Hung 1992,
Antoniotti et al 1994). The mode of action of oestrogen receptor on the c-erb B2
gene is not known, but may include an intermediary step between the two, possibly
involving c-myc (Suen and Hung 1990).
This strong association of oestrogen receptor with c-erb B2 expression has great
relevance to analysis of the clinical features of breast cancers. The treatment of
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cancers with the anti-oestrogen tamoxifen, may act to downregulate c-erb B2
expression (LeRoy et al 1991). However, addition of tamoxifen to breast cancer
cells caused an increase in the c-erb B2 expression (Antoniotti et al 1992), so the
association between oestrogen receptor, tamoxifen and c-erb B2 may be complex.
The nuclear receptor gene THRA1, which shares considerable homology to
oestrogen receptor (King 1992) was also examined for possible involvement in c-erb
B2 suppressor activity (Chapter 6), but none was found. THRA1 and c-erb B2 genes
are co-amplified in approximately 20% of breast cancers (Tsuda et al 1989, Tavassoli
et al 1989), but this may be merely due to physical linkage on chromosome 17q21.
While my attempts to determine the co-amplification of THRA1 were not fully
successful, SSCP analysis of the zinc finger DNA sequences showed that the binding
specificity of the receptor molecule remained unaltered.
8.4 Cancer Progression and c-erb B2
I have discussed the possible role of c-erb B2 in cancer cell proliferation. However,
there are other elements in cancer progression, such as metastatic potential. C-erb
B2 overexpression has been suggested to be more common with node positive
cancers (Berger et al 1988, Borg et al 1990) and c-erb B2 expression has been linked
to the intercellular adhesion molecule, ICAM-1 and to urokinase plasminogen
activator, uPA, both ofwhich are thought to be involved in cancer cell dissemination.
Unlike some previous studies, my estimations of c-erb B2 disregulation, either
amplification or overexpression, found no relationship to node positive status
(Chapter 4). This does concur with some other similar studies (Gusterson et al 1988,
Thor et al 1989). The reason for these apparent discrepancies is not clear, but may
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reflect selection of cases for study sets. My study set drew from a wide screening
population so may be more representative of a longer progression period. The
intercellular adhesion molecule ICAM1 aids tissue cohesion, by binding cells to each
other. In one study, it was found to be expressed in invasive breast cancers which
were also positive for c-erb B2 protein overexpression (Bacus et al 1993). However,
most node negative invasive cancers in that study were negative for ICAM1
expression, indicating a possible role in metastasis.
The urokinase plasminogen activator uPA can act to break down the extracellular
matrix of solid tissue, thereby promoting cancer cell dissemination. It has been
shown to be overexpressed in epithelial cells in some invasive breast cancers
(Chapter 7, Foekens et al 1992, Grondahl-Hansen et al 1993). I demonstrated that
overexpression of uPA was not due to gene amplification, therefore transcriptional
control mechanisms must play an important role. Most cancers which overexpressed
uPA also overexpressed c-erb B2 protein (Chapter 7), suggesting either a possible
link, such as a common mechanism of transcriptional control, or coincidence. The
many factors known to affect the expression of uPA (Hart and Rehemtulla 1988)
would complicate any detailed analysis.
Although the biological functions of c-erb B2 remain unresolved, it is clear that there
is a high frequency of disregulation at this locus. This could indicate that it may play
some role in cancer progression. Establishing a role for candidate genes in cancer
progression has proved difficult due to the considerable heterogeneity within the
disease. I have been fortunate to be able to study cancers which may represent
different chronological stages of the disease, namely prevalence, incidence, interval
and never screened cancers (Chapter 4), and thence relate the molecular disregulation
of c-erb B2 to these sets.
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The newly screened group (prevalence cancers) contained more cancers with "early"
characteristics, such as in situ and special type cancers, and small, node negative,
oestrogen receptor positive cancers. The never screened group contained more
cancers with "late" characteristics, such as invasive carcinomas of no special type,
and large, node positive, oestrogen receptor negative cancers. Interestingly, the
previously screened group (incidence and interval cancers) contained a number of
cancers (approximately 40%) with "late" characteristics, particularly high grade
invasive cancers and oestrogen receptor negative cancers. A proportion of cancers in
the newly screened group will be slow growing and may be at a screen detectable
stage over a long time period, therefore the prevalence screen will detect many more
small, low grade cancers. Less of these cancers will be detected on incidence
screening because of the relatively short time period between screens. This may
indicate that a "length bias", could occur in the prevalence screen.
Cancer size and lymph node status are probably the most reliable characteristics of
"early" or "late" cancer status, but histopathological type and grade, oestrogen
receptor status and DNA ploidy are also of value for interpretation of cancer
progression, see Table 20 Chapter 4. An important finding was that c-erb B2 gene
amplification was not significantly associated with any of these cancer characteristics
(Chapter 4). It would therefore appear to be an independent but common event,
suggesting that it could be an early and possibly stable disregulation in some cancers.
8.5 Hypothesis and Model.
In contrast to c-erb B2 gene amplification, c-erb B2 gene product overexpression
was significantly associated with histopathological type and oestrogen receptor status
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(Chapter 4). A model of breast cancer progression, incorporating a previous model
(Allred et al 1992) and results of this study is illustrated in Figure 59. It is suggested
that overexpression decreases within individual tumours as they evolve from in situ
to increasingly invasive lesions. Alternatively, invasive carcinomas, negative for c-
erb B2 product overexpression, could arise de novo without progressing through a
significant in situ stage.
It is possible that c-erb B2 protein overexpression is an early event in cancer
initiation, rather than in cancer progression, as overexpression is common in "early"
in situ cancers (Allred et al 1992, Chapter 4). In this study, c-erb B2 amplification
was found to be an early event, but product overexpression was associated with both
"early", in situ and "late", high grade, oestrogen receptor negative cancers. The
latter finding could be explained by the strong relationship between c-erb B2 product
overexpression and absence of oestrogen receptors, see Figure 60. The findings of
this study therefore suggest that c-erb B2 amplification and product overexpression
are early events, but that overexpression may not be a stable event, as it can be
affected by other changes in cellular biochemistry.
Studies of gut and nervous system cancers have suggested that amplification of c-erb
B2 and other genes is a relatively late event in progression of these cancers (Brodeur
et al 1984, Ekstrand et al 1991, Ranzani et al 1990). Previous determination of the
chronology of genetic events in breast cancer is complicated because results are often
derived from symptomatically detected cancers, which may represent a relatively
"late" stage of progression. In this study, cancers of likely "early" status still had a
high rate of c-erb B2 amplification and amplifications were just as frequent in large
cancers, as is suggested by some other studies (Iglehart et al 1990, Borg et al 1990).
The amplification of c-erb B2 may therefore occur differently to that of oncogenes in
286
Figure 59.
An illustration of a proposed model of breast cancer progression, with suggested
levels of c-erb B2 product overexpression in the various cancer types.
Level of c-erb B2 product overexpression is represented by:
*** High, > 50% of cancer group;
** Medium, 15 to 50 % of cancer group;
* Low, 0 to 15 % of cancer group;
a C-erb B2 product not detected;
b Not known.
DCINST = invasive ductal carcinoma, no special type.
Histopathological grades I, II and III are described in Chapter 4.
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Figure59 Lobular in situa
0 Invasive lobulara 0 DCINSTb













A model of the relationship between c-erb B2 product overexpression and oestrogen
receptor status in in situ and invasive cancers.
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other groups of cancers. Understanding the mechanisms of its amplification could
help to determine the role of c-erb B2 in breast cancer progression. The finding of
disregulated c-erb B2 in "early" breast cancers, has not been reflected in any of the
proposed precursor lesions, such atypical hyperplasias (Allred et al 1992), but these
were not examined in this study.
8.6 Future Developments
This study has highlighted the need for a fuller understanding of the biology of c-erb
B2 in breast cancer in order to assess its relevance to the disease. Initiation and
progression represent different stages of cancer development and my study only
addressed the latter. The complex factors which control the expression of c-erb B2,
and the uncertainty about its biological functions make it possible that associations of
c-erb B2 disregulation with clinical features of cancers may be subject to unseen bias.
The presence of normal or disregulated c-erb B2 may therefore have some unseen
beneficial function. Interestingly, some therapies of breast cancer have been designed
to reduce the activity of the c-erb B2 gene, including anti-pl85 monoclonal
antibodies (Hudziak et al 1989) or oligonucleotides capable of binding to c-erb B2
mRNA (Colomer et al 1994). While my study of c-erb B2 in breast cancer has made
a significant contribution to an understanding of its role, many other aspects of breast
cancer remain to be explored. The availability of screen detected cancers gives a
valuable study set for continued work. Areas of interest in future studies could
include an examination of the mechanisms controlling transcription of c-erb B2, such
as the nature of the promoter region; an analysis of c-erb B2 disregulation in familial
cancers; and an analysis of c-erb B2 disregulation in incidence and interval cancers
for better chronological separation of cancer status.
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Appendix 1
General Solutions and Reagents














HC1 to pH 8.4
2mM EDTA





stock 10% w/v in dE^O
Isopropylthio-P-D-galactoside (IPTG)
stock 20% w/v in dH^O
Chloroform: isoamylalcohol 24:1 v/v
5-Bromo-4-chloro-3-indolyl-(3-D-galactoside (x-gal)
20mg/ml dimethylformamide
Proteinase K stock 20mg/ml in H2O
Agarose gel loading buffer lOx 30%w/vFicoll
0.25% w/v Orange G (Sigma)
0.5mM EDTA
98% deionised formamide
50mM Tris borate pH8.3
lOmMEDTA
0.025% w/v xylene cyanol FF
0.025% w/v bromophenol blue
11. Sequencing gel loading buffer 2x
12. N,N,N',N'-Tetramethyl-ethylenediamine (TEMED) Sigma Ltd 99.7% pure.
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13. Lysis solution for preparation ofDNA from fixed paraffin embedded tissues.








as L-Broth with 12g/L Bacto agarose
1Opg/ml ampicillin (added when the agarose











1. DNA extraction from frozen tissue.
1. Chop frozen tissue into small pieces in 0.5ml Tris EDTA, 10% SDS.
2. Add proteinase K to 0.5mg/ml and incubate samples overnight at 48°C, mix
samples and return to 48°C for a further 24hours.
3. Follow protocol for purification and precipitation ofDNA (see below).
2. Purification of nucleic acids.
Extraction with phenol:chloroform
1. Add an equal volume of Tris saturated phenol to DNA sample and mix till
an emulsion forms.
2. Centrifuge the mixture at 12,000g for 1 minute at room temperature.
3. Remove aqueous phase to fresh tube.
4. Repeat steps 1-3 till no protein is visible at the interface.
5. Add an equal volume of24:1 chloroform:isoamylalcohol and repeat steps
2-4.
6. Recover DNA by precipitation with ethanol
3. Precipitation of DNA
1. Add l/10th volume of 0.3M sodium acetate (pH5.2), and 2 volumes of
ethanol to DNA in solution, mix by inversion.
2. Cool at -70°C for 30 minutes
3. Centrifuge at 12,000g for 10 minutes.
4. Remove supernatant.
5. Wash DNA pellet in two volumes of 70% ethanol.
6. Centrifuge at 12,000g for 10 minutes.
7. Remove supernatant
8. Repeat steps 5-7 once.
9. Dry DNA pellet under vacuum.
9. Resuspend DNA pellet in Tris EDTA pH8.4.
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4. Dynabead purification and preparation of single stranded biotinylated PCR
product (Dynal)
1. Prepare Dvnabeads. Throughout, superparamagnetic Dynabeads are
separated from supernatant fluids using a magnetised strip. For each DNA
sample wash 20pi ofDynabeads twice in 20pl ofDNA binding and washing
solution (Dynal, 2x = lOmM Tris HC1 (pH 7.5}, ImM EDTA, 2M NaCl).
The final pellet of beads is resuspended in 40pl of binding and wash
solution.
2. Add 40pl of amplified DNA to 40pl ofwashed Dynabeads, and incubate
for 15 minutes at room temperature, mixing gently. Magnetise beads and
remove supernatant.
3. Wash beads twice in binding and washing buffer as in step 1.
4. Resuspend beads in 8pl of 0.1M NaOH, and incubate at room
temperature for 10 minutes. Separate beads and remove supernatant to fresh
tube (contains non-biotinylated DNA strand).
5. Repeat step 4.
6. Wash beads once in 40pl of binding and wash buffer, and once in 50pl
TE buffer. Resuspend final bead pellet in 20pl distilled water.
5. Wizard ™Miniprep DNA purification system (Promega).
Preparation ofDNA from plasmid DNA from E.coli. cultures.
1. Pellet 3ml ofbacterial cells by centrifugation for 2 minutes at 12,000g.
Resuspend cell pellet in 200pl of Cell resuspension solution (Promega) and
add 200pl ofCell lysis buffer (Promega), mix by inversion. When solution
clears add 200.pl ofNeutralisation solution (Promega). Centrifuge at
12,000g for 5 minutes. Decant supernatant to new microcentrifuge tube.
2. Add 1ml ofWizard Resin to the supernatant from step 1. Push resin/DNA
mix into mini column (Promega) using a 3ml disposable syringe. Push 2ml of
Column wash solution (Promega) through resin in mini column.
3. Centrifuge mini column at 12,000g for 20 seconds. Add 20.pl of distilled
water to top ofmini column, and incubate at 65°C for 1 minute. Centrifuge
at 12,000g for 20 seconds. The supernatant contains purified plasmid DNA.
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6. Purification of DNA using G50 sephadex columns.
Quick Spin™ Columns (Boeringer Mannheim Biochemica Ltd) contain 0.8 ml of pre-
swollen Sephadex G-50 in lOmmol Tris HC1 pH8, lmmol EDTA, 0.1mol/l NaCl.
1. Mix sephadex by inversion to resuspend the medium within the column,
and centrifuge at 1100 rpm for 2 minutes. Discard eluted buffer.
2. Add DNA solution to the top of the sephadex column. Centrifuge for 4
minutes at 1100 rpm. The eluate from this spin contains the purified DNA
sample.
7. NuseiverSeakem (FMC Ltd) agarose gels
General agarose gel for separation ofPCR products.
1.5% w/v Nuseive agarose
0.5% w/v Seakem agarose
in 0.5x TBE
1. Heat in microwave to melt agarose, cool to 55°C. Add 1/10,000th
volume of ethidium bromide. Pour gel into gel cast, allow to set at 4°C.
8. Metaphor agarose gels
1. Add 1.8% w/v metaphor agarose (FMC Ltd) to 0.5x TBE buffer.
2. Heat in microwave till agarose dissolves.
3. Cool to <55°C, while stirring
4. Add 1/10,000th volume ofEthidium bromide
5. Pour gel at room temperature.
6. When set, cool at 4°C for 30 minutes prior to electrophoresis.
9. MDE™ Polyacrylamide Gel
0.5xMDEgel 25ml MDE gel.
69ml deionised water
6ml lOx TBE buffer
0.4ml 10% ammonium persulphate
0.04ml TEMED
10. Denaturing polyacrylamide gel
5% polyacrylamide gel used to separate DNA sequencing reactions.
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For 50ml of gel
5ml lOx TBE buffer




250]_il 10% ammonium persulphide
After pouring allow to set at room temperature for 1 hour. Preheat gel to
55°C prior to electrophoresis.
Silver staining polyacrylamide gels
Biorad kit - Silver Stain Plus no 161-0449
1. Immerse polyacrylamide gel in 400mls of gel fixative, with gentle shaking
for 20 minutes.
Gel fixative 200ml Methanol
40ml Acetic Acid
40ml Fixative enhancer concentrate (BioRad)
120ml Deionised Distilled Water.
2. Pour off fixative and rinse gel twice in 400mls deionised distilled water for
20 minutes.
3. Pour offwater and immerse gel in 300mls staining solution, with gentle
shaking for approximately 20 minutes, or until desired staining intensity is
reached.
Gel stain 15mls Silver Complex Solution (BioRad)
15mls Reduction Moderator Solution (BioRad)
15mls Image Development Reagent (BioRad)
105mlsDeionised Distilled Water
150mls Development Accelerator Solution (BioRad)
4. Pour off developer solution and stop reaction in 5% v/v acetic acid in
deionised distilled water for 15 minutes with gentle shaking
5. Rinse gel in 400mls of deionised distilled water.
6. Dry gel on filter paper support on Hoeffer vacuum gel drier for 2 hours.
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12. DNA Sequencing
A. Cyclist™ sequencing kit (Stratagene)
1. Add 3|a.l of the appropriate ddNTP to each of 4 termination tubes. Cap and
keep on ice.




4pl of lOx sequencing buffer
lOpCi a-35S dATP
2 units Taq polymerase
water to final volume of 30 pi.
3. Aliquot 7pi of the reaction mixture from step 2 into each of the 4
termination tubes from step 1.
4. Overlay with 15pi ofmineral oil.
5. Cycle the sequencing reaction through an appropriate temperature profile.
Denature at 95°C for 5 minutes, then 30 cycles of
95°C for 30 seconds
5 5 °C for 30 seconds
72°C for 60 seconds
6. Add 5pl of stop mix to the reaction.
7. Heat denature at 80°C for 5 minutes, then load 3 pi of each sample onto a
sequencing gel.
B. Sequenase T7 DNA polymerase (United States Biochemical)




2pl Annealing buffer (USB)
H2O to lOul
Warm annealing mixture to 65°C for 2 minutes, allow to cool to room
temperature over 30 minutes. Chill on ice
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2. Labelling reaction. To the annealing mix add the following;
ljj.1 DTT (0.1M)
2pl Labelling nucleotide mix
5pCi a-35S dATP
3 units Sequenase enzyme
Incubate at room temperature for 3 minutes.
3. Termination reaction. Add 2.5 pi of the appropriate ddNTP to each of
four termination tubes. Prewarm to37°C
Add 3.5pi of the labelling reaction to each of four ddNTP tubes. Incubate at
37°C for 5 minutes. Add 4pl of stop solution to each tube.
Heat denature samples at 95°C for 5 minutes prior to loading 3pi per lane on
a polyacrylamide gel.
13. Fresh tissue fixation and processing.
Fresh breast tissue was fixed in 6:3:1 methanol .chloroform:acetic acid at 4°C
overnight. Fixed tissues were processed to paraffin wax using the following protocol.
1. 70% alcohol 1 hour
2. 64op alcohol 1.5 hours
3. 64op alcohol 2 hours
4. 74op alcohol 2 hours
5. 74op alcohol 2 hours
6. absolute alcohol 2 hours
7. absolute alcohol 2 hours
8. Xylene 2 hours
9. Xylene 2 hours
10. Xylene 2 hours
11. Wax (Ralwaxl) 2 hours
12. Wax (Ralwaxl) 2 hours
13. Vacuum in wax bath in processing room.
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Critical determination of the frequency of c-cr^B-2 amplification in
breast cancer
A.L. Hubbard1, C.P. Doris1, A.M. Thompson2, U. Chetty3 & T.J. Anderson1
'Department of Pathology, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, UK; 2Department of
Surgery, Royal Infirmary, Edinburgh EH3 9YW, UK; 3Longmore Breast Unit, Western General Hospital, Edinburgh EH4 2HU,
UK.
Summary Tissues from 323 methacarn-fixed and paraffin-embedded breast cancers were assessed for c-erbB-2
gene amplification by differential polymerase chain reaction (dPCR). The sensitivity of dPCR was ascertained
using cell lines with c-erbB-2 amplification, and the relationship between dPCR ratio value and gene copy
number was established. In clinical material the technique was not affected by the DNA contribution of
normal tissue elements or by cancer DNA ploidy change. c-erbB-2 gene amplification was detected in 55% of
invasive cancers and in 66% of in situ cancers. c-erbB-2 protein overexpression in breast cancer cells, as
determined by specific immunohistochemistry, was only detected in 11% of invasive cancers and 43% of in situ
cancers. Comparisons show that a substantial number of cancers with c-erbB-2 amplification lack detectable
protein overexpression. This illustrates the complex nature of c-erbB-2 gene disregulation in cancer and
suggests that multiple combinations of biological events and consequences are possible.
Disregulation of the proto-oncogene c-erbB-2 (also known as
HER-2/wetr) has been implicated in the aetiology of breast
cancer. Since the publication of a study linking c-erbB-2 to
poor prognosis in breast cancer patients (Slamon el al., 1987)
there have been many studies examining c-erbB-2 gene
amplification, mRNA production and protein overexpression.
Recent reviews have collated the results from over 50 studies
and found a general agreement between them on the fre¬
quency of c-erbB-2 disregulation in terms of gene
amplification and protein overexpression, as measured by
Southern blotting and immunohistochemistry respectively
(Perren, 1991; Singleton & Strickler, 1992). However, there
are major differences in the association of c-erbB-2 disregula¬
tion with histopathological features and with prognosis, mak¬
ing its involvement in cancer development and progression
difficult to determine. It is not clear whether differences in
results between studies have been the result of variations in
sample selection, experimental technique or genuine
biologically relevant disparity between populations.
Of the techniques for measuring gene amplification,
Southern or dot blotting suffers from the disadvantages that
microgram quantities of DNA are required for analysis and
tissue morphology is destroyed in the extraction process.
Recent advances in polymerase chain reaction (PCR) tech¬
nology have made possible the analysis of minute quantities
of DNA, with semiquantitative differential estimations
(dPCR) demonstrating increased gene copy number in cell
lines (Frye el al., 1989). The present work explores the
sensitivity of dPCR in detecting an increased gene copy
number in a large series of clinical cancers by extending the
application of this technique to paraffin-embedded tissues,
with a view to evaluating the relationship between c-erbB-2
gene amplification and expression.
Materials and methods
Study set
The study tissues (336 cases) were collected from primary
operable (clinical stage I and II) breast cancers at routine
operations, which included mastectomy and excisional biopsy
for both palpable and non-palpable lesions. Samples were
restricted to the age group 50-65 and were collected over the
period of January 1988 to May 1990. They were fixed in
Correspondence: T.J. Anderson.
Received 23 November 1993: and in revised form 21 April 1994.
methacarn (6:3:1 methanol-chloroform-acetic acid) over¬
night at 4°C, processed according to routine methods and
embedded in paraffin. Control tissue (43 cases) was obtained
from breast tissue distant to the lesion site or from non-
cancer-bearing breasts. Pathological characterisation was
taken from overall evaluation of material used for routine
diagnosis, and included an evaluation of a 4 pm section
immediately adjacent to sections taken for dPCR (see below).
This section confirmed the nature of the tissue used in the
PCR reaction, and in addition the cellularity of each speci¬
men was assessed subjectively for the proportion of the
cancer cellular content and designated as either 1 = more
than 75%, 2 = 25-75% or 3 = <25%. In some cases
samples of the lesion were taken and stored frozen in liquid
nitrogen for RNA analysis.
Flow cytometric analysis
Paraffin-embedded tumours were processed for DNA flow
cytometry according to the method of Hedley et al. (1983).
Briefly, two 50 pm sections were dewaxed using two changes
of xylene and rehydrated. The tissue was incubated for
30 min at 37°C in 0.5% pepsin (Sigma) in 0.9% saline
adjusted to pH 1.5 with 2n hydrochloric acid. The isolated
nuclei were counted and analysed using an EPICS C flow
cytometer (Coulter Electronics, Hileah, FL, USA), after
staining with 0.1% propidium iodide containing 0.004%
RNAse. Ten thousand nuclei were counted at 480 nm excita¬
tion and the coefficient of variation calculated using STAT-
PACK software (Coulter Electronics).
Ploidy was assessed as either diploid (DNA index, DI,
between 0.9 and 1.10) or aneuploid (DI >1.10 and <1.90 or
>2.10). Tetraploids were classified as DI between 1.90 and
2.10 with more than 20% of the cells apparently in G2 plus
M phase of the cell cycle. For inclusion the coefficient of
variation for the peak value had to be less than 8%.
Cell lines and culture conditions
Human breast cancer cell lines known to have an
amplification of c-erbB-2 were used to calibrate the relation¬
ship between differential PCR ratio values and gene copy
number. The epithelial cell line 21MT2 was obtained from R.
Sager (Dana-Farber Cancer Institute, Boston, MA, USA)
and contains a 40-fold increase of the c-erbB-2 gene (Band et
al., 1989). The cell line UISO BCA1 was obtained from R.R.
Mehta (University of Illinois, Chicago, IL, USA) and con¬
tains a 10-fold increase in the c-erbB-2 gene (Sasi et al.,
1991).
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Each cell line was grown at 37°C in air with 5% carbon
dioxide added. 21MT2 was cultured in alpha minimum essen¬
tial medium (MEM) (Gibco) containing 10% fetal calf
serum, 2 mM L-glutamine, ImM sodium pyruvate, 0.1 mM
non-essential amino acids, l/rgml-1 insulin, 2.8 pM hyd¬
rocortisone 12.5 ngml-1 epidermal growth factor and 10 mM
HEPES. UISO BCA1 was cultured in Glasgow's minimum
essential medium (GMEM) (Gibco), 10% fetal calf serum
and 2 mM L-glutamine. For calibration experiments, DNA
was prepared from each cell line (Sambrook et al., 1989) and
was mixed with control DNA derived from normal placenta
(p258, one c-erb-B-2 gene copy), in proportions which gave a
series of known c-erbB-2 copy numbers. The 21MT2 DNA
was diluted to give c-erbB-2 copy numbers of 32, 24, 16, and
8, and UISO BCA1 was diluted to give copy numbers of 9, 6,
5, 4 and 3.
Immunohistochemistry
Overexpression of c-erbB-2 was ascertained using the rabbit
polyclonal antibody, 2IN, to the c-erbB-2 protein (Gullick et
al., 1987). Four micron sections of fixed tissue were dried at
56°C then stained in a three-stage peroxidase-antiperoxidase
technique (Sternberger, 1986). The primary antibody, 2IN,
was used at a concentration of 3.3pgmU' in 0.1 M Tris-
buffered saline (pH 7.6) containing 5% normal swine serum.
Each section was incubated at room temperature for 90 min.
Endogenous peroxidase was blocked by exposure to 1%
hydrogen peroxide in methanol for 30 min before staining.
Overexpression of c-erbB-2 was defined as the presence of
brown staining of surface membrane of cancer cells. To score
positive, more than 10% of cells had to show moderate to
strong staining. Controls included a known positive case and
a negative control employing a preincubation of the antibody
with its corresponding peptide (1 mgml"1).
mRNA
Messenger RNA was extracted from frozen tumour samples
and analysed by Northern blot (Thompson et al., 1990).
Twenty micrograms of total RNA was denatured with for-
mamide and formaldehyde at 55°C for 20 min and RNA
species separated by electrophoresis on a 1.1% agarose gel.
The RNA was transferred to a nylon filter (hybond-N,
Amersham, UK) by capillary action using 10 x SSC and
covalently fixed to the membrane using a UV transil-
luminator. To detect c-erbB-2 mRNA the filters were hy¬
bridised with A107, a 1.7 kb fragment of \-erbB-2 (Semba et
al., 1985), according to the method of Church and Gilbert
(1984), washed to remove non-specifically attached probe and
exposed to preflashed Kodak XAR film at — 70°C. Filters
were stripped and reprobed with a-actin (Minty et al., 1981)
as an internal control for loading. The extent of hybridisa¬
tion of radiolabelled probe to the mRNA species was deter¬
mined using densitometry and expressed with respect to hyb¬
ridisation to the actin probe.
Primers and the polymerase chain reaction
Primers used in the differential PCR are listed in Table I.
They were DNA sequences specific for interferon gamma
(IFN-y 150), c-erbB-2 and interferon beta (IFN-fS). The single-
copy reference sequence was the 150 bp sequence from the
IFN-y gene. For dPCR four 10-pm sections of fixed paraffin-
embedded tissue were added to 100 pi of lysis buffer (50 mM
Tris-HCl, pH 8.4, 1 mM EDTA, 0.5% Tween 20) and boiled
for 8 min (Hubbard & Anderson, 1993). Differential PCR
was performed on a Techne PHC3 thermal cycler incor¬
porating 5 pi of prepared lysed paraffin section or 200 ng of
extracted DNA, 0.25 pM each primer (except for primers for
IFN-fi, 0.125pM), 200 mM dNTPs (Pharmacia), Xl Taq
polymerase buffer (Northumbria Biotechnology Limited,
NBL), 1 unit of Taq polymerase (NBL) and 3 pCi of
[32P]CTP (New England Nuclear). Cycling parameters were
one cycle of 94°C for 5 min, 50°C for 1 min, 70°C for 1 min,
followed by 30 cycles of 94°C for 1 min, 50°C for 1 min, 70°C
for 1 min, and one cycle of 94°C for 1 min, 50°C for 1 min,
70°C for 5 min. Duplicate PCR products were separated by
size on 2% agarose gels, and stained with ethidium bromide.
Visible bands were excised, finely chopped and added to 5 ml
of Optiphase-safe scintillation fluid and radioactivity present
assessed as counts per minute (c.p.m.) on a Beckman scintil¬
lation counter. A correction factor was applied to compen¬
sate for the differences in numbers of CTP bases between
reference and test gene. All specimens were assessed in dupli¬
cate experiments.
The results from dPCR are expressed as ratio values and
were calculated by averaging the c.p.m. from duplicate gel
tracks and subtracting the average experimental blank. For
c-erbB-2 a correction factor of 1.25 was applied to compen¬
sate for differences in dCTP content between IFN-y 150 (69 C
bases) and c-erbB-2 (55 C bases). To ascertain the relative
quantity of c-erbB-2 gene with respect to the reference gene,
the corrected average c.p.m. for c-erbB-2 was divided by the
average c.p.m. for IFN-y 150, giving in each case a result
expressed as a ratio value. Similar correction factors were
calculated and applied to dPCR involving amplification of
IFN-0.
Results
Validation of differential PCR method
Calibration of ratio values Differential PCR was assessed for
sensitivity and reproducibility in determining gene copy
number. As defined here, 'one gene copy' corresponds to the
normal diploid content of one cell. The results of differential
PCR on the various DNA solutions of p258 and cell lines
21MT2 and UISO BCA1 with known c-erbB-2 gene copy
number, using primers for IFN-y 150 and c-erbB-2. are shown
in Figure 1. A comparison of the known copy numbers in
each cell line sample and differential PCR ratio values
showed that increasing gene copy number resulted in increas¬
ing ratio values; mean values for 1 and 40 gene copy
numbers were 1.66 and 11.46 respectively. While comparison
of the ratio values obtained for given copy numbers shows
some variation between experiments, there was a consistent
increment in this value within each experiment. Samples with
large amplifications (> 32) showed increased variation
between duplicate tests. For the purposes of standardisation
it was considered best to work on a mean value for these
Table I DNA sequences of primers used in differential PCR
Gene Sequence Reference
c-erbB-2
Sense 5'-CCT CTG ACG TCC ATC ATC TC-3' Frye et al. (1989)
Antisense 5'-ATC TTC TGC TGC CGT CGC TT-3'
IFN-y 150
Sense 5'-TCT TTT CTT TCC CGA TAG GT-3' Frye et al. (1989)
Antisense 5'-CTG GGA TGC TCT TCG ACC TC-3'
IFN-P
Sense 5'-GTG TCT CCT CCA AAT TGC TC-3' Neubauer et al. (1992)
Antisense 5'-GCC ACA GGA GCT TCT GAC AC-3'
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Figure 1 Relationship between c-erbB-2 copy number and differ¬
ential PCR ratio value. Each copy number was derived by dilu¬
tion of DNA from c-erbB-2 amplified cell lines 21MT2 or UISO
BCA1 with placental DNA (one copy). Each point on line M
represents the mean of triplicate experiments. Individual
experiments are represented by lines 1, 2 and 3.
experiments, depicted by open circles in Figure 1. Thus a
mean ratio value of 2 approximated to five copies of c-erbB-
2. Note that each ratio value is a derived value and does not
equate with but is directly proportional to the copy
number.
Factors affecting dPCR ratio values Application of this tech¬
nique in a series of paraffin-embedded specimens required
stringent controls. Confirmation that IFN-y was present as a
single-copy gene was obtained in 57 cancer and 27 control
specimens by performing differential PCR with primers for
both IFN-y 150 and IFN-/3. The ranges of ratio values
detected were similar for cancers (0.81-1.9) and control tis¬
sues (0.4-1.7), suggesting that IFN-y was present in both as
a single-copy gene.
Satisfactory analysis of DNA ploidy by flow cytometry
was obtained from 240 cancers. In 117 the phenotype was
diploid, and 123 were aneuploid or tetraploid. The frequency
of amplification of c-erbB-2 in specimens assessed by flow
cytometry was found to be highest in cancers which were
diploid (60%), with lower percentages of aneuploid (47%)
and tetraploid (42%) cancers being amplified. These
differences were not significant.
A third potentially confounding factor was the dilutional
effect of normal cells present within the cancer tissue, per¬
haps reducing the detection frequency of amplification. The
proportion of amplified and non-amplified cases of invasive
cancer ranked according to section cancer cellularity is shown
in Figure 2. Amplification was found in each of the groups,
including those specimens in which cancer cells constituted
less than 25% of total cellularity.
c-erbB-2 amplification and overexpression in breast cancers
Gene amplification determined by differential PCR A total of
323 breast cancer specimens and 43 controls were tested for
c-erbB-2 amplification using primers for c-erbB-2 and IFN-
yl50. Figure 3 shows representative PCR products obtained
from fixed tissue specimens of three different cancers and one
DNA extracted by routine phenol/choroform procedures
from fresh tissue preserved at — 70°C from one of these
cancers. Differential increase of c-erbB-2 products indicating
amplification is illustrated, with corresponding ratio values of
1.4, 2.1 and 3.6 for the fixed cancer tissue, 3.7 for DNA of




Figure 2 Relationship between cancer cellularity and frequency
of c-erbB-2 amplification in 277 breast cancers. Cancer cellularity
was assessed visually as >75% cancer cells = 1, 25-75% cancer
cells = 2, <25% = 3. □, Specimens with a dPCR ratio value less
than 2; ■. Specimens considered to be amplified (dPCR ratio
value of 2 or above).





Figure 3 Differential PCR products from IFN-y 150 (150 bp) and
c-erbB-2 (98 bp) size separated on a 2% agarose gel. Lanes are:
A, BRL molecular weight marker V; 1, 2 and 3, three different
cancers; 4, DNA from the same cancer as lane 3; 5, normal
control DNA (p258). Differential PCR ratio values for lanes 1-5
are 1.3, 2.1, 3.5, 3.6 and 1.1 respectively. Lanes 2, 3 and 4 all
show clear amplification of c-erbB-2 product.
The ratio values obtained using primers for c-erbB-2 and
IFN-y 150 from both normal and cancer tissues are shown in
Figure 4. The ratio range for 43 normal tissues fell con¬
sistently between 0.6 and 1.9 (mean 1.2, s.d. 0.36), and
therefore values of 2 or above were considered to signify gene
amplification. This value corresponds to approximately five
gene copies (see Figure 1), and indicates that dPCR, in its
present form, is unsuitable for exact specification of those
cases with low copy number (<5). The results of duplicate
experiments for each clinical case showed consistency for
identification of gene amplification as being of low-medium
copy number (ratio value range 2-3) or high copy number
(ratio greater than 3). In cancer tissues the range was
0.6-19.2 (n = 323), indicating copy numbers encompassed by
the range of copies assessed in the calibration (from 1 to 40).
A total of 183 cancers had ratio values of 2 or above,
signifying gene amplification in at least 57% of this study set.
For 287 invasive cancers, the ratio values ranged from 0.6 to
19.2 with ratio values > 2 in 159 (55%), corresponding to
low-medium copy number in 99 (34.5%) and high copy
number in 60 (20.5%). For 36 in situ cancers the ratio ranged
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from 1.0 to 8 with ratio values ^ 2 in 24 (66%), of which 15
(42%) were low-medium and nine (25%) were high copy
number.
Protein overexpression assessed by immunohistochemistry
Immunohistochemistry for c-erbB-2 overexpression was per¬
formed on 336 breast cancer specimens. Overexpression of
c-erbB-2 was detected in 23 of 54 (43%) of in situ carcinomas
and in 31 of 282 (11%) invasive carcinomas. In cases in
which in situ and invasive forms of cancer were present on
the same slide, no detectable differences in the staining pat¬
tern between them was observed. Staining was concentrated
on epithelial cell membranes and stained cells were present
evenly throughout the cancer, except in one cancer in which
focal staining of cancer cells was observed.
Overexpression was not observed in normal epithelial or
stromal cells.
Comparative evaluation of protein overexpression and gene
amplification A case comparison of gene amplification
determined by dPCR with protein expression determined by
immunohistochemistry is shown in Table II. Thirty-nine of
49 immunopositive cases (80%) had gene amplification (with
ratio values ranging from 2.0 to 19.2). There were ten cases
in which differential PCR did not detect gene amplification in
the presence of protein overexpression. However 146 of 274
immunonegative cases (53%) had PCR-detectable amplifi¬
cation of the c-erbB-2 gene, and this included 43 cases with
ratio values > 3, indicating high copy number. The range of
differential PCR values was similar between the immuno¬
positive and immunonegative groups (Figure 5) and applied
to both in situ and invasive cancers. Of the 13 samples
assessed by immunohistochemistry but not available for
PCR. five were immunopositive.
mRNA measurement Specific messenger RNA was measured
in 26 breast cancer cases, and increased levels of c-erbB-2
mRNA corresponding to densitometry values four times con¬
trol or greater were found in 11 cases (42%). The correlation
between c-erbB-2 mRNA levels and gene amplification and
overexpression is shown in Table III. All cases with positive
immunohistochemistry contained elevated levels of c-erbB-2
mRNA. Furthermore, 4 of 19 cases negative for immuno¬
histochemistry also had elevated levels of mRNA; gene
amplification determined by dPCR was present in two of
these cases.
Discussion
This study with fixed paraffin-embedded tissue has demon¬
strated that dPCR is a highly sensitive technique for the
detection of gene amplification and is also sufficiently robust
to be applied to tumours of differing cellularity and DNA
ploidy. For invasive cancers the frequency of gene amplifi¬
cation (55%) was considerably higher than anticipated from
reports of conventional methods based on Southern or dot
blotting techniques. In ten major studies of breast cancer,
each assessing 100 or more cancer cases, the frequency of
amplification varied between 17% and 23% (see review by
Singleton & Strickler, 1992). Because of the size of the dis¬
parity some initial comment on comparability of methods is
appropriate.
Study of gene amplification is complicated by terminology
for an increased gene number, which may be expressed as
either a fold difference, increased copy number or both; fold
difference is equated with copy number in some reports (Ali
et al., 1988; Garcia et al., 1989). We have assumed that the
fold differences ascertained for the cell lines used in calibra¬
tion of the dPCR are valid reflections of gene copy number,
and have therefore expressed the altered dPCR ratio values
as increased gene copy number. Owing to the arbitrary cut¬
off point for 'amplification' outwith the range observed in
normals, dPCR would appear to lack the specificity to iden¬
tify low copy number. Caution must be applied when ratio
values are extrapolated to gene copy number in clinical cases.
Experimental variation and approximations inherent to DNA
analysis, including Southern or dot blotting techniques, may
affect the precise relationship between classifications. Yet
studies using Southern or dot blotting claim to detect inc¬
reases as low as 2-fold without quoting the full range of
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Figure 4 Distribution of differential PCR ratio values for c-
erbB-2 in 323 cancer tissues and 43 normal control tissues.
Figures in columns are expressed as percentage of cancers (■) or
percentage of normal controls (□).
Table II Comparison of c-erbB-2 protein overexpression measured
by immunohistochemistry and c-erbB-2 gene amplification measured
by dPCR in 323 breast cancers
Overexpression No overexpression
Amplification 39 146
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Figure 5 Distribution of dPCR ratio values for immunohisto¬
chemistry positive (■) and negative cancers (□).
Table III Association of increased c-erbB-2 mRNA expression with
protein overexpression and gene amplification
Immunohistochemistry
Positive Negative
mRNA Positive Negative Positive Negative
Amplified 4 0 2 10
Non-amplified 3 0 2 5
All cancers with protein overexpression show elevated levels of
mRNA. Four of 19 cases which were negative for protein over-
expression have increased mRNA. Messenger RNA level appears to
be independent of gene amplification.
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or recorded cancer cellularity differences. It is of interest that
a large proportion of amplified cases show a low increase in
gene copy number by all techniques; for example, 44% have
2-5 copies on Southern blotting (Borg et al., 1990), while in
this study 61% have ratio values of 2-3. There remains some
uncertainty about the most appropriate cut-off point on
which to base an amplified finding, but for the purposes of
this evaluation a ratio value of 2 was chosen, as this was
always above the values obtained for control samples. Rais¬
ing the cut-off point to a ratio value of 2.5 would reduce the
numbers amplified to levels equivalent to those previously
reported. However, differences in amplification frequency
depending on technique have also been observed in studies of
the ovary. dPCR detected c-erbB-2 amplification in 40% of
cancers (Hruza et al., 1993); in contrast, previous studies by
Southern blotting detected amplification in 1-26% of
ovarian cancers (Slamon et al., 1989; Zang et al., 1989;
Imyanitov et al., 1992). This suggests that there may be
differences in sensitivity between these techniques. The pos¬
sibility of artefactual elevation of dPCR ratio values in fixed
tissue extracts was examined by comparing them with sam¬
ples of DNA from the corresponding fresh tissue in a subset
of cases, but we found no evidence for this (data not shown).
There is also the issue of selection bias towards larger size of
cancer where there is a requirement to submit tissue for
extraction in DNA analysis. This does not apply to dPCR
studies which, as in the present series, can be applied in a
consecutive manner.
A higher degree of sensitivity than in the present study was
claimed in a previous investigation of c-erbB-2 amplification
using dPCR (Frye et al., 1989). One extra copy (2-fold
increase) was detectable, but that study used high-quality,
homogeneous DNA derived from cell lines in a single experi¬
ment. Further developments of the technique on clinical
material classified amplification in terms of fold differences,
the most sensitive level detecting a 2- to 4-fold increase in
c-erbB-2 product (Liu et al., 1992; Neubauer et al., 1992).
Those studies used a complex algorithm of experimental
exclusions involving four different dPCR reactions resulting
in a selected population of cancers, and detected c-erbB-2
amplification in 48% of in situ cancers and in 21% of
invasive cancers (Liu et al., 1992). Details of interexperimen-
tal variation, ranges of dPCR ratio values and criteria for
exclusion at each step of the algorithm were not stated. This
makes direct comparison of amplification frequencies with
the current study difficult. In addition Liu et al. (1992)
restricted their series to stage II node-negative disease,
whereas the present series was a consecutive group of
operable cancer including both node-positive and node-
negative cases. However, despite the problems of com¬
parability, we consider that the technique as currently
applied has major potential to give a valid but different
perspective of gene disregulation relevant to study of the
development and progression of cancer.
Detection of overexpression of c-erbB-2 by immunohisto-
chemistry is subject to considerable variation between studies
(Singleton & Strickler, 1993) in part because of the different
primary antibodies, fixation methods, study set composition
and criteria for assessing positive staining. The dilution used
in this study of antibody 21N has been calibrated as detec¬
ting around 12 or more copies of c-erbB-2 (Gusterson et al.,
1988), therefore cases with an amplification of between five
and 12 copies may appear to be immunonegative. Evidence
from the present mRNA studies supports this limitation to
detecting expression as 21% of our immunonegative cases
tested had increased mRNA levels. That changes in methods
can affect the frequency of detection is evident from a recent
report by Poller et al. (1992), in which modification of
fixation and immunohistochemical techniques increased the
proportion of invasive cancers with c-erbB-2 overexpression
to 39.7% from 15% (Lovekin et al., 1991). As in other
studies, we found good correlation between overexpression
and amplification: 80% of immunopositive cancers had
detectable gene amplification. However, the ranges of gene
copy values found by dPCR in immunopositive and immuno¬
negative cancers of the current study set indicate that for
both invasive and in situ cancers amplification does not
necessarily mean an equivalent overexpression, and some
cases with strong immunostaining showed normal or modest
increases in gene copy numbers. This suggests that factors
which cause overexpression of c-erbB-2 in the absence of
gene amplication may also play a role when gene amplifi¬
cation is present.
The disparity in frequency of c-erbB-2 gene activation
between in situ (around 44%) and invasive cancer (around
22%) noted in previous studies (see review by Singleton &
Strickler, 1992) is considerably diminished in the present
analysis, but the implications for relevance in cancer progres¬
sion are uncertain. An evaluation to test a hypothesis of
cancer natural history in the breast by Allred et al. (1992)
commented on c-erbB-2 overexpression in selected groups of
45 hyperplastic and dysplastic lesions as well as 708 in situ
and invasive cancers. They concluded that abnormal activa¬
tion of the gene was likely to be a significant but not the sole
initiating factor for many cancers. The limitations of simple
immunohistochemistry as a measure of disregulated gene
activity have been recognised (Anderson, 1992; Wynford-
Thomas, 1992). Improved sensitivity of detecting abnormal
gene activity through fluorescent (or other methods of) in situ
hybridisation (Kallionemi et al., 1992; Smith et al., 1993) is
likely to reveal considerably more about the heterogeneity
and degree of gene disregulation within cell populations. The
potential to explore mechanisms of gene control by further
analysis of material selected according to results of dPCR,
Northern analysis and/or immunohistochemistry is however
apparent from the results reported here.
The present studies show that amplification of c-erbB-2 is a
frequent event in breast cancer and that the relationship
between gene amplification and overexpression may be com¬
plex. Although the insensitivity of current immunohisto¬
chemistry in detecting small increases in protein is a factor
complicating interpretation, it is nevertheless likely that each
part of the replication/transcription/translation process can
be disregulated. Thus combininations of such events could
account for the distribution of cases among the categories of
Table III. Indeed, it appears that the frequency of these
various disorders of gene number and expression is not
equivalent. A small percentage of cases overexpress c-erbB-2
in the absence of amplification, while a larger number fail to
show a detectable overexpression of the gene in the presence
of amplification even though a small number of this group
also have increased mRNA levels. Factors acting as pro¬
moters or suppressors of gene function may directly affect
transcription regardless of the amplification status. Further
direct evidence of factors affecting transcription comes from
studies of breast cancer cell lines in which c-erbB-2 protein
can be down-regulated by oestrogen complexed with its
receptor (Russell and Hung, 1992). Increased c-erbB-2
mRNA levels resulting from elevated amounts of a transcrip¬
tion factor have also been observed in cancer cell lines which
have no detectable gene amplification (Hollywood & Hurst,
1993). Other explanations of disorder include physical
damage to the gene, mutation or the absence of promoters.
This variety of biological events and consequences suggest
that a more realistic model to evaluate c-erbB-2 disregulation
in breast cancer must encompass a greater number of cir¬
cumstances and consider the interaction of other biological
processes. The potential to study these in subgroups of
suitably characterised breast cancer cases is apparent.
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Simple 10 min preparation of fixed, embedded breast tissue for the polymerase
chain reaction
A. L. Hubbard and T. J. Anderson
The Department ofPathology, The University ofEdinburgh, Edinburgh, Scotland, UK
SUMMARY. A speedy method of preparing archival material for polymerase chain reaction studies is
presented.
INTRODUCTION
Analysis of putative oncogenes or tumour supressor
genes within breast cancers has recently been greatly
simplified by the polymerase chain reaction (PCR).
However sample preparation can be a major time
consuming component of test amplifications with the
PCR. We have therefore developed a rapid method of
sample preparation from fixed tissues, including those
embedded in paraffin, which gives reproducible, high
quality amplification of single copy gene markers by
PCR, even from small breast specimens. It is eco¬
nomical with valuable historical material and the fewer
stages of manipulation leads to fewer opportunities for
specimen contamination. A wide variety of preparative
methods for PCR from fixed material have been
described previously but comparative drawbacks
include lengthy preparation and incubation steps or an
excessive requirement for source material.
Methodology
We obtained breast tissue removed at routine surgical
operations and fixed either in methacarn (6:3:1
methanol, chloroform, acetic acid) or 10% buffered for¬
malin. The fixed tissues were each routinely processed
and embedded in paraffin. Prior to sectioning, excess fat
was trimmed and then ten micron sections were cut on a
Reichert-Jung 2030 microtome and transferred to sepa¬
rate 1.5ml eppendorf tubes. The knife was cleaned with
xylene between each specimen. lOOp.1 of lysis buffer
(50mM Tris pH 8.4, ImM EDTA, 0.5% Tween 20) was
Address for Correspondence: A. L. Hubbard, The Department of
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added and the specimen was boiled for 8 minutes in a
heated water bath. The resulting tissue DNA solution
was used either directly or stored frozen at -20°C. For
control purposes, DNA was prepared from fresh breast
tissue, taken at surgery from the same specimens at
adjacent sites, according to routine extraction methods.
Amplification of DNA from each solution was
performed on a Techne PHC3 thermal cycler using 5|J.l
of the prepared specimen, 200 |dM dNTP, 250 pM each
of sense and antisense primers, 1 unit of Taq polymerase
(NBL), 5fxl of xlO reaction buffer (NBL) to a total
volume of 50pl. Using primers for c-erb B2 and
interferon gamma (IFNG), 30 cycles were performed at
their respective optimal temperatures. We tested four
other primer sets developed for detection of poly¬
morphic sites in the human genome.
Results of amplification procedures are shown in the
figure. The specificity of the PCR reaction for c-erb B2
and IFNG in breast specimens is the same for DNA,
formalin and methacarn fixed specimens. Apparent dif¬
ferences in band intensities are probably due to dif¬
ferences in the quantity of template added to the initial
PCR reaction. In general, it appeared that formalin fixed
tissue gave a weaker signal than methacarn fixed tissue
in comparable blocks (data not shown), therefore it is
possible that methacarn fixation is less deleterious to
tissue DNA than formalin. DNA, including that from
single copy genes (IFNG) was successfully amplified
using six different primer sets, the longest sequence of
amplified DNA was 400bp. The upper limits of ampli-
con size using this preparative technique have not been
established. We have successfully analysed over 300
specimens using this preparative technique including
normal breast tissue, breast cancer and lymph node.
Detectable PCR product has been obtained from as little
as one 5 micron section although the amount of tissue
Polymerase chain reaction 51
DMFDMF
1 2 3 4 5 6
* Fig—PCR amplified DNA from control DNA (D), methacarn fixed
(M), and 10% buffered formalin fixed (F) tissue. The amplimers used
were c-erb B2 (tracks 1-3) and IFNG (tracks 4-6). The samples were
' electrophoresed on a 2% agarose gel and stained in ethidium bromide.
proteinase K. However when preparing template DNA
from fixed embedded tissue the process has been
extended by dewaxing and a lengthy (such as 5 days)
incubation in proteinase K. Also specimens prepared
using proteinase K, without subsequent DNA extraction,
can be unstable after freezing. This method substitutes
boiling in detergent for proteinase K digestion and DNA
extraction. The present findings suggest that this method
releases sufficient DNA from the tissue for successful
PCR and that irrelevant protein which may also be
released does not greatly affect the reaction. Despite
recent suggestions by Doyle and O'Leary that fixation
methods may play a role, we found that the subsequent
preparative technique was of as great a significance in
successful PCR.
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required is likely to depend on the sectional area and
cellularity of each specimen. Prepared specimens can be
successfully stored at -20°C, and undergo at least 8
freeze-thaw cycles without diminution of amplified pro¬
duct. This is of great advantage where multiple tests are
required on each specimen.
COMMENT
Preparation of PCR template from cell lines and
peripheral blood leucocytes commonly employ a non-
ionic detergent incubation followed by digestion with
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Disregulation of Urokinase Plasminogen Activator
Gene in Breast Cancer
A.L. Hubbard, J. Lauder, R.A. Hawkins and T.J. Anderson
Disregulation of urokinase plasminogen activator (uPA) was assessed in 134 breast cancer specimens. Over-
expression ofuPA was determined by immunohistochemistry using the specific monoclonal antibody, #394. Gene
amplification was assessed by differential polymerase chain reaction, using primers designed to amplify a 111 bp
segment of the uPA gene. Overexpression of uPA was detected in 33% of breast cancers, including 4 of 21 in situ
carcinomas, 7 of 14 lobular and 2 of 10 tubular carcinomas. Overexpression of uPA did not correlate with the
presence or absence of oestrogen receptors. uPA gene amplification was not detected in any cancer. We conclude
that uPA gene amplification is not a major mechanism instigating uPA overexpression in breast cancer, and that
overexpression is likely to be controlled by other mechanisms.
Key words: breast carcinoma, urokinase plasminogen activator, gene amplification, gene overexpression
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INTRODUCTION
Overexpression of the serine pro tease,urokinase plasminogen
activator (uPA) in epithelial cells has been linked to aggressive
behaviour in breast cancer [1, 2]. The biochemical action of the
enzyme may promote metastasis by degradation of proteins,
such as collagen, in the extracellular tumour stroma [3]. The
conversion of plasminogen to plasmin by uPA is thought to be a
critical step in this degradation [4]. Previous studies of breast
cancers with immunohistochemistry using a monoclonal anti¬
body directed against human uPA have shown overexpression
ejc 31:1-e
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of uPA in all of 115 cancers tested [1], Analysis of uPA antigen
by ELISA in the cytosolic fraction of these cancers indicated
that they contained, on average, 11 times more uPA than normal
breast tissue [1], High concentrations of uPA in breast cancer
tissue may be an independent prognostic factor in predicting
early relapse [1, 5, 6, 7].
The mechanisms of overexpression of uPA in breast cancer
are not clear, and may involve disregulated promoter and/or
suppressor activity, or fundamental DNA changes such as gene
amplification. The regulation of the concentration of uPA in the
cytoplasm of cells is complex; it can be influenced by a number
of cell signals such as hormones [8], phorbol esters [9], growth
factors [ 10], and cytokines [11]. Another possible mechanism for
overexpression is gene amplification. Overexpression associated
with gene amplification has been demonstrated in breast cancer
for some oncogenes, such as c-erb B2 and c-myc [12-14], and
have shown that these genes can be disregulated bymore than one
mechanism. We examined the possibility that overexpression of
uPA could be due, in some cases, to uPA gene amplification.
MATERIALS AND METHODS
Breast tissues
Samples of tissue were collected from 134 breast cancers at
routine surgical operations, which included mastectomy and
open biopsy for both palpable and non-palpable lesions; all were
primary cancers which had not been included in neo-adjuvant
treatment studies [15]. Samples were restricted to the age group
50-65 years and were collected from January 1988 to May 1990.
They were fixed in methacarn (6:3: 1, methanol
: choloroform : acetic acid) overnight at 4°C, processed accord¬
ing to routine methods and embedded in paraffin. Control tissue
was obtained from breast tissue distant from the lesion site or
from non-cancer bearing breasts. Pathological characterisation
was taken from overall evaluation of material used for routine
diagnosis and assessed according to standard criteria for histo¬
logical type, grade, and node status [16], This included an
evaluation of a 4 |xm section immediately adjacent to the tissue
used for differential PCR (see below) to confirm its histopathol-
ogical nature. The specimen's cellularity, namely the proportion
of cancer cells present, and ploidy status was assessed according
to published methods [17].
Oestrogen receptors
Oestrogen receptors were measured from tissue collected,
frozen and stored at — 196°C at the time of operation. A
radioligand-binding assay using dextran-coated charcoal was
used according to the method of Hawkins and colleagues [18].
The concentration of oestrogen receptors in each cancer sample
was expressed as a concentration of protein, with values of
>20 fmol/mg protein considered clinically significant.
Immunohistochemistry
Expression of uPA protein was examined with a murine
monoclonal antibody, #394, claimed as specific for human
urokinase plasminogen activator (American Diagnostica Inc.
New York, NY, U.S.A.). Four micron paraffin sections of all
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cancers were dried at 56°C overnight. The sections were dewaxed
in xylene and rehydrated to water. Endogenous peroxidase was
blocked by exposure to 1% hydrogen peroxide in methanol for
15 min before staining. The sections were washed in Tris-
buffered saline (TBS pH 7.6), followed by a 10 min incubation
with normal rabbit serum (Scottish Antibody Production Unit,
Carluke, U.K.) diluted 1 : 5 with TBS. The primary antibody
was applied at a 1 : 100 dilution in normal rabbit serum/TBS
and incubated at room temperature for 30 min. Normal rabbit
serum was used in place of the primary antibody as a negative
control. An ABComplex method was carried out according to
manufacturers instructions (Dako K355). The sections were
lightly counterstained in haematoxylin. To score positive, indi¬
cating uPA expression, cancer cells had to show weak, moderate
or strong brown staining of cytoplasm above normal stromal
components of the tissue section, excluding macrophages. The
assessment ofuPA expression was based on a single tissue section
from each specimen and was jointly assessed by TJA and ALH.
A positive control, a cancer previously identified as showing
strong staining with #394, and a negative control were incorpor¬
ated in each set of sections for staining. Some variation in
staining intensity was noted in positive control sections. As the
titre of antibody #394 dropped from 1 : 100 to 1 : 10 during
overnight storage after reconstitution of the lyophilised prep¬
aration, fresh dilutions of #394 were prepared for each batch of
slides. This occurred with three separate batches of antibody.
Primers and the differential polymerase chain reaction
Primers for differential PCR for uPA were designed from the
human gene sequence published elsewhere [19]. The primer
sequence for the sense strand was 5'
CAGTTTACCCTCACCCTGGA 3' (1631-1650 bp), and the
antisense strand 5' AGCCAACTGTTGTAGGGGTG 3'
(1757-1738 bp). PCR using these primers yields a 111 bp pro¬
duct from the intron 2-exon 3 boundary of the published
sequence. The single copy reference gene used in dPCR was a
150 bp sequence of human interferon gamma [20]. For dPCR,
four 10 pm sections of fixed, paraffin-embedded tissue were
added to 100 pi of lysis buffer (50 mM Tris HC1, pH 8.4, 1 mM
EDTA, 0.5% Tween 20) and boiled for 8 min [21]. Differential
PCR was performed on a Techne PHC 3 thermal cycier incorpor¬
ating 5 pi of prepared lysed paraffin section or 200 ng of control
DNA (human placental), 0.25 pM each primer,
200 mM dNTPs (Pharmacia), xl Taq polymerase buffer
(Northumbria Biotechnology Limited NBL), 1 unit of Taq
polymerase (NBL) and 3 pCi of 32P CTP (New England
Nuclear). Cycling parameters were one cycle of 94°C for 5 min,
50°C for 1 min, 70°C for 1 min, followed by 30 cycles of 94°C
for 1 min, 50°C for 1 min, 70°C for 1 min and one cycle of 94°C
for 1 min, 50°C for 1 min, 70°C for 5 min. Duplicate PCR
products were separated by size on 2% agarose gels, and stained
with ethidium bromide. Visible bands were excised, finely
chopped and added to 5 ml of Optiphase-safe scintillation fluid.
Radioactivity was assessed as counts per minute (CPM) on a
Beckman scintillation counter. Results from dPCR are expressed
as ratio values and were calculated by averaging the CPM from
duplicate gel tracks and subtracting the average experimental
blank. For uPA, a correction factor of 1.04 was applied to
compensate for differences in dCTP content between amplicons
IFNG150 (69 C bases) and uPA (66 C bases). To ascertain the
relative copy number of uPA to the reference gene, the corrected
average CPM for uPA was divided by the average CPM for
IFNG150, giving in each case a result expressed as a ratio value.
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This method has been previously validated for use of fixed
breast tissues and shown to detect amplifications of the onco¬
genes c-erb B2, EGFR and N-ras [17, 20].
RESULTS
Immunohistochemistry
Immunohistochemistry for expression of uPA protein was
performed on 134 breast cancer specimens. Overexpression of
uPA protein was observed in 40 of 113 (35%) invasive cancers
and in 4 of 21 (19%) in situ cancers, (total cancers 33%). Staining
was concentrated in the cytoplasm of the cells, and usually
present evenly throughout the cancer cell population (Figure 1).
Staining of the cell membrane was present in some positive
cancers, however, this was always in association with cytoplasmic
staining. In some cases, weak staining was observed in normal
stroma and infiltrating lymphocytes, but this was always in
association with positively stained cancer cells. Strong staining
was observed in cells identified as macrophages in a small
number of cases, and if staining was present only in macro¬
phages, specimens were considered negative.
Table 1 summarises the association between uPA protein
overexpression and features of the cancers studied. uPA
expression was more common in invasive cancers, and within
that group was more frequent in oestrogen receptor negative
cancers. "Positive" staining was present in similar proportions
in each of the ploidy groups, diploid (36%), aneuploid (43%)
and tetraploid (38%). We found no correlation between size of
cancer or node status with overexpression. Grade 1 cancers
showed a lower frequency of overexpression (24%) than grade 2
or 3 (38%), but these differences were not significant.
Overexpression was not confined to any particular histological
type of cancer, but noteworthy was the high proportion in
lobular carcinomas (7 of 14), and overexpression was also present
in some tubular carcinomas (2 of 10). Freqency ofoverexpression
in each type of cancer is shown in Table 1.
Differential PCR
Figure 2 shows representative dPCR products obtained from
three cancer specimens and a normal DNA control (derived
from human placenta). Differential PCR ratio values were
obtained for 134 cancer specimens and 33 control tissues
(Table 2), and ranged from 0.52 to 1.54 (mean 0.9) in control
tissues and 0.41-1.83 (mean 1.1) in cancer tissues. Ratio values
of 2 or above have been considered to signify gene amplification
Figure 1. Four micron section of a lobular carcinoma showing strong
positive staining with anti-uPA antibody (#394). Magnification x 160.
Table 1. Clinical features of the study population with uPA
immunohistochemistry
Number of Percentage with positive
cases immunohistochemistry
Invasive cancers 113 35
In situ cancers 21 19
Invasive cancers only
Oestrogen receptor status
<20 fmol/mg protein 32 41



























Invasive cancer types are DCINST, ductal carcinoma ofno special type;
LCI, lobular carcinoma; TCI, tubular carcinoma; and OTH, other
special types; NK, not known.
in other studies [17]. There was no clear difference in range of
values between invasive cancers (0.41-1.83) and in situ cancers
(0.7-1.55). The distribution of ratio values was similar for
immunohistochemistry-positive and -negative cancers
(Figure 3). Cancers shown to be overexpressing uPA protein
were distributed evenly over the range of dPCR values, indicat¬
ing that cancers which overexpress uPA are not associated with
high dPCR values. Differential PCR values were not influenced
by specimen cellularity or DNA ploidy.
DISCUSSION
Using dPCR to study gene disregulation at the uPA locus, we
found no evidence for amplification of this gene. We could not
detect any relationship between overexpression of uPA protein
and dPCR ratio values indicating increased gene copy number.
We therefore conclude that uPA gene amplification is not amajor
influence on immunohistochemically detected overexpression of
uPA in breast cancer. However, other interesting features were
observed and are noteworthy of discussion.
Although no difference was detected between the ranges of
dPCR ratio values for cancers and controls, cancers had a higher
mean dPCR value. This could reflect a low level of chromosomal
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Figure 2. Differential PCR products from three different breast
cancers (Tracks A, B and C) and one control placental DNA (Track
D), separated on 2% 3 : 1 Nuseive/Seakem agarose gel. Track E
contains the experimental negative control (PCR reaction minus
template DNA). PCR products for IFNG (reference gene) and uPA
are indicated at 150 bp and 111 bp, respectively.
Table 2. Ranges of dPCR ratio values found for invasive,
in situ breast cancers and control tissues
Number of dPCR ratio Mean dPCR
cases range ratio value
Invasive cancers 113 0.41-1.83 1.12
In situ cancers 21 0.7 -1.55 1.18
Controls 33 0.52-1.54 0.90
instability, yet there was no association between high dPCR
values and abnormalities of DNA ploidy. Furthermore, cases
overexpressing uPA protein were not solely restricted to those
with dPCR ratio values at the upper end of the normal range,
indicating that overexpression was not due to minor chromoso¬
mal deregulation. The possibility that gene overexpression can
lead to gene amplification has been suggested [22, 23], but has
not been confirmed experimentally and seems unlikely to be true
















Figure 3. Range of dPCR values for immunohistochemistry positive
and negative cancers.
We found uPA expression to be common in invasive lobular
cancers. These cancers characteristically infiltrate through stro¬
mal elements as individual units in linear array, and uPA may
play some part in this process. However, both invasive tubular
carcinomas and in situ cancers also expressed uPA, yet these
histological types are recognised for cell cohesion, differentiation
and lack ofmetastasis [24, 25]. This suggests that overexpression
of uPA can be an 'early' event and that additional factors are
required for the development of invasion resulting in a poorer
prognosis. The presence of uPA in the cytoplasm is probably
only one of several possible factors involved in cancer cell
dissemination. Examination of lung carcinoma cell lines have
indicated that functionally active, receptor-bound, uPA is essen¬
tial for tissue invasion [26]. Studies of uPA overexpression
combined with assessment of cell surface receptors (uPAR) may
illuminate the significance of overexpressing uPA, especially in
cancers which have a favourable outcome.
Assessing the mechanisms accounting for overexpression of
uPA in breast cancer is likely to be complex, and may involve
factorswhich affect transcription, translation and post-transcrip-
tional processing. Increased levels of specific uPA inhibitors,
PAI-1, PAI-2 and protease nexin, in breast cancer cells have
been shown to regulate cytoplasmic concentration of uPA [27].
Post-transcriptional activation mechanisms of uPA may also be
disregulated in cancer cells [28]. Immunohistochemistry is a
convenient method for demonstrating disregulated gene
expression, and detection frequency is usually high, in the order
of 88-100% of breast cancers [1, 29]. However, this study
detected overexpression of uPA in only 33% of breast cancers, a
frequency similar to another immunohistochemical study of
breast cancer, although that study was based on frozen sections
[30]. This recorded disparity in frequency of positivity is a cause
for concern, but could be due to criteria for scoring positivity,
differences in immunohistochemical protocols and antibodies,
or both of these. Present requirement for staining above that of
normal stroma was an excluding factor in only 6 cases, and is
unlikely to be a major factor influencing the frequency of
positivity. The instability of the antibody used here is a major
factor causing concern and has been noted in other laboratories
(M. Walch, personal communication) for unidentified reasons.
There are alternative antibodies available for uPA which also
detect high frequencies of expression in ELISA [7], but present
experience suggests caution before drawing conclusions from
immunohistochemistry alone.
Other features of our cancer population, such as size and
ploidy, show no particular associations with uPA expression.
The trends toward elevated uPA expression in grade 2 or 3
cancers and in negative lymph node status cancers were noted
previously [6, 7], Correlations of biochemical and immunochis-
tochemical procedures generally have indicated that measured
concentrations of uPA protein correlate with the strength of
immunostaining, although individual cases can show major
discrepancies [1]. This suggests that the relationship between
immunohistochemical staining and detection of uPA protein in
breast cancers is not strictly quantitative. Furthermore, the
results of biochemical studies may be confounded by the pres¬
ence of uPA-rich macrophages [31], indicating that a combi¬
nation of immunohistochemistry and ELISA would be more
informative than either technique alone. Comparability between
studies is further confounded by differences in the experimental
strategy and antibodies employed [1, 2, 6, 7, 30]. The concen¬
trations of uPA in the cytoplasm of cancer cells is known to
be affected by growth factors, phorboi esters, cytokines and
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hormones [9-11, 32]. Studies of cell lines have shown that
oestrogen complexed with its receptor can induce uPA synthesis
[32]. We found no significant difference in the frequency of uPA
protein overexpression in oestrogen receptor-positive and -
negative cancers, suggesting that oestrogen is not a major
influence in the complex regulatory mechanisms of uPA pro¬
duction.
In summary, our study has provided evidence that uPA is
overexpressed in at least some breast cancers which may relate
to gene deregulation, though not to gene amplification.
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